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Abstract
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the
world. Identifying clinically relevant COPD phenotypes has the potential to reduce the
global burden of COPD by helping to alleviate symptoms, slow disease progression and
prevent exacerbation by stratifying patient cohorts and forming targeted treatment plans.
In this regard, quantitative pulmonary imaging with hyperpolarized 3He magnetic
resonance imaging (MRI) and thoracic computed tomography (CT) have emerged as
ways to identify and measure biomarkers of lung structure and function.
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He MRI may

be used as a tool to probe both functional and structural properties of the lung whereby
static-ventilation maps allow the direct visualization of ventilated lung regions and 3He
apparent diffusion coefficient maps show the lung microstructure at alveolar scales. At
the same time, thoracic CT provides quantitative measurements of lung density and
airway wall and lumen dimensions. Together, MRI and CT may be used to characterize
the relative contributions of airways disease and emphysema on overall lung function,
providing a way to phenotype underlying disease processes in a way that conventional
measurements of airflow, taken at the mouth, cannot. Importantly, structure-function
measurements obtained from 3He MRI and CT can be extracted from the whole-lung or
from individual lung lobes, providing direct information on specific lung regions. In this
thesis, my goal was to identify pulmonary imaging phenotypes to provide a better
understanding of COPD pathophysiology in ex-smokers with and without airflow
limitation. This thesis showed: 1) ex-smokers without airflow limitation had imaging
evidence of subclinical lung and vascular disease, 2) pulmonary abnormalities in exsmokers without airflow limitation were spatially related to airways disease and very
mild emphysema, and, 3) in ex-smokers with COPD, there were distinct apical-basal lung
phenotypes associated with disease severity. Collectively, these findings provide strong
evidence that quantitative pulmonary imaging phenotypes may be used to characterize
the underlying pathophysiology of very mild or early COPD and in patients with severe
disease.
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CHAPTER 1
INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is characterized by progressive airflow
limitation caused by a combination of airways disease and emphysema due to
inflammatory responses in the lung to noxious particles (1). The objective of Chapter 1 is
to provide an overview of the global health burden imposed by COPD and the
pathophysiology, symptoms and medical complications associated with the disease.
Chapter 1 will also describe the conventional methodology for measuring pulmonary
function and diagnosing COPD and discuss the use of pulmonary imaging for identifying
clinically relevant COPD biomarkers and phenotypes.

1.1 Chronic Obstructive Pulmonary Disease: A Leading
Cause of Death Worldwide
Chronic obstructive pulmonary disease (COPD) affects 10% of the adult population
worldwide (2). A decade ago, COPD was the 4th leading cause of death in the world. At
that time, based on global estimates of the rising use of tobacco smoke and biomass fuels,
concomitant with the aging population, the World Health Organization (WHO) and
others projected COPD to rise to the 3rd leading cause of death in the world between the
years 2020 – 2030 (1, 3). Despite this threat, therapies and research efforts did not result
in a reduced COPD mortality rate and it subsequently became the 3rd leading cause of
death in the world in the year 2010, a decade earlier than expected (4).

Table 1-1. Leading Causes of Death Worldwide in 2012 (Adapted from The
World Health Organization Report 2014 (5))
Rank Disease
Deaths (millions) % Deaths Worldwide
1
Ischemic Heart Disease
7.35
13.2
2
Cerebrovascular Disease
6.67
11.9
3
COPD
3.10
5.6
4
Lower Respiratory Infections
3.05
5.5
5
Respiratory Cancers
1.60
2.9
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COPD also causes life-altering disability to those affected and is expected to become the
5th leading cause of disability worldwide by the year 2030 making it one of the fastest
rising disability threats in the world (Table 1-2).

Table 1-2. Worldwide leading causes of disability in 2004 and their predicted
rank in 2030 (Adapted from ‘The Global Burden of Disease: 2004 Update, World
Health Organization’ (3))
2004 Rank* Disease or Injury
2030 Rank* Disease or Injury
1
Respiratory Infections
1
Depressive Disorders
2
Diarrhoeal Diseases
2
Heart Disease
3
Depressive Disorders
3
Traffic Accidents
4
Heart Disease
4
Cerebrovascular Disease
5
HIV / AIDS
5
COPD
6
Cerebrovascular
6
Respiratory Infections
Disease
7
Premature birth
7
Hearing loss
8
Birth trauma
8
Vision problems
9
Traffic Accidents
9
HIV / AIDS
10
Neonatal Infections
10
Diabetes
13
COPD
*Rank based on the disability adjusted life years (DALY), one DALY is equivalent to
the loss of one year of full health

Given the staggering statistics on the mortality and disability rates, it is not surprising that
COPD also has the highest rate for hospital admissions and readmissions among chronic
illnesses in the United States, Canada and Europe (Figure 1-1) (6, 7).
Along with having a significant frequency of hospitalization, it is estimated that each
hospitalized COPD exacerbation costs on average $10,000 CAN and the overall national
economic burden for COPD hospitalizations ranges from $646 million to $736 million
each year (8).

Unfortunately, these costs are expected to rise in tandem with the

increasing burden of COPD disability over the next two decades.
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Figure 1-1. Hospitalizations and repeat hospitalizations by health condition
Adapted from the Canadian Institute for Health Information (CIHI) (6)

Collectively, these reports on the prevalence of COPD mortality, morbidity and disability
have established that the burden of COPD is a global health issue. At the same time
however, epidemiological studies are showing that anywhere from 20-80% of individuals
with impaired lung function consistent with COPD are not diagnosed nor treated for the
condition (9, 10). This may partly explain one reason why COPD is such a deadly and
disabling disease as it suggests that individuals are not likely to seek care or treatment for
their respiratory symptoms until their lung function has declined severely and may not be
able to be adequately controlled with treatment or surgery. As will be explained in more
detail in this thesis, another explanation for the high mortality and disability rates of
COPD is related to poor characterization of pulmonary pathophysiology of at-risk
individuals who may be in the early subclinical stages.
It has become obvious that there is room for improvement in regard to screening methods
and diagnostic strategies for COPD. In the following subsections of the Introduction I
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will provide background knowledge on pulmonary pathophysiology in the healthy and
COPD lung with emphasis on the varying contributions of airways disease and
emphysema from patient to patient. In the latter part of the introduction I will discuss
conventional lung function testing and pulmonary imaging methods for characterizing,
diagnosing and grading COPD. Chapters 2, 3 and 4 are original research investigations
focused on identifying clinically meaningful pulmonary imaging biomarkers and
phenotypes to provide a better understanding of airflow limitation in ex-smokers with and
without COPD. Lastly Chapter 5, the Conclusion, will summarize the key pulmonary
imaging findings from the studies in Chapters 2, 3 and 4 and discuss future work needed
to address unanswered questions pertaining to pulmonary imaging abnormalities and their
clinical relevance in ex-smokers with and without COPD.

1.2

COPD: A Heterogeneous Disease of the Lung

COPD is an umbrella term that encompasses airways disease and emphysema. Both
airways disease and emphysema contribute differently to airflow limitation in each and
every patient making the clinical presentation of COPD vary immensely among
individuals who are demographically the same, who have the same smoking history and
even among people with the same lung function and respiratory symptoms. Decades of
research has been put in to characterizing the pathophysiological and biochemical
processes in the airways and lung parenchyma involved in lung function decline. In this
section I will discuss how pathophysiological changes to the airways and alveoli cause
the irreversible airflow limitation characteristic of COPD

1.2.1

Chronic Bronchitis

Chronic bronchitis is characterized by extended periods of excessive cough and mucus
and sputum production. The inflammation triggered by noxious particles (from cigarette
smoke or other pollutants) in the large or central airways (> 4mm in diameter) is the key
cause of bronchitis. The inflammatory response imposed by tobacco smoke triggers
increased production of mucus and sputum with concomitant decrease in mucus
clearance from the large central airways due to damage to the airway epithelial barrier.
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There is also evidence that the bronchial walls thicken (causing the airway lumen to
narrow) as a result of the abnormal accumulation of connective tissue within the medium
and large airway walls (11). Methods have been developed (12) to diagnose chronic
bronchitis based on the ratio of mucus gland to bronchial wall thickness (Reid Index)
however an clinical definition based on the frequency and duration an individual
experiences of a debilitating cough is more commonly used (1).

1.2.2

Small Airways Disease

The airways < 2mm in diameter are the major site of airflow obstruction in COPD (13).
These are airways (bronchioles) beyond the fourth generation of branching (Figure 1-2).
As the bronchial tree branches non-dichotomously, the number of airways with each
successive generation increases and so does their total cross sectional area (14). The
majority (75%) of airway resistance in the bronchial tree is attributable to the large
(central) conducting airways (conducting airways > 2mm) while only a fraction of
resistance is located in the small airways of the respiratory zone (15). Therefore, the
small airways contribute very little to overall airway resistance. However, it is in these
airways that disease can accumulate over long timeframes without having a significant
effect on overall lung function and without causing noticeable respiratory symptoms (16).
As already mentioned in 1.2.1, the introduction of toxins to airway epithelium increases
mucus production, injures and impairs the mucociliary escalator and triggers an
inflammatory response in the bronchi. This is true for the small airways also. The excess
mucus and inflammatory markers (B cells, CD4 and CD8 lymphocytes) that are produced
in response to the noxious particles accumulate and obstruct the small airways. There is
also evidence that a portion of mucus present in the small airways in COPD may actually
be aspirated there from the large and central airways (15).

In addition to airway

obstruction, the abnormal deposition of inflammatory cells and connective tissue in the
small airway wall causes fibrosis of the airway wall and airway lumen obstruction in
severe disease (13). The progression of COPD with respect to lung function decline from
mild to severe grades has been most closely associated with the thickening of the airway
wall and surrounding compartments and less closely related to the degree of
inflammation and mucus secretion within the small airways (13).

6

Figure 1-2. Diagram of airway tree including the conducting and respiratory zones
and showing the airway generations. The conducting zone comprises the large and
small central airways up to the 16th generation that do not participate in gas exchange.
The transition and respiratory zone comprise airways >17th generation. Surface area
increases with airways generation and gas exchange processes occur in the respiratory
bronchioles, alveolar ducts and sacs. Reproduced from Respiratory Physiology: The
Essentials, 8th Edition (14)
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1.2.3

Emphysema

Emphysema is defined as dilation and destruction of lung parenchyma distal to the
terminal bronchiole (17) (see Figure 1-3). In emphysema the airspaces involved in gas
exchange enlarge and coalesce which reduces the surface area within the lung to carry out
necessary gas exchange processes. There are several subphenotypes of emphysema
which are named according to the lung units that are involved.

Centrilobular, or

centriacinar emphysema arises from damage and enlargement of the respiratory
bronchioles (Figure 1-2 and 1-3) and is most commonly associated with cigarette
smoking. Centrilobular emphysema predominantly occurs in the apical-lung and it is
postulated that this is a result of the elevated ventilation (V) – perfusion (Q) ratio (V/Q)
in this part of the lung (14). Since the ventilation largely outweighs perfusion (~3/1) in
the apical lung, it is thought that noxious particles from cigarette smoke may be deposited
in the distal airspaces without passing into the pulmonary circulation inducing
inflammation and subsequent destruction of parenchynmal tissue. A second form of
emphysema, panlobular or panacinar emphysema, is more common in non-smoking
related COPD and in particular alpha-1 antitrypsin deficiency (AATD). AATD is an
autosomal hereditary disorder and the panlobular emphysema characteristic of AATD
destroys the structure of the entire distal bronchiole starting with the alveolar ducts and
sacs and gradually degrading the structure of the respiratory bronchiole (Figure 1-2 and
1-3) (18). AATD is a result of reduced serum levels of alpha-1 antitrypsin, a protease
that is responsible for protecting the lung from proteolytic activity of neutrophil elastase.
The unchecked levels of neutrophil elastase result in destruction of the alveolar walls.
AATD associated panlobular emphysema has been found to occur predominantly in the
highly perfused basal-lung region where neutrophils and proteases are circulating within
the blood (18). Lastly, paraseptal emphysema is defined as dilation of the airspaces near
or adjacent to the lung pleura and septa. In paraseptal emphysema the most peripheral
airspaces (Figure 1-2 and 1-3) are destroyed but typically these emphysematous lesions
are asymptomatic and not associated with cigarette smoke but with lung trauma such as
pneumothorax (19).
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Figure 1-3. Schematic of healthy, panlobular, centrilobular and paraseptal acini.
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1.2.4

COPD – Asthma Overlap

Although Asthma is not the direct focus of work presented in this thesis, a significant
proportion of individuals who experience symptoms of COPD also exhibit symptoms
consistent with Asthma. This clinical presentation has recently been termed ‘AsthmaCOPD Overlap Syndrome (ACOS)’ and warrants explanation (20, 21). While COPD
encompasses both an airway and emphysema component, asthma is characterized by
inflammatory and hyperresponsive airways. Unlike in COPD, the airway obstruction in
asthma is reversible with the use of inhaled corticosteroids and long-acting
bronchodilators. Although there are clearly defined clinical characteristics to stratify
asthma and COPD patients (20), these guidelines fail to acknowledge the spectrum of
ACOS. This is an issue because based on these guidelines asthmatics are often excluded
from large-scale and longitudinal COPD studies even if they are current- or ex-smokers.
One study (22) found in a group of adults (> 55 yrs) with either COPD or asthma, 65% of
subjects had overlap of asthma and COPD while only 16% and 21% of subjects had
definite asthma or COPD respectively. There are many possible origins of the ‘overlap’
between asthma and COPD and most likely the origin is different for every patient with
ACOS. It is widely known that asthma is most commonly diagnosed in childhood, but
childhood respiratory disease is also closely linked to the development of impaired lung
function and COPD later in life. At the same time, cigarette smoking and an asthma
diagnosis are risk factors for the development of COPD, and cigarette smoking alone
promotes asthma. Therefore there is substantial overlap even among the individual risk
factors for asthma and COPD which may accumulate and increase the likelihood of
developing just one of these diseases on its own (23, 24).

1.2.5

COPD – Bronchiectasis Overlap

Bronchiectasis is another chronic respiratory illness that has been closely linked with
COPD. It is characterized by persistent bronchial sepsis due to irreversibly damaged and
enlarged bronchi (25). The enlarged airways are injured in such a way that they are not
able to clear mucus adequately. Mucus builds up within the large and small bronchi
promoting a cycle of repeated lung infections. Each subsequent infection imposes more
damage to the airways and a cyclical process ensues.

There are many causes of
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bronchiectasis ranging from abnormal congenital etiology and childhood development
disorders to poorly healed respiratory infections. There is evidence that bronchiectasis is
present in anywhere from 30% to 70% of patients with COPD (26-28) and those patients
with concomitant COPD and bronchiectasis experience a more severe clinical course
involving more hospitalizations and higher mortality (29). It is unclear what the exact
underlying mechanisms involved in the development of co-occurring COPD and
bronchiectasis are. It could be that the constant exposure to toxins in cigarette smoke
repeatedly trigger respiratory infections promoting bronchiectic pathophysiology in the
lungs of COPD patients. Another hypothesis is that the airway obstruction presented in
bronchiectasis due to mucus plugging imposes airflow limitation severe enough to
warrant a COPD diagnosis (30). It is not known for sure whether bronchiectasis is
caused by COPD and repeated exposure to cigarette smoke or if the opposite is correct
and COPD is a consequence of bronchiectasis pathophysiology. It seems likely that the
same is true for ACOS and the exact cause of concomitant bronchiectasis and COPD is
different for each patient.

1.3

COPD and Cardiovascular Disease

Over the past two decades there has been increasing evidence that both COPD and
cardiovascular disease, and in particular vascular atherosclerosis are closely related.
Large-scale epidemiological and experimental studies (31-35) have established that
cardiovascular diseases and complications are the leading cause of hospitalization among
COPD patients and are second only to lung cancer as the leading cause of death.
Therefore it is clear that there is a serious burden of cardiovascular disease in COPD
patients. Both COPD and cardiovascular disease share a common risk factor in cigarette
smoke and air and gas pollution, however it is now known that the mechanistic link
between cardiovascular and pulmonary disease pathophysiology extends beyond the
toxicity imposed by inhaled toxins (32). The ‘lung permeability’ theory was recently
proposed (36) as a potential mechanism for atherogenesis (atherosclerotic plaque
development) in COPD patients. Figure 1-4 presents a schematic of this mechanism.
This concept suggests that inflammatory stress similar to what occurs in COPD patients
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might cause the alveolar – capillary layer to become increasingly permeable to
inflammatory mediators. These inflammatory markers, mainly the interleukins, are free
to pass from the lungs into the systemic circulation where they trigger a secondary
inflammatory response of procoagulant and inflammatory markers from the liver (Creactive protein, fibrinogen, serum amyloid protein) that promote atherogenesis at various
locations throughout the body. While this process may occur chronically in the inflamed
COPD lung, cyclical insults of cigarette smoke would cause the alveolar – capillary layer
to become chronically permeable, up-regulating the atherogenic response. Given this
mechanistic hypothesis it seems plausible that there is a dose-response relationship
between the severity of lung disease and vascular disease and several studies (35, 37-41)
have confirmed that this is the case. The severity of atherosclerosis has been shown to be
correlated with lung function decline whereby COPD patients have quantitatively more
atherosclerotic plaque (37, 40, 42, 43) and more plaque that is vulnerable to rupture
causing embolism and stroke (44). However it is not known for certain if cardiovascular
disease causes COPD or vice-versa, and the question about ‘which comes first’ cannot
yet be answered with certainty (45). What is known is that cardiovascular disease and
acute ischemic events play one of the most important roles in the clinical course of
COPD patients (46).
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Figure 1-4. Schematic of the mechanistic link between COPD and atherosclerosis.
Reproduced with permission from ‘Imaging Evidence of the Relationship Between
Atherosclerosis and Chronic Obstructive Pulmonary Disease’ Imaging in Medicine; DOI:
10.2217/iim. 13.70, 2013 (47)
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1.4 Subclinical COPD and Identifying Susceptible
Individuals
1.4.1

Undiagnosed, Early and Subclinical COPD

Typically, individuals with COPD present with obvious symptoms of airflow limitation
including chronic cough, breathlessness and wheezing. These symptoms are related to
the various contributions of airways disease and emphysema that reduce the ability to
move air in and out of the lungs and participate in gas exchange. However there are
many ex- and current-smokers who experience respiratory symptoms and may or may not
have airflow limitation consistent with COPD and never receive treatment for a
pulmonary condition. Ex- and current-smokers are most likely to encounter pulmonary
function testing or be referred to a respirologist by a primary care provider only when
pulmonary symptoms start to alter their exercise capacity and drastically impact their
quality of life. A study in the province of Ontario, Canada reported that up to 75% of exand current-smokers had impaired lung function consistent with COPD but had not
previously sought medical help for respiratory illness; (9) this may have reflected the fact
that most of these individuals could still carry-out day-to-day activities. Unfortunately,
other studies (48, 49) have recognized that COPD underdiagnosis is common in other
countries as well. There are several reasons COPD might go undiagnosed and untreated
in the general population. First, since lung function decline is a chronic process, it can
take decades before obvious symptoms present. At the same time, many ex- and currentsmokers often attribute impaired lung function to normal aging and not an indicator of
respiratory illness. Second, certain individuals may be ‘protected’ from being diagnosed
with airflow limitation because of anatomical or comorbid conditions that prevent them
from performing diagnostic pulmonary function tests (to be discussed in section 1.4.2).
Lastly, as was previously mentioned in section 1.2.2, the small airways are the major site
of airflow obstruction in COPD, but these airways only account for a fraction of overall
airway resistance. Given this, it has been speculated that disease processes can occur in
the small airways or the ‘silent zones’ over very long timeframes without having a
noticeable influence on lung function (16). Therefore it is likely that small airways
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disease can accumulate without detection until a critical point is reached and overall lung
function starts to decline rapidly.

1.4.2

Airflow Limitation in Obese and Overweight Individuals

Obesity, defined as a body mass index (BMI) greater than 30kg/m2, and being overweight
is a biomarker for dyspnea which is one of the major and predominant symptoms of
COPD (50).

Therefore, breathlessness in overweight individuals might be directly

related to their obesity or a manifestation of an underlying and untreated lung condition
such as COPD. High BMI is associated with a decrease in functional residual capacity
(FRC) and total lung capacity (TLC) due to the increase in adipose tissue in the thoracic
trunk of affected individuals (51). The smaller lung capacity combined with increased
adipose deposits cause impaired movement of the diaphragm, and reduced chest wall
compliance and ultimately both the forced expiratory volume in one second (FEV1) and
forced vital capacity (FVC) decrease. It has also been reported that the decrease in FVC
is more severe than FEV1, leading to a subsequent increase in FEV1/FVC in these
individuals (52, 53). Therefore overweight and obese individuals might be ‘protected’
from developing airflow limitation based on the FEV1/FVC ratio due to extrapulmonary
or anatomical impairment (50).

As a result, many overweight individuals may go

untreated due to the absence of a COPD diagnosis (on spirometry) even though they may
experience dyspnea that is attributable to airflow limitation and not solely a symptom
associated with being overweight. These individuals may make up a large percentage of
people with ‘undiagnosed’ or very early or mild COPD. At the same time, it is difficult
to know for sure if the symptoms these subjects experience are secondary only to obesity
or directly related to impaired lung function – this is postulated to be the primary reason
obese or overweight individuals do not seek further treatment from a respirologist beyond
the primary care setting.

1.4.3

Identifying Individuals Susceptible to Developing COPD

The Fletcher and Peto curve (Figure 1–5) that describes the natural history of COPD
popularized the concept that both smokers and non-smokers alike, reach and maintain

16

maximum lung function during the first half of adulthood before lung function starts to
decline (54). Fletcher and Peto suggested that while both smokers and non-smokers
experience a decline in lung function, smokers decline much more rapidly and develop
airflow obstruction due to their rapidly declining trajectory.

The concept of rapid

declining lung function in smokers has been confirmed more recently but the rate of
change in lung function over time is now known to be highly variable (55). Recently, the
seminal findings of Fletcher and Peto were extended when it was suggested that there
exists another group of individuals who develop COPD aside from ‘rapid decliners’.
These individuals attain a low maximal lung function in adulthood and subsequently
experience a rate of decline of lung function that is normal (similar to what is observed in
non-smokers).

This study found that among COPD patients, approximately half

experienced a rapid-decline in lung function leading to airflow limitation while the other
half reached a low maximal lung function before declining at a normal rate (56). This
was an exciting finding because it suggested that lung function at young ages and
maximally attained lung function in adulthood might serve as important biomarkers
related to the development of COPD.
At the same time, it is clear that identifying which ‘trajectory’ an individual follows may
not be enough to identify who will develop COPD. Many ex- and current-smokers have
an ‘early’ or subclinical form of COPD that does not satisfy the criteria for a COPD
diagnosis based on lung function or pulmonary symptoms. Disease might accumulate
‘silently’ (16) in the small airways (13) of the peripheral lung for many years without any
symptomatic or lung function indications making it difficult to identify which trajectory
an individual might follow (rapid decliner, normal decliner etc.). The identification of
early and subclinical COPD in individuals who smoke or who have smoked has many
benefits with respect to treatment planning and lifestyle change recommendations.
Concomitant with the objectives of any COPD treatment plan, which are to reduce
recurrent respiratory symptoms and prevent exacerbation episodes, the identification of
very early forms of the disease can help individuals and their health care team put
together a targeted therapy strategy to achieve the most optimal outcome for a certain
individual at the onset of disease.
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Unfortunately, as discussed in section 1.4.1, many smokers develop respiratory
symptoms over the span of several years but may not consider them significant enough to
seek help from a primary care provider who could help kickstart a treatment plan. In this
way COPD progression may continue for decades before treatment begins at which point
it may be in the severe and debilitating stages and be very difficult to manage.
Furthermore, as will be described in more detail in section 1.5, conventional and goldstandard pulmonary function tests for assessing lung function and diagnosing COPD do
not fully characterize small changes in lung function that might indicate very early or
subclinical disease progression.

Therefore the combination of very few individuals

visiting the primary care setting along with poor characterization of small changes by
gold-standard tools for diagnosing COPD makes the identification, treatment and
longitudinal monitoring of COPD from the earliest stages extremely difficult in clinical
practice.

Figure 1–5. Lung function decline over time in never-smokers, current-smokers
and individuals who quit smoking. Adapted from ‘The Natural History of Chronic
Airflow Obstruction’ (54) and ‘Lung-Function Trajectories Leading to Chronic
Obstructive Pulmonary Disease’ (56).
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In the next section I will describe the methodology for measuring pulmonary function
and diagnosing COPD.

An overview of these methods will highlight the inherent

drawbacks of these conventional breathing tests for characterizing the early and
subclinical forms of COPD – another potential reason the prevalence of unerdiagnosis
and undertreatment of COPD is so high.

1.5

Pulmonary Function Tests

Established methods for measuring pulmonary function focus on the assessment of
expiratory flow volumes through spirometry, lung volumes through plethysmography and
the diffusing capacity of the lungs.

1.5.1

Spirometry

Spirometry tests measure the volume of air an individual inhales or exhales as a function
of time. Spirometry can be used to measure expiratory volumes and flow, although
expiratory volumes are diagnostic for COPD. In particular, the spirometry measurements
of the forced expiratory volume in one second (FEV1) and the forced vital capacity
(FVC) are the two most widely used measurements. FVC is the maximal volume of air
that can be forcefully exhaled from maximal inspiration while FEV1 is the maximal
volume of air that is exhaled in just the first second of a forced expiration maneuver.
The American Thoracic Society (ATS) and European Respiratory Society (ERS) have
collaborated to publish standards for which spirometry testing worldwide should follow
when collecting measurements (57). First, since spirometry is the diagnostic test for both
Asthma and COPD, measurements should always be collected by a trained and certified
technician. Second, the spirometry test to measure FEV1 and FVC is broken down into
three distinct phases: 1) Maximal inspiration, 2) a ‘blast’ of exhalation and 3) continued
exhalation until the end of the test. Third, for the test to be considered acceptable, a
minimum of three forced expiration maneuvers repeatable to within 0.15L of each other
must be performed. Lastly, ATS and ERS specify that the National Health and Nutrition
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Examination Survey (NHANES III) reference standard equations be used to provide
appropriate percent predicted spirometry values based on sex, age, height and ethnicity
(58). This allows measurements to be recorded on a ‘percentage predicted’ (%pred) scale
from 0% to 100% (or higher) instead of interpreting raw volume measurements that vary
greatly depending age, sex, height and ethnicity.
The global initiative for chronic obstructive lung disease (GOLD) has deemed spirometry
as the diagnostic tool for COPD and grading disease severity (1). According to GOLD
guidelines, assessing airflow limitation in an individual should be carried out after the
administration of a short-acting inhaled bronchodilator. A post-bronchodilator FEV1
consistently below 70% of the FVC (FEV1/FVC < 70%) indicates that irreversible
airflow limitation is present which warrants a COPD diagnosis. Once an individual’s
measurements fall below the FEV1/FVC < 70% threshold, their severity of airflow
limitation is graded based on FEV1 percent predicted. There are 4 grades of COPD
disease severity as shown in Table 1-3 and severity increases with each grade.

Table 1-3. Grading of COPD severity based on post-bronchodilator spirometry
GOLD Grade
Severity
FEV1/FVC < 70% and GOLD 1
Mild
FEV1%pred ≥ 80%
GOLD 2
Moderate
50% ≤ FEV1%pred < 80%
GOLD 3
Severe
30% ≤ FEV1%pred ≤ 50%
GOLD 4
Very Severe
FEV1%pred < 30%
GOLD: Global initiative for chronic obstructive lung disease, FEV 1: Forced
expiratory volume in one second, FVC: Forced vital capacity, %pred: Percent of
predicted value

1.5.2

Plethysmography

Plethysmography is used to measure lung volumes. Similar to spirometry, the ATS and
ERS have specified guidelines (59) for measuring eight lung volumes as shown in Figure
1-6. The inspiratory reserve volume (IRV) is maximum volume that can be inhaled from
the end of normal inspiration. The tidal volume (TV) is the volume of air an individual
inhales or exhales during normal ‘tidal’ breathing. The expiratory reserve volume (ERV)
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is the volume of air that can be exhaled from end-expiration of tidal breathing. The
inspiratory vital capacity (IVC) is the volume of air that can be moved in and out of the
lungs during full inspiration and full expiration. The residual volume (RV) is the amount
of air or gas that remains in the lungs after maximal expiration. The inspiratory capacity
(IC) is the maximum amount of air that can be inhaled from expiration during tidal
breathing. The functional residual capacity (FRC) is the sum of RV and ERV, it is the
amount of air remaining in the lungs at end expiration of tidal breathing. Finally, the
total lung capacity (TLC) is the volume of air in the lungs after maximal inspiration.
Figure 1-6 shows an inspiratory – expiratory curve with all lung volumes labelled.

Figure 1-6. Inspiratory – expiratory curve showing lung volumes measured by
plethysmography.
IRV: Inspiratory reserve volume, TV: Tidal volume, ERV: Expiratory reserve volume,
IVC: Inspiratory vital capacity, RV: Residual volume, IC: Inspiratory capacity, FRC:
Functional residual capacity, TLC: Total lung capacity

1.5.3

Diffusing Capacity of the Lung

The diffusing capacity of the lung for carbon monoxide is commonly used to evaluate
pulmonary microcirculation and diffusion of gases across the alveolar – capillary
membrane. There are two terms used for this measurement; the diffusing capacity for
carbon monoxide (DLCO) and the transfer factor for carbon monoxide (TLCO). While
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both are acceptable, there is no concrete consensus as to which term is the correct one,
although it has been suggested, but not agreed upon, that TLCO is more appropriate
because the measurement does not solely reflect diffusion (60). Throughout the rest of
this Thesis the DLCO term will be used when referring to this measurement.
To measure diffusing capacity a trained technician coaches an individual through a
maneuver involving 1) full exhalation to RV, 2) maximum inhalation to TLC, 3) a ~ 10
second breath-hold at TLC and 4) exhalation (61). During the inhalation step the test
subject will inhale a gas mixture of helium (~10%), carbon monoxide (~0.3%) and room
air (~85-90%). During the breath-hold step the carbon-monoxide and helium diffuse
across the alveolar-capillary membrane throughout the lung. Finally, after the breathhold the residual carbon-monoxide and helium is expired and this concentration is
compared to the amount that was inhaled to estimate the amount of carbon monoxide that
diffused into the pulmonary circulation. One important consideration when collecting
DLCO measurements is that the first bolus of air expired after the breath-hold was
predominantly in the ‘anatomical dead-space’ of the large and central airways where gas
exchange does not occur. Therefore, technology for measuring DLCO discards this deadspace air (the volume of which is known through an equation: 2.2ml • kg body weight)
and only collects the air which was in contact with the respiratory zone. In-line with the
standardization of spirometry and plethysmography, the ATS and ERS have specified
standards for the collection of DLCO – TLCO measurements as well (61).

1.6

Measuring Exercise Capacity and Pulmonary Symptoms

Measuring exercise capacity with a walk test and breathlessness and pulmonary
symptoms through questionnaires can be used along with pulmonary function tests to
better understand the impact of pulmonary function on daily activity.

1.6.1

The Six-Minute Walk Test

The six-minute walk test (6MWT) is an exercise test that is designed to measure the
distance an individual can walk on a flat surface in six minutes (62). The test is supposed
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to reflect the exercise capacity of activities a person would experience in their daily lives.
Importantly, the results of the six-minute walk test, the six-minute walk distance
(6MWD) in COPD patients have been shown to be reproducible, correlate with frequency
of exacerbation episodes and mortality in COPD (63).

1.6.2

The St. George’s Respiratory Questionnaire

The St. George’s Respiratory Questionnaire (SGRQ) is used to measure the impact of
respiratory disease on an individual’s overall health, daily activities and perceived wellbeing (64).

The questionnaire has four scores to rate the different components of

respiratory disease: the symptoms score, the impact score, the activity score and the total
score. For each component score the values range from zero to one-hundred with higher
scores being more severe. Similar to other established measures of pulmonary function,
SGRQ scores in COPD patients have been shown to be reproducible (64-66) and
associated with other measures of pulmonary function (67).

1.6.3

Modified Medical Research Council Dyspnea Scale

The modified Medical Research Council (mMRC) dyspnea scale measures the impact of
breathlessness on an individual’s daily activity. The mMRC uses a straightforward scale
of five grades ranging from 0 (no respiratory disability) to 4 (severe dyspnea with many
limitations) to measure disability due to dyspnea (Table 1-4). It has been found that
mMRC dyspnea scores are related to disease severity and predict all-cause mortality in
COPD patients (68, 69).

Table 1-4. Modified Medical Research Council (mMRC) Dyspnea Scale (Adapted
from ‘Evaluation of Clinical Methods for Rating Dyspnea’(70))
Grade
Description
0
Not troubled with breathlessness except with strenuous exercise
1
Shortness of breath when hurrying on the level or walking up a slight hill
2
Walks slower than people of the same age on the level because of
breathlessness or has to stop for breath when walking at own pace on the
level
3
Stops for breath after walking ~100m or after a few minutes on the level
4
Too breathless to leave the house or breathless when dressing or undressing
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1.7

The Role of Imaging to Study COPD

Although FEV1 serves as the major endpoint for assessing the severity of airflow
limitation and diagnosing COPD, it is clear that spirometry alone cannot fully
characterize the heterogeneity of the disease. As previously mentioned in Section 1.2,
COPD is an umbrella term encompassing large and small airways disease and
emphysematous tissue destruction of the lung parenchyma, and the extent of each of
these abnormalities vary from patient to patient (71).

Therefore, simply measuring

expiratory volumes at the mouth does not provide any regional information on lung
pathophysiology nor indications on the relative contributions of airways disease and
emphysema to lung function decline. In this regard, thoracic computed tomography (CT)
and pulmonary magnetic resonance imaging (MRI) have emerged as robust and reliable
tools for in vivo imaging of COPD. In recent years both CT and MRI have played
important roles in advancing our knowledge on COPD heterogeneity and underlying
pathophysiology and have simultaneously introduced the concept of radiological
phenotyping to COPD to provide better stratification and targeted treatment options
within COPD populations.

1.7.1

High-resolution Computed Tomography of the Lung

Conventional x-ray imaging is inherently limited to providing two-dimensional (2D)
images of three-dimensional (3D) anatomical structures. CT technology overcomes this
drawback by rotating the conventional x-ray tube around a patient to construct a 3D
volume of the region of interest. The 3D volume created from the CT scan is made up of
voxels (volume elements), each of which has a Hounsfield Unit (HU) associated with it
based on the attenuation of x-rays through that region. The HU scale uses water as a
reference, where water has a HU = 0, air has HU = -1000 and solid structures such as
bone have HU > +1000 (72). Ultimately, CT provides 3D images of the anatomy based
on density and since many tissues and organs within the body have different densities,
good contrast can be achieved with conventional CT imaging.
As described in Section 1.2, one pathophysiological phenotype of COPD is emphysema.
When the alveoli are destroyed, alveolar ducts and sacs coalesce and the distal airspaces
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enlarge to ultimately cause a decrease in parenchymal density. Therefore, on CT images,
emphysematous regions within the lung have attenuation values close to that of air (≤950HU) and appear darker than the higher density parenchyma surrounding them.
Extensive research and debate is ongoing to determine an optimal HU threshold to define
emphysema on CT.

Currently, the most commonly used HU threshold to identify

emphysema is -950HU, whereby regions of the lung with attenuation ≤-950HU are
considered to be emphysematous. This threshold has been confirmed to correspond to
emphysematous lesions on pulmonary histology of macroscopic (73) and microscopic
(74) emphysema. Figure 1-7 shows emphysematous lung regions ≤-950HU on CT in a
healthy volunteer and a COPD patient. It is important to note that other thresholds are
also in use for the purpose of identifying mild emphysema (-910HU) and gas trapping on
expiratory CT (-856HU) (75-77). Another method for quantifying emphysema on CT is
focused on the HU below which fifteen percent of all x-ray attenuation values fall (PD15).
Using this method, the measurement of emphysema is a HU not a percent of the lung as it
is with the threshold cutoff. While both the threshold and percentile methods are widely
used and considered appropriate for cross-sectional studies, the 15th percentile analysis is
recommended for longitudinal studies because it is less sensitive to changes in CT
scanner technology that may occur over time (78). At the same time, methods for
quantitatively describing the size and distribution of emphysematous clusters (regions of
RA950) on CT have also emerged (79). The value of measuring these low attenuation
clusters (LAC) relies on the concept that emphysematous lesions tend to coalesce and
form larger clusters (bullae) as emphysema progresses.

The total number of

emphysematous clusters (clusters of voxels <-950HU) is plotted against the cluster size
in the log-log domain. The slopes of the plots can then be described by the power law
and the value of the slope is obtained by linear regression and used to quantify the LAC.
In this manner subjects with early or mild forms of emphysema have smaller and more
emphysematous clusters and subsequently have a more negative LAC (higher slope)
while COPD subjects who have larger emphysematous bullae and fewer total clusters
have a more positive LAC (flatter slope).
Along with regionally mapping and quantifying emphysema within the lung, thoracic CT
is also used to evaluate airway structure. By measuring the cross section of the airways,
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measurements of the airway lumen and wall thickness can be assessed.

The

measurements of airway wall area percent (WA%) and lumen area (LA) were the first to
be shown to significantly correlate with measures of lung function in COPD patients
where the airway wall thickness increased and airway lumen area decreased as FEV1
decreased (80). However this early work focused predominantly on measuring the large
and central airways which do not reflect the main site of airflow obstruction in COPD.
Subsequent studies have transitioned to measuring higher generation airways (81),
counting the number of airways visible on CT (82) and estimating small airway
dimensions (83). Figure 1-7 shows CT airway trees in a healthy volunteer and COPD
patient. Visibly, the COPD subject has few and thinner airways than the healthy subject.

Figure 1-7. Thoracic CT and segmented airway tree of a healthy volunteer and a
COPD patient.
Emphysema, or areas of the lung ≤-950HU on CT are shown in yellow. Compared to the
healthy subject, the COPD patient has more severe emphysema and fewer airways
present as measured by CT.
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Lastly, an important consideration for using CT to evaluate and monitor COPD is the
radiation dose associated with each scan. In COPD, longitudinal monitoring is necessary
for evaluating disease progression or response to treatment or surgery. The radiation
dose associated with a single conventional chest CT is estimated to be ~7 mSv which is
equivalent to 2.8yr of natural background radiation (84). Therefore, if CT is the only
option available for pulmonary imaging at a specific centre or within a region, it is clear
that careful planning is required in order to longitudinally image a COPD patient because
of the risk of radiation-induced cancers from cumulative dose of serial CT scans. One
potential solution to the burden of radiation dose associated with chest CT scanning is the
further development of iterative reconstruction techniques and their incorporation into
clinical use instead of, or along with, filtered back projection (FBP) reconstruction
approaches. Unlike FBP which is rapid and requires little computational processing,
iterative approaches correct image data using a variety of models and require long
computing times (85). Current iterative reconstruction techniques can produce thoracic
CT images of similar or better quality (based on signal-to-noise ratio) using a lower dose
than images acquired using FBP (86). The downside is that the reconstructive approach
used during acquisition influences quantitative (and potentially qualitative) measurements
of emphysema and airways disease. Therefore, scientists and clinicians would need to
meet and overcome the challenge of standardizing reconstructive approaches across
academic centres where large-scale and long-term follow-up studies are ongoing in order
to compare and concatenate data.

1.7.2

Nuclear Medicine: Ventilation Scintigraphy

Single photon emission computed tomography (SPECT) is a tool that can provide
information of pulmonary ventilation and perfusion through the use of radiolabeled
aerosols and gases.

In SPECT, gamma radiation from an injected or inhaled

radiopharmaceutical is received by detectors which convert the radiation into visible light
that can be used to produce an image based on its spatial and quantitative information.
For pulmonary ventilation imaging using SPECT, a radiolabeled aerosol or gas inhaled at
the mouth during tidal breathing is used to provide gamma energy necessary to create
ventilation images.

The most important consideration for ventilation imaging with
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SPECT is the choice of which radiotracer to use. Within the past thirty years

99m

Tc-

Technegas aerosol has emerged as the most widely used radiotracer for pulmonary
SPECT. Other popular radiotracers used for pulmonary SPECT include
with diethylaminetriaminepentacetic acid (DTPA),

133

Xe, and

99m

Tc labelled

81m

Kr. Unlike Technegas

aerosol however, the laborious and expensive production along with their nuclear and
133

physical properties have limited their use in ventilation studies.

Xe has a half-life on

the order of days and low gamma radiation energy which has deterred its routine use.
81m

Kr on the other hand has an optimal gamma energy and short biological half-life

making it suitable for ventilation imaging.

However the availability of rubidium

generators required to produce the metastable Kr are limited, expensive and require
almost daily replacement so the production of

81m

Kr for ventilation imaging is often not

feasible. At the same time an important consideration acknowledged by physicists and
clinicians using these techniques was the size of these radiotracers being inhaled.
Particles larger than 2µm are predominantly deposited in the large and central airways
whereas particles <1µm are deposited in the distal alveoli, therefore larger size
radiotracers (>1µm) do not provide much information about distal lung regions when
used for ventilation imaging.

99m

Tc-DTPA particles are 1µm-2µm in size which has

made it a popular alternative to 99mTc-Technegas aerosol. Technegas labelled with 99mTc
is a newer solid aerosol type radiotracer with particle sizes ranging from 0.005µm-0.2µm
(87). The small size combined with Compton-scattering predominant gamma energy and
easy and inexpensive production have made it the radiotracer of choice for ventilation
scintigraphy.

Several studies have compared the common radiotracers used for

ventilation scintigraphy and have consistently reported superior results with
Technegas (88-90). Importantly, both

99m

Tc-Technegas and

99m

Tc-

81m

Kr have been shown to

produce similar quality ventilation images (91), however Technegas is favored due to its
inexpensive and efficient production.
SPECT imaging of pulmonary ventilation has been used extensively for the assessment
and diagnosis of pulmonary embolism but has not been widely exploited to evaluate and
characterize COPD. Unlike CT (Section 1.7.1) techniques, SPECT pulmonary structurefunction relationships and measurements in COPD are not as well established which has

29

limited its routine use in clinical practice and subsequently in large-scale epidemiological
COPD studies.

1.7.3

Pulmonary Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) is a tool that provides high-resolution images of the
anatomy based on the magnetic properties of the protons in a tissue. Unlike CT, MRI
does not require the use of ionizing radiation from x-ray beams or any other forms of
contrast making it an attractive option for pulmonary imaging at first glance. However,
the physical properties of the lungs are very different from other tissues in the body and
pose unique challenges to generate clinically useful pulmonary images using
conventional MRI methods.
When a sample containing protons is placed inside an MRI machine, the nuclear
magnetic moment of the protons within the sample or tissue align with the magnetic field.
To collect the signal necessary to generate an image a radiofrequency pulse (RF) is
applied which tilts the protons nuclear magnetic moments away from its axis in the
magnet. After this, the proton magnetization returns to its equilibrium state through
longitudinal (T1) and transverse (T2) components of relaxation. Relaxation causes a
changing magnetic field which induces a voltage in a receive coil (Faraday’s Law of
induction) that is spatially encoded to produce an MR image. The signal intensity in an
MR image is proportional to the proton density of the sample being imaged (92).
The lungs have a tissue density that is approximately ten times lower than other tissues in
the body, meaning they also have ten times lower proton density per gram of tissue
compared to other tissues as well (93). Therefore, assuming perfect imaging conditions,
the achievable MRI signal of the lungs is still ten-fold weaker than other tissues.
Secondly, the lungs are almost entirely made up of air – tissue boundaries. Oxygen in
room air is paramagnetic and in tissue it is diamagnetic and therefore there is a net
magnetic susceptibility difference at each and every air – tissue boundary. This magnetic
susceptibility difference spread over millions of air – tissue boundaries produces a highly
inhomogeneous local magnetic field in the lungs which causes extremely fast relaxation
of the protons after the initial RF pulse and associated with this, rapid signal decay. With
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the combination of a low proton density and highly inhomogeneous local field within the
lungs, conventional MRI methods such as those applied clinically to tissues like the brain
or liver do not produce clinically relevant images of the lung parenchyma or airways.
Until recently, this has limited the application of MRI to evaluate COPD predominantly
to perfusion and hemodynamic studies using contrast-enhanced techniques (94). Figure
1-8 shows conventional MR images in a healthy individual and a COPD patient. It is
visibly obvious that the proton MR image does not provide a wealth of information on
pulmonary parenchymal structure or function. However, an emerging series of MRI
pulse sequences, called ‘ultra-short echo time’ (UTE) pulse sequences have been
developed (95) and optimized to capture the rapidly decaying MR signal in the lung
before it is lost. These UTE sequences are different from conventional proton MRI
sequences in that they combine a fast RF pulse and rapid data acquisition steps to
measure relaxation before it is completely lost. Recent research with UTE sequences
suggests that UTE pulmonary MRI is capable of producing images of similar quality to
thoracic CT (96).
Pulmonary MRI with hyperpolarized noble gases (3He and

129

Xe) is another method of

providing high-resolution images of the lungs that has gained traction in research settings
over the past few decades. This MRI method is based on previous nuclear physics
research (97) that recognized the potential for capturing MR signal from polarized 3He
and

129

Xe in the gaseous phase. This previous work showed that through a technique

called ‘spin-exchange optical pumping’, collisions between 3He or

129

Xe with gaseous

rubidium could transfer angular momentum to the noble gas nuclei amplifying the
achievable MR signal with these gases. In the early stages this work focused on using
129

Xe but became more common in 3He due its ease in MR imaging compared to

129

Xe

(98). Currently however this area of MRI research is transitioning back to 129Xe owing to
its lower cost and higher natural abundance over 3He. Once the noble gas of choice is
hyperpolarized, to collect images of the lungs an individual must inhale the gas and
perform a short breath-hold while an MRI sequence collects the data. Several methods
exist for doing this but the most commonly used method is to coach the patient to breathe
the gas in from a bag (99). After a subject inhales the noble gas from the bag, there is an
option of collecting ‘static-ventilation’ images or diffusion-weighted MR images, both of
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which provide distinct measurements on lung pathophysiology. Figure 1-8 shows 3He
(cyan) and

129

Xe (purple) static-ventilation MR images in a healthy volunteer and a

COPD patient. Compared to the healthy subject, the COPD patient exhibits markedly
greater ventilation heterogeneity on both 3He and 129Xe images.

Figure 1–8. 1H, 3He and 129Xe MRI of a healthy and COPD patient.
Reproduced with permission from ‘Imaging Evidence of the Relationship Between
Atherosclerosis and Chronic Obstructive Pulmonary Disease’ Imaging in Medicine; DOI:
10.2217/iim. 13.70, 2013 (47).
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Static-ventilation hyperpolarized noble gas images show which regions of the lung
participate in ventilation. Several studies have confirmed that static-ventilation MR
images show that healthy non-smoking subjects without airflow limitation exhibit
homogeneous ventilation signal throughout their lungs (shown in Figure 1-8 and 1-9)
(100, 101). In contrast, in subjects with COPD, it has been observed (101-104) that
ventilation signal is heterogeneous with many regions within the lung not receiving any
ventilation at all. Importantly, these regions of signal void or ‘ventilation defects’ have
also been shown to be reproducible over time (105). Ventilation defects have become
central to image analysis techniques for quantifying disease on noble gas MR images
since they are speculated to represent regions of the lung with underlying disease.
Initially, visual grading of ventilated and unventilated regions was used to evaluate
disease severity from noble gas MR images (101), but more recently, methods that
normalize the volume of ventilation defects to the total thoracic cavity volume to
calculate a ventilation defect percent (VDP) have become more common (106).
Diffusion-weighted MRI is a tool that provides information on the movement of nuclei in
a sample. With regards to hyperpolarized noble gas MRI of the lung, diffusion-weighted
methods have been harnessed to provide details on alveolar microstructure (107). After
the gas is inhaled, diffusion-weighted MRI pulse sequences can be applied to sensitize
the data acquisition to the diffusion of gas within the alveoli. Over a pre-specified timeinterval, the gas nuclei move within the airspaces, bouncing off the alveolar walls.
Diffusion-weighted sequences provide information pertaining to the distance the nuclei
travel per unit time within the airspaces. Ultimately, this type of imaging is used to
calculate the apparent diffusion coefficient (ADC) that reflects the amount of restriction
of the gas nuclei in the distal lung airspaces. These are valuable measurements for
assessing structural changes to the lungs in COPD because emphysematous destruction is
characterized by airspace enlargement. Previous work (107-110) has established that
noble gas MRI ADC measurements are correlated with lung function in COPD and
importantly, the ADC measures of microstructure seem to be more sensitive to early- or
pre-clinical changes to lung structure than conventional pulmonary function testing and
CT (111).
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Figure 1-9 shows 3He static-ventilation and diffusion-weighted MR images in a healthy
subject and four COPD patients with increasing grades of severity.

In the healthy

subject, the ventilation pattern is homogeneous throughout the lung with the lung
periphery and contour of the diaphragm clearly visualized by the 3He gas. Similarly, in
the healthy subject the ADC map shows low ADC throughout the lung. In contrast, in
the COPD subjects the ventilation signal becomes increasingly heterogeneous with more
and larger ventilation defects visible in more severe grades of disease. Concomitant with
the increasing ventilation heterogeneity, ADC maps get brighter (worse) indicative of
worse microstructural emphysema with increasing disease severity.
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Figure 1-9. Static-ventilation (SV) and apparent diffusion coefficient (ADC) 3He
MR images in a healthy volunteer and four COPD patients with increasing severity
of airflow limitation.
Reproduced with permission from ‘Imaging Evidence of the Relationship Between
Atherosclerosis and Chronic Obstructive Pulmonary Disease’ Imaging in Medicine; DOI:
10.2217/iim. 13.70, 2013 (47).
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1.8

COPD Phenotypes

It is now known that the relative contributions of airways disease and emphysema on
airflow limitation vary greatly from patient to patient (71).

With this emerging

knowledge, phenotyping COPD patients based on underlying pathophysiology has
become an attractive concept as it would allow scientists and clinicians to stratify patients
into distinct groups to study clinical features and form targeted treatment plans. At the
same time, advances in quantitative pulmonary imaging with CT and MRI have become
the methods of choice for identifying distinct COPD phenotypes. Since imaging is well
suited to measure airway dimensions and quantify the severity of emphysema, imaging
studies have focused on three phenotypes in particular; an emphysema – predominant
phenotype, an airways disease – predominant phenotype and a mixed airways disease –
emphysema phenotype.

Whether or not an individual phenotype predicts worse

pulmonary function or outcomes is an area of active research but studies have shown
distinct clinical features among different phenotypes (112). For example, it has been
shown that patients with predominant emphysema have worse exercise capacity, tend to
have more exacerbations and have more rapid disease progression than patients with
airways disease (113, 114). While it has also been found that subjects with predominant
airways disease exhibit worse overall symptoms including coughing and wheezing (114).
However, a combination of both airways disease and emphysema appears to be
associated with the highest risk of exacerbations and debilitating respiratory symptoms
(113). Interestingly the development of a predominant phenotype does not appear to be
related to smoking history, whereby patients who have the same number of pack years
may develop either emphysema or airways disease or a mix of the two. Given this, it
seems likely that there is an important genetic component which determines the
phenotype individuals will develop during the course of the disease and several studies
have provided evidence of this (115, 116).
Along with whole-lung phenotyping methods, ‘regional’ emphysema phenotyping studies
have also emerged (117-120). These studies are motivated by the fact that patients with
the same amount of emphysema show high heterogeneity in clinical features.
Unfortunately, phenotyping patients based on the spatial location of emphysema has
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yielded inconsistent results and the clinical relevance of emphysema distribution is still
not entirely clear.
Given that smoking history is not associated with the development of a particular COPD
phenotype over another, it seems plausible that the different pathophysiological and
biochemical construction of the lungs between males and females might be partly
responsible for phenotype heterogeneity among cohorts. Currently, more females than
males have COPD. It is not known for sure what has caused the drastic increase in
COPD diagnoses among females over the past few decades, but one hypothesis attributes
the rising incidence of COPD among females to their steadily increasing use of cigarette
smoking since World War II (121).

In line with this theory, biochemical and

epidemiological studies suggest that female lungs are more susceptible to the toxic effects
of cigarette smoke than males (122). With regards to COPD phenotypes, it has been
found that females predominantly suffer from airways disease while males have more
emphysema (123, 124).

A better understanding of the connection between COPD

phenotype and sex might serve as a valuable endpoint to treat COPD, and sophisticated
imaging techniques may provide valuable information on this relationship in the future
(123, 125, 126).
The two major goals of COPD therapy are 1) to alleviate respiratory symptoms and 2) to
prevent or avoid exacerbation episodes. Phenotyping COPD patients has the potential to
do both of these things. However, many questions remain unanswered with regards to
the origins of COPD phenotypes in pre- or sub-clinical disease. It seems likely that if we
could develop a better understanding of the origins and progression of lung disease
phenotypes as they occur in pre- or subclinical stages, we would be able to create patientspecific treatment plans to better satisfy the two major goals of COPD therapy.

1.9

Thesis Hypothesis and Objectives

The prevalence and underdiagnosis of COPD and shortcomings of COPD treatments may
be attributable to the paucity of information that exists on early- or subclinical structural
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and functional changes to the lungs of ex- or current-smokers. This may be partly due to
the fact that imaging studies have focused on cohorts with diagnosed and established
COPD to provide a better understanding of pathophysiology in disease and less on
susceptible individuals without airflow limitation (127). Furthermore, most histological
investigations on the underlying origins of disease and disease progression have also been
biased to post-mortem or post-surgical specimens of excised lung tissue from localized
regions of the lung (13, 128, 129).

Therefore, there is little information available

regarding susceptible groups of ex-smokers without evidence of airflow limitation. This
would help to provide a better understanding on pre- or subclinical COPD
pathophysiology and perhaps strategies on how to treat it. Pulmonary imaging with
hyperpolarized 3He MRI and CT can provide high-resolution images and quantitative
measurements of pulmonary ventilation, alveolar microstructure and macroscopic
emphysema. Therefore, the overarching goal of this thesis was to exploit sensitive and
direct pulmonary imaging measurements in ex-smokers without airflow limitation to
better characterize and phenotype early- or subclinical forms of COPD.
As described in Section 1.3, there is strong evidence to support underlying mechanistic
links between COPD and cardiovascular disease. Studies investigating the relationship
between comorbid vascular and lung disease have predominantly focused on either
cardiovascular disease or COPD patients who have a long-standing diagnosis of either
condition. Therefore, while it has been established that a relationship between lung
function decline and cardiovascular disease exists, little is known about the pre- or
subclinical origins of this comorbid relationship.

Furthermore, few studies have

exploited pulmonary structural and functional imaging with MRI and CT to characterize
whether a particular COPD phenotype is associated with cardiovascular disease
complications. Hence, the aim of Chapter 2 was to evaluate 3He MRI, CT and carotid
ultrasound data from ex- and never-smokers without airflow limitation or diagnosis of
cardiovascular disease to provide a better understanding of the pathophysiological link
between subclinical COPD and vascular disease. We hypothesized that ex- and neversmokers without airflow limitation would show pulmonary imaging evidence of airways
disease that would be related to subclinical atherosclerosis independently of smoking
history.
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Findings in Chapter 2 showed that ex-smokers without spirometry evidence of airflow
limitation showed evidence of pre- or subclinical lung disease on 3He MR images. In that
study, ex-smokers without airflow limitation had significantly higher 3He VDP than
never-smokers but were not different with regards to pulmonary function test
measurements. This suggested that ex-smokers without airflow limitation have pre- or
subclinical airways disease and/or emphysema that is apparent on 3He MRI but not with
spirometry or other breathing tests. In Chapter 3 our objective was to improve our
understanding of the underlying lung disease phenotype that cause 3He ventilation defects
in ex-smokers without airflow limitation by using regional 3He MRI ventilation and
diffusion-weighted

measurements

and

regional

CT

airway

and

emphysema

measurements. Owing to research that suggested airway obstruction and obliteration is
the dominant COPD phenotype in mild disease, we hypothesized that 3He ventilation
defects in ex-smokers without airflow limitation would be spatially and quantitatively
related to airway remodeling but not emphysema.
The study in Chapter 3 showed that hyperpolarized 3He ventilation heterogeneity is
present in ex-smokers without airflow limitation and the underlying etiology of
ventilation defects in such subjects could be phenotyped using regional MRI and CT
measurements. We therefore wanted to use regional MRI and CT measurements to
phenotype ex-smokers with a COPD diagnosis. It is widely known that ex-smokers with
COPD exhibit ventilation defects and emphysema throughout the lung, however the
clinical relevance of the spatial location of ventilation heterogeneity and emphysema
within the lung is not completely understood.

Our objective in Chapter 4 was to

phenotype ex-smokers with COPD based on the apical-to-basal distribution of ventilation
abnormalities and emphysema to better understand how regional phenotypes change as
COPD progresses. Data presented in Chapter 4 show that with increasing disease
severity there is a basal-to-apical progression of ventilation abnormalities and an apicalto-basal progression of emphysema, suggestive of distinct apical-basal lung COPD
phenotypes.
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Lastly, Chapter 5 will provide an overview and summary of the findings and conclusions
from Chapters 2-4, address study specific and general limitations of the imaging studies
presented in this thesis and provide motivation for future imaging studies in COPD.
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CHAPTER 2
To provide a better understanding of the mechanistic links between pre- or sub-clinical
atherosclerosis and chronic obstructive pulmonary disease we acquired threedimensional carotid ultrasound and pulmonary hyperpolarized 3He magnetic resonance
imaging measurements in ex- and never-smokers without clinical evidence of vascular or
pulmonary disease.
The contents of this chapter have been previously published in COPD: Journal of
Chronic Obstructive Pulmonary Disease (JCOPD) and permission to reproduce the
article was granted by Taylor and Francis Publishing Group on behalf of JCOPD and is
provided in Appendix D.
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2

Pulmonary Abnormalities and Carotid Atherosclerosis in
Ex-Smokers Without Airflow Limitation

2.1

Introduction

Cardiovascular disease is the single largest cause of hospitalization in patients with mild
and moderate chronic obstructive pulmonary disease (COPD), and after lung cancer, the
leading cause of death (1, 2).

In addition, in COPD patients, there is a dose-response

relationship for pulmonary structure-function abnormalities with carotid atherosclerosis
(3-8), coronary artery calcification (9-12) and vascular dysfunction (13-16). While these
studies have shown the presence of cardiovascular disease in patients with COPD that
cannot be explained by smoking history alone (3, 4, 6-8, 17), the mechanisms by which
cardiovascular disease may be accelerated in COPD are not clear, nor is our
understanding of these relationships in early or milder subclinical stages.
While the diagnosis and monitoring of COPD is mainly based on spirometry
measurements of airflow obstruction (18, 19), such measurements cannot fully
characterize the pathophysiological changes that occur in obstructive lung disease (20).
These include regional small-airways disease and microstructural changes in the terminal
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bronchi and parenchyma. In this regard, regional imaging measurements provided by
hyperpolarized 3He magnetic resonance imaging (MRI) are highly sensitive to pulmonary
abnormalities in asymptomatic ex-smokers (21, 22) and never-smokers with second-hand
smoke exposure (23). Similarly, airway morphology and parenchyma density x-ray
computed tomography (CT) measurements from the ECLIPSE (24) and COPDGene (25)
studies showed the utility of CT phenotypes (26) for stratifying COPD patients (27-29).
Cardiovascular disease, predominated by large vessel atherosclerosis, is associated with
obstructive lung disease (30, 31) that can be regionally and quantitatively evaluated using
carotid ultrasound (US). The burden of atherosclerosis can be quantified (32) using
carotid intima-media thickness (IMT) measurements and this is believed to reflect medial
hypertrophy and intima abnormalities, and importantly, IMT correlates with
cardiovascular outcomes (32, 33). In a similar manner, three-dimensional ultrasound
(3DUS) carotid atherosclerosis measurements (34) of carotid wall and plaque
abnormalities are sensitive predictors of cardiovascular risk (35-37) and in some patients,
these provide a better estimate of plaque burden and risk (37).
There is a paucity of direct evidence relating subclinical lung disease and atherosclerosis
in otherwise healthy ex-smokers. To provide a better understanding of the relationship
between carotid atherosclerosis and pulmonary abnormalities common to ex-smokers
with obstructive lung disease, our objective was to acquire highly sensitive pulmonary
and carotid 3D imaging measurements in never- and ex-smokers with normal pulmonary
function. We hypothesized that quantitative 3D imaging phenotypes would provide a
way to tease out potential relationships for early or mild sub-clinical emphysema or
airways disease with atherosclerosis in subjects at risk.

2.2
2.2.1

Materials and Methods
Study subjects

Ex-smokers (≥10 pack-year smoking history) without symptoms or a physician-diagnosis
of COPD and normal spirometry (FEV1/FVC ≥ 70%) as well as never-smokers (<1 packyear smoking history) with no history of chronic respiratory or significant or uncontrolled
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cardiovascular disease between 50-90 years of age were recruited.

These subjects

enrolled in response to advertisements placed within the community and at local healthy
aging exercise and atherosclerosis prevention clinics.

All subjects provided written

informed consent to a protocol approved by a local research ethics board and Health
Canada.

2.2.2

Spirometry and plethysmography

Spirometry, plethysmography and diffusing capacity of carbon monoxide (DLCO)
measurements were performed according to the American Thoracic Society guidelines
(19). An ndd EasyOne spirometer (ndd Medizintchnik AG, Zurich, Switzerland) was
used to measure FEV1 and FVC. Whole body plethysmography was performed for lung
volumes and DLCO measurements were recorded using a gas analyzer (MedGraphics
Corporation, St. Paul, Minnesota, USA).

2.2.3

Imaging

High-resolution B-mode ultrasound (US) images were acquired (ATL HDI 5000; Philips,
Bothel, Washington, USA) as previously described (38) using a 50 mm L12-5 MHz
transducer (frequency=8.5 MHz, Philips).

Gain, focal points and time-depth

compensation were optimized by the sonographer taking into consideration neck size,
carotid anatomy and tissue depth. Two dimensional images were reconstructed into a 3D
volume as previously described (39, 40). MRI was performed on a whole body 3.0 Tesla
Discovery 750MR (General Electric Health Care, Milwaukee, Wisconsin, USA) MRI
system. 1H and 3He MRI were performed as previously described (41) with the subject in
an inspiration breath-hold (FRC+1L). For ex-smokers only, computed tomography (CT)
was acquired within 10 minutes of MRI and at the same lung volume (FRC+1L) to
ensure similar parenchymal distension in a method previously described (41).

2.2.4

Image analysis

Carotid IMT was measured from the longitudinal plane of the 3DUS volume using
Prowin 24.0 software (Medical Technologies International Inc., Palm Desert, California,
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USA) as previously described (42). Carotid total plaque volume (TPV) and vessel wall
volume (VWV) were measured as previously described (43).
3

He MRI ventilation defect percent (VDP) and apparent diffusion coefficients (ADC)

were measured using semi-automated segmentation generated using custom-built
software in MATLAB R2007b (The Math-works Inc., Natick, Massachusetts, USA) as
previously described (44, 45). CT volumes were analyzed using Pulmonary Workstation
2.0 (PW2, VIDA Diagnostics Inc., Coralville, Iowa, USA). Pulmonary CT images were
analyzed for airway dimensions including wall area percent (WA%), lumen area (LA)
and standardized wall thickness of airways with an inner perimeter of 10 mm (Pi10) (46).
In addition, the relative area of the lung with CT attenuation values less than -950HU
(RA950) and total airway count were also measured using PW2.

2.2.5

Statistics

Normality of data was tested using the Shapiro-Wilk test and when significant, the MannWhitney U test for nonparametric data was performed using SPSS Statistics V20.0 (SPSS
Inc., Chicago, Illinois, USA). Unpaired two tailed t-test comparisons were performed
using GraphPad Prism V4.0 (GraphPad Software Inc., California, USA) and Welch’s
correction used when the F test for equal variances was significant.

The Holm-

Bonferroni correction (47) was performed for multiple unpaired t-test comparisons.
Multiple regression analyses were performed in SPSS to determine the relationship
between carotid US measurements with
parameters.

3

He MRI VDP and pulmonary function

Partial correlations were computed using SPSS. Multiple regression and

correlation models were adjusted for age, BMI and DLCO since these parameters are
established risk factors for cardiovascular and pulmonary diseases (8, 48). Results were
considered significant when the probability of two-tailed type I error was less than 5%
(p<0.05) and summary data are presented as mean ± SD unless otherwise indicated.
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2.3

Results

As shown in Table 2-1, 61 subjects including 27 ex-smokers (73±9yr, 18 male) and 34
never-smokers (72±6yr, 18 male) were evaluated. Except for BMI, (p=0.001) there were
no significant differences between subject groups for demographic characteristics.

56

Table 2-1. Demographic, pulmonary function, thoracic CT and carotid
ultrasound data for all study subjects
Ex-smokers
Never-smokers
Significance of
n=27
n=34
Difference p*
Age yrs (±SD)
73 (9)
72 (6)
1.0
Male n
18
18
BMI kg·m-2 (±SD)
30 (3)
27 (3)
0.001
Pack years (±SD)
27 (18)
Years quit (±SD)
26 (6)
FEV1%pred (±SD)
106 (16)
106 (18)
0.89
FVC %pred (±SD)
97 (13)
101 (17)
1.0
FEV1/FVC (±SD)
81 (7)
77 (5)
0.36
TLC %pred (±SD)
102 (14)
106 (15)
1.0
IC %pred (±SD)
107 (14)
107 (22)
1.0
RV %pred (±SD)
110 (26)
109 (29)
1.0
RV/TLC (±SD)
42 (7)
39 (13)
0.96
Raw%pred (±SD)
115 (72)
76 (34)
0.11
DLCO%pred (±SD)
83 (17)
87 (20)
1.0
2
1
2
ADC cm /s (±SD)
0.29 (0.04)
0.26 (0.03)
0.20
VDP % (±SD)
7 (3)1
3 (2)2
0.001
IMT mm (±SD)
0.84 (0.10)
0.77 (0.09)
0.11
TPV mm3 (±SD)
250 (200)
60 (90)
0.002
VWV mm3 (±SD)
910 (190)3
890 (170)4
1.0
th
5 gen. WA% (±SD)
61 (2)
5th gen. LA mm2 (±SD)
17 (11)
Pi10 mm (±SD)
4.1 (0.17)
RA950 % (±SD)
1.5 (1.4)
Airway Count n (±SD)
127 (35)
BMI: Body mass index, FEV1: Forced expiratory volume in one second, FVC: Forced
vital capacity, TLC: Total lung capacity, IC: Inspiratory capacity, RV: Residual
volume, Raw: Airways resistance, DLCO: Diffusing capacity for carbon monoxide,
ADC: Apparent diffusion coefficient, VDP: Ventilation defect percentage, IMT:
Intima-media thickness, TPV: Total plaque volume, VWV: Vessel wall volume, 5th
gen.: Fifth generation airway, WA%: Airway wall area percentage, LA: Airway lumen
area, Pi10: Standardized wall thickness of airways with an inner perimeter of 10mm,
RA950: Relative area of the lung with attenuation values below -950HU, SD: Standard
deviation, %pred: Percent of predicted value
*Data are Holm-Bonferroni corrected p-values for unpaired t-test comparisons
1
n=26, 2n=29, 3n=22, 4n=30
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Figure 2-1. Representative 3He MRI and 3DUS images for two never-smokers (S1
and S2) and two ex-smokers (S3 and S4). Never-smoker S1 is a 67-year old female
with FEV1=120%, FEV1/FVC=0.77, 3He MRI VDP=3%, TPV=20mm3 and
IMT=0.79mm.
Never-smoker S2 is a 68-year old male with FEV1=93%,
3
FEV1/FVC=0.79, He MRI VDP=2%, TPV=30mm3 and IMT=0.73mm. Ex-smoker S3 is
a 79-year old female with FEV1=88%, FEV1/FVC=0.71, VDP=8%, TPV=500mm3 and
IMT=0.94mm. Ex-smoker S4 is a 85-year old male with FEV1=139%, FEV1/FVC=0.79,
VDP=8%, TPV=340mm3 and IMT=0.96mm. The axial 3DUS image of the common
carotid artery shows the intima-lumen boundary in green and carotid plaque-lumen
boundary in yellow. The longitudinal 3DUS carotid image shows IMT segmentation of
the common carotid artery.
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Figure 2-1 shows 3He MRI centre coronal slices and 3DUS axial and longitudinal images
for representative ex- and never-smokers.

3

He MRI ventilation images show

homogeneous ventilation in never-smokers, whereas there is heterogeneous signal
intensity with visually obvious ventilation defects in ex-smokers. 3DUS axial images
show carotid plaque that is qualitatively greater in the two ex-smokers.
Quantitative results are provided in Figure 2-2 and Table 2-1 that show that the exsmokers subgroup had significantly greater TPV, (250±200mm3, p=0.002) and 3He MRI
VDP, (7±3%, p=0.001) than never-smokers. No significant differences were observed
for VWV (p=1.0), IMT (p=0.11), ADC (p=0.20) or FEV1 (p=0.89). For ex-smokers, CT
mean RA950 (1.5±1.4%), airway wall thickness at an internal perimeter of 10mm (Pi10,
4.1±0.17mm), WA% (61±2%), and LA (17±11mm2) were within normal range as
previously published (49, 50).

Figure 2-2. Imaging phenotypes in asymptomatic ex-smokers and never-smokers.
Ex-smokers have significantly greater: A) TPV (p=0.002) and D) VDP (p=0.001) than
never-smokers. No significant differences were observed for: B) IMT (p=0.11), C) VWV
(p=1.0), E) ADC (p=0.20). Holm-Bonferroni corrected p-values are shown.
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Using previously established age-normalized values for IMT (51), 28 subjects (15 exsmokers and 13 never-smokers, 28/61=46%) exceeded the upper limit of normal for IMT
and 33 subjects (12 ex-smokers and 21 never-smokers, 33/61=54%) had normal IMT. As
shown in Figure 2-3, subjects with abnormally elevated IMT had significantly greater
VDP (p=0.04) than subjects with normal IMT, but the two subgroups were not
significantly different with respect to ADC (p=0.06), FEV1%pred (p=1.0) or DLCO%pred
(p=0.85).

CT measurements for the 15 ex-smokers with abnormal IMT were not

significantly different than ex-smokers with normal IMT for RA950 (p=0.96), WA%
(p=0.66) or LA (p=0.63).

Figure 2-3. Never- and ex-smokers with IMT ≥ age-related upper limit of normal
(IMT >97.5% confidence interval (CI)) and subjects with IMT < age-related normal
limit (IMT ≤97.5 CI). A) Subjects with abnormally elevated IMT have statistically
significantly different 3He MRI VDP (p=0.04) than subjects with normal IMT. No
significant differences were observed for: B) ADC (p=0.06), C) FEV1 (p=1.0) or D)
DLCO (p=0.85). Comparisons displayed are Holm-Bonferroni corrected p-values.
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As shown in Figure 2-4, univariate Pearson correlations between 3He MRI VDP and
carotid ultrasound measurements revealed a moderate significant relationship for VDP
with carotid IMT (r=0.42, p=0.004), TPV (r=0.41, p=0.006) and VWV (r=0.40, p=0.007).
Multivariate regression models for IMT, VWV and TPV are provided in Table 2-2. VDP
was a significant determinant of IMT (β=0.41, p=0.001), VWV (β=0.45, p=0.003) and
TPV (β=0.38, p=0.005). For the ex-smokers alone, CT-derived measurements including
RA950 and airway count, WA%, LA and Pi10 did not correlate with carotid US
measurements of IMT, TPV and VWV.

Table 2-2. Multiple regression models for IMT, VWV and TPV
IMT
VWV
TPV
β
p
β
p
β
p
Age
0.005
0.02
-0.08
0.63
0.18
0.20
BMI
0.20
0.11
-0.11
0.44
0.09
0.47
FEV1
-0.03
0.81
0.21
0.18
0.10
0.48
DLCO
0.15
0.22
-0.08
0.59
-0.10
0.46
VDP
0.41
0.001
0.45
0.003
0.38
0.005
Dependent Variables: IMT, r2=0.27, p=0.001; VWV, r2=0.21, p=0.08; TPV, r2=0.16,
p=0.02
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Figure 2-4. Relationships for carotid atherosclerosis and pulmonary VDP.
Significant relationships between 3He MRI VDP and: A) carotid IMT (r=0.42, p=0.004),
B) VWV (r=0.40, p=0.007) and C) TPV (r=0.41, p=0.006).
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2.4

Discussion

We tested the hypothesis that atherosclerosis and pulmonary structure-function
measurements were significantly different in ex-smokers without airflow limitation or
symptoms consistent with COPD than in never-smokers. We observed: 1) ex-smokers
had significantly greater carotid TPV and worse 3He VDP than never-smokers, but were
not significantly different with respect to pulmonary function test measurements, 2) 28
subjects including 15 ex- and 13 never-smokers with abnormally elevated IMT had
significantly worse VDP but ADC, FEV1, DLCO and CT measurements were not different
compared to subjects with normal IMT, 3) 3He VDP was significantly related to carotid
atherosclerosis measurements (IMT, VWV and TPV) but pulmonary function tests were
not, and 4), multivariate regression models showed that VDP, a measurement of small
airway function, was the only significant determinant of carotid artery IMT, VWV and
TPV.
In these older subjects without COPD, we observed, as expected, that spirometry and
plethysmography measurements were not different in ex- and never-smokers, but
importantly 3He VDP was significantly worse for ex-smokers. This finding is concordant
with previous findings in asymptomatic ex-smokers that showed significant differences in
3

He MRI ventilation defects compared to never-smokers (22). Although we did not

observe differences between subgroups for 3He MRI ADC, abnormally elevated 3He
ADC has been previously reported in asymptomatic smokers (21) and never-smokers
with second-hand smoke exposure (23). Our finding of abnormal 3He ventilation in the
absence of abnormal DLCO, ADC or CT RA950 in ex-smokers is in agreement with the
notion that “silent” airway disease (20) and small airway remodeling (52) may be the
source of ventilation defects in these subjects. We think that the significant differences
observed for VDP in the absence of differences in DLCO, ADC or RA950 suggests mild,
sub-clinical airway abnormalities, although we must point out that a definitive structurefunction etiology for 3He ventilation defects (46, 53, 54) is yet to be determined. It is
also worth noting that for the healthy ex-smokers evaluated here, there was no CT
evidence of emphysema or airways disease and such values were in agreement with those
reported in healthy non-smokers in the COPDGene study (49, 50).

This finding
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underscores the sensitivity of 3He MRI ventilation measurements for detecting functional
abnormalities that may not be apparent using CT or spirometry.
Previous work in COPD patients (3, 4, 6, 7, 17, 55, 56) reported a relationship for IMT
with FEV1 and emphysema measurements, but this was not observed here in ex-smokers
without COPD. We were likely underpowered to detect differences in IMT between
subgroups as these previous studies investigating IMT in COPD and healthy older
subjects used sample sizes ranging from 305 to 14,480 subjects. On the other hand,
significantly elevated 3DUS TPV in ex-smoker subgroup was consistent with previous
work (35, 36) that showed smaller sample sizes can be used when employing 3D
measurements of plaque as compared to IMT. Although no difference was observed for
IMT between ex- and never-smokers, when age-normalized IMT values were used to
stratify subjects (51), subjects with abnormal IMT had significantly worse VDP. This
finding suggests that in both never- and ex-smokers with elevated IMT, there is evidence
of mild, subclinical airways disease that may be related to factors other than cigarette
smoking.
We also observed significant univariate relationships for 3He VDP with carotid artery
IMT, TPV and VWV, consistent with previous studies that showed relationships between
spirometry measurements and carotid IMT (3, 4, 6, 17, 55, 56), although this is the first
report of such relationships in subjects with normal pulmonary function. Similarly,
multivariate regression models that controlled for cardiovascular and pulmonary disease
risk factors showed that VDP was the only significant determinant of carotid artery IMT,
VWV and TPV.

It is also important to note that carotid TPV and VWV provide

measurements of intima echogenic (TPV and VWV) and echolucent (VWV) plaque (38,
57, 58). Hence, these relationships between VDP and IMT, VWV and TPV suggest that
in this relatively small group of never- and ex-smokers, mild, subclinical airways disease
may be related to carotid plaque burden and wall thickening. While it was recently shown
that COPD patients may have atherosclerotic plaque characteristics that make them more
vulnerable to rupture (6), we did not evaluate carotid plaque composition here. The
significant carotid plaque burden quantified in some of the ex-smokers investigated here
may be amenable to more complex image methods (59) to develop a better understanding
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of plaque composition/texture and outcomes. We acknowledge that the main limitation
of this study was the relatively small sample size of never- and ex-smokers, and that this
may have limited our power to detect any potential differences in IMT and FEV1 between
subgroups. Certainly, one of the strengths of 3D imaging is that significantly different
measurements can be detected in small groups of subjects, because of the high dynamic
range and sensitivity of 3D measurements to structure-function abnormalities. This is an
important consideration when powering studies to detect differences in small groups of
subjects. Finally, we cannot infer the temporal or causal nature of carotid and pulmonary
abnormalities in this cross-sectional evaluation. Questions related to “which came first”
still need to be answered in longitudinal natural disease and intervention studies (60).
In conclusion, we acquired sensitive 3D imaging measurements of atherosclerosis and
pulmonary structure-function in order to illuminate potential relationships between early
or mild sub-clinical pulmonary disease with atherosclerosis in otherwise healthy exsmokers. Although a number of studies have provided evidence that pulmonary and
carotid abnormalities are both present and related in COPD patients, here, this important
relationship was shown in never- and ex-smokers smokers with normal pulmonary
function. Whilst the clinical relevance of these observations is not yet clear, these data
suggest that lung abnormalities and carotid atherosclerosis in never- and ex-smokers
without airflow limitation may be directly related. As our knowledge of comorbid lung
and vascular disease increases, such findings may potentially have implications for
patient management decision strategies in preclinical stages.
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CHAPTER 3
The study in Chapter 2 showed how hyperpolarized 3He MRI reveals clinically relevant
ventilation defects in the lungs of ex-smokers without airflow limitation. This suggests
that ex-smokers without spirometry evidence of COPD may suffer from a form of pre- or
sub-clinical obstructive lung disease attributable to airway and/or parenchymal
abnormalities which are not detected using conventional spirometry or plethysmography.
Here, we aimed to provide a better understanding of the underlying pathophysiology of
ventilation defects in ex-smokers without airflow limitation by collecting regional 3He
ventilation and diffusion-weighted imaging data, as well as regional thoracic computed
tomography airway and emphysema measurements in ex-smokers without airflow
limitation.
The contents of this chapter have been previously published in Academic Radiology and
permission to reproduce the article was granted by Elsevier Publishing and is provided
in Appendix D.
D Pike, M Kirby, F Guo, DG McCormack and G Parraga. Ventilation Heterogeneity in
Ex-smokers without Airflow Limitation.
Academic Radiology; DOI:
10.1017/j.acra.2015.04.006

3

Ventilation Heterogeneity in Ex-smokers without Airflow
Limitation

3.1

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow
limitation caused by small airway remodeling, airway obliteration (1) and
emphysematous tissue destruction (2). COPD is typically diagnosed after respiratory
symptoms become obvious and intolerable (3), and this usually occurs when spirometry
measurements of lung function reflect airflow limitation and obstruction. However it is
well-understood that ex- and current-smokers may report normal lung function (3) and
mild symptoms and this may represent an early or ‘subclinical’ phase.

A deep

understanding of the underlying morphological changes that accompany this ‘subclinical’
phase is lacking, mainly because methods for evaluating pulmonary function cannot
detect very mild or early structure-function abnormalities.
Hyperpolarized 3He magnetic resonance imaging (MRI) ventilation heterogeneity has
been shown in healthy older subjects (4) and patients with COPD (5) and asthma (6). To
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evaluate the underlying anatomical and structural determinants of ventilation
heterogeneity, thoracic x-ray computed tomography (CT) has been used to help
determine the spatial relationship of airways disease and emphysema with ventilation
abnormalities. For example, recent work (7) provided evidence that in COPD, 3He
ventilation defects represent regions of emphysema and airways disease and that this
relationship depends on disease severity. In asthma (6), 3He ventilation heterogeneity
was also shown to be spatially related to abnormally remodeled airways. Whilst previous
work reported the presence of ventilation heterogeneity in ex-smokers with normal
spirometry (8), the underlying etiology and clinical relevance of these findings is not
well-understood.
In order to better understand the pathophysiological features of ventilation heterogeneity
in the ‘subclinical phase’ of obstructive lung disease in otherwise normal healthy exsmokers, we evaluated a group of well-characterized ex-smokers without airflow
limitation using both MRI and CT.

Based on previous work using micro-CT that

suggested that airway obstruction and obliteration may provide the dominant contribution
to airflow limitation in COPD (1), we hypothesized that in normal ex-smokers, 3He
ventilation abnormalities would be spatially and quantitatively related to airway
remodeling and not emphysema.

3.2
3.2.1

Materials and Methods
Study Subjects

Study participants provided written informed consent to a protocol approved by a local
research ethics board and Health Canada and was compliant with the Personal
Information Protection and Electronic Documents Act (PIPEDA, Canada) and Health
Insurance Portability and Accountability Act (HIPAA, USA). Research volunteers were
recruited from a tertiary health care practice. Each visit was completed in approximately
two hours when spirometry, plethysmography, the six-minute walk test (6MWT), St.
George’s Respiratory Questionnaire (SGRQ), 3He MRI and CT were completed.

73

3.2.2

Spirometry and Plethysmography

Spirometry was performed according to the American Thoracic Society guidelines (9).
Whole-body plethysmography was used to measure lung volumes (MedGraphics
Corporation, St. Paul, Minnesota, USA) and the attached gas analyzer was used to
measure diffusing capacity of the lung for carbon monoxide (DLCO).

3.2.3

Imaging

MRI was performed on a 3T Discovery MR750 (General Electric Health Care,
Milwaukee, Wisconsin, USA) system with subjects in inspiratory breath hold at
functional residual capacity (FRC)+1L.

1

H MRI was acquired prior to 3He MRI after

inhalation of 1L high purity, medical grade nitrogen (N2) from FRC using the wholebody radiofrequency coil and a fast spoiled gradient-recalled-echo sequence (10).

3

He

MRI was acquired with subjects in inspiratory breath-hold after inhalation from FRC of a
1L mixture of hyperpolarized 3He (5ml/kg body weight) diluted with N2.

3

He static-

ventilation and diffusion-weighted MRI was performed as previously described (10, 11).
CT was acquired within 30 minutes of MRI using a 64 slice Lightspeed VCT system
(General Electric Health Care, Milwaukee, Wisconsin, USA) and a single spiral
acquisition from apex to base with the subjects in the supine position. Subjects were
transported to the CT suite by wheelchair to prevent the potential for exercise-induced
changes between MRI and CT image acquisitions. CT was acquired during inspiratory
breath-hold of FRC+1L of N2 as previously described (12). The total effective dose was
1.8 mSv as calculated using manufacturer settings and the ImPACT CT dosimetry
calculator based on Health Protection Agency (UK) NRPB-SR250.

3.2.4

Image analysis

Ventilation heterogeneity or regions of “signal void” were quantified as 3He ventilation
defect percent (VDP) using semi-automated software generated in MATLAB
(Mathworks, Natick, Massachusetts, USA) as previously described (13). Lobar VDP was
generated by registering the segmented thoracic CT lobe mask from VIDA Pulmonary
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Workstation 2.0 (VIDA Diagnostics Inc., Coralville, Iowa, USA) to 3He MRI ventilation
images using deformable registration, and generating VDP for each lobe (right upper lobe
(RUL), right middle lobe (RML), right lower lobe (RLL), left upper lobe (LUL), left
lower lobe (LLL)) using hierarchical k-means clustering (13). All ex-smokers were
classified on the basis of the 95% confidence interval for VDP in healthy elderly neversmokers of 4.3% as previously described (4). Therefore, ex-smokers with VDP<4.3%
were classified as normal whereas ex-smokers with VDP≥4.3% were classified as having
abnormally-elevated VDP.

3

He MRI apparent diffusion coefficients (ADC) were

generated as previously described (11).
CT volumes were evaluated using Pulmonary Workstation 2.0 to generate airway wall
area percent (WA%), lumen area (LA) and airway count. It was previously shown that
airway lumen area is related to body surface area (BSA) (14, 15) and therefore LA was
normalized to BSA (LA/BSA).

CT WA%, LA and LA/BSA were measured for

subsegmental bronchi including RB1, RB5, RB8, LB1 and LB8 airways because each of
these feed individual lobes (RB1-RUL, RB5-RML, RB8-RLL, LB1-LUL and LB8-LLL)
and they were measureable for each subject. Emphysema was also measured using
Pulmonary Workstation 2.0 including the relative area of the lung with attenuation ≤ -950
Hounsfield units (HU) (RA950) for whole-lung and each individual lung lobe.

3.2.5

Statistics

All tests were performed in IBM SPSS V22 (SPSS Inc., Chicago, Illinois, USA).
Normality was tested using the Shapiro-Wilk test. A one-way analysis of variance
(ANOVA) was used to compare multiple parameters and univariate comparisons were
investigated using unpaired two-tailed t-tests (parametric data) or Mann-Whitney U tests
(non-parametric data). Spearman correlations were performed for non-parametric data.

3.3

Results

A summary of demographic, pulmonary function test and imaging measurements is
provided in Table 3-1 for all 60 subjects, while Supplemental Table 3I-1 (online)
provides a subject listing of data.

All participants reported normal spirometry
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measurements (FEV1=104±13%, FEV1/FVC=80±6%) and no subjects reported Global
initiative for Chronic Obstructive Lung Disease (GOLD) unclassified COPD (16).
Eighteen subjects (18/60=30%) reported normal VDP and 42 (42/60=70%) subjects
reported abnormally-elevated VDP. As shown in Figure 3-1 for four representative
subjects, volunteers with normal VDP showed small or no ventilation defects along the
periphery of the lung, whereas participants with abnormally-elevated VDP showed
evidence of patchy ventilation throughout the lung and on the periphery. The qualitative
spatial relationship for patchy ventilation and subsegmental airway morphology
reconstructed from CT is also shown in Figure 3-1.
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Figure 3-1. 3He MRI Ventilation and CT airway trees in representative ex-smokers
with normal (S1–S3) and abnormally-elevated VDP (S4–S6). S1=70y female, 12 pack
years, FEV1=93% and VDP=2%. S2=59y female, 18 pack years, FEV1=97% and
VDP=2%. S3=51y female, 20 pack years, FEV1=103% and VDP=4%. S4=74y male,
50 pack years, FEV1=89% and VDP=6%. S5=79y male, 10 pack years, FEV1=88% and
VDP=8%. S6=74y male, 60 pack years, FEV1=95% and VDP=11%.

As shown in Table 3-1, subjects with abnormally-elevated VDP were not significantly
different (p>0.05) with respect to pulmonary function test or CT measurements but they
did report significantly greater (p=0.02) 3He ADC than subjects with normal VDP.
Table 3-1. Demographic, pulmonary function and imaging data
Parameter (±SD)
All
Normal VDP
Elevated VDP
(n=60)
(n=18)
(n=42)
Age yr
69 (9)
67 (10)
70 (9)
Male n (%)
38 (63)
9 (50)
29 (69)
Pack years
28 (16)
27 (14)
28 (17)
BMI kg/m2
29 (4)
29 (5)
30 (4)
FVC%pred
97 (13)
100 (10)
95 (14)
FEV1%pred
104 (13)
106 (12)
102 (14)
FEV1/FVC %
80 (6)
80 (6)
80 (6)
RV/TLC%pred
103 (15)
104 (12)
103 (16)
DLCO %pred
80 (20)
87 (16)
77 (22)
6MWD m
404 (95)
433 (81)
392 (98)
SGRQ total
36 (26)
22 (20)
23 (22)
WA %
65 (2)
65 (2)
65 (2)
LA mm2
14 (3)
13 (2)
14 (4)
2
2
LA/BSA mm /m
7 (2)
7 (1)
7 (2)
Airway count
115 (37)
106 (28)
119 (40)
RA950 %
1.2 (1.0)
0.8 (0.5)
1.4 (1.1)
VDP %
6 (3)
3 (1)
7 (3)†
ADC cm2/s
0.28 (0.04)
0.26 (0.03)
0.29 (0.03)†
BMI: Body mass index, FVC: Forced vital capacity, FEV1: Forced expiratory volume in
one second, RV: Residual volume, TLC: Total lung capacity, DLCO: Diffusing capacity
for carbon monoxide, SGRQ: St. Georges Respiratory Questionnaire, 6MWD: Six
minute walk distance, WA%: Mean fifth generation airway wall area percent, LA:
Mean fifth generation airway lumen area, BSA: Body surface area, RA950: Relative area
of the lung parenchyma with attenuation ≤ -950HU, VDP: 3He MRI ventilation defect
percent, ADC: 3He MRI apparent diffusion coefficient, SD: standard deviation
†
Significantly different p<0.05
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Table 3-2 shows quantitative airway morphology and emphysema measurements for
subjects with normal and abnormally-elevated VDP. No significant differences were
observed for whole-lung airway (mean of fifth generation airways) WA% (p=0.88), LA
(p=0.50) or LA/BSA (p=0.57) and this was consistent in all lung lobes. Table 3-2 and
Figure 3-2 show that only 3He MRI ADC was significantly greater in the apical lung
(RUL: p=0.02, RML: p=0.04 and LUL: p=0.009) in subjects with elevated VDP.
Table 3-3 shows the relationships for VDP with airway morphology and emphysema
measurements. Whole lung VDP was significantly correlated with whole lung ADC
(r=0.40, p=0.001) and whole lung RA950 (r=0.34, p=0.008). As shown in Table 3-3 and
in more detail in Figure 3-3, regional VDP correlated with regional ADC in each of the
lung lobes (RUL: r=0.32, p=0.01, RML: r=0.46, p=0.002, RLL: r=0.38, p=0.003, LUL:
r=0.35, p=0.006 and LLL: r=0.37, p=0.004). As shown in Table 3, whole lung VDP did
not correlate with whole lung (mean of fifth generation airways) WA%, LA or LA/BSA.
There were no significant correlations for regional VDP and airway morphological
measurements in the RML (RB5 morphology), LUL (LB1 morphology) or LLL (LB8
morphology). However, as shown Figure 3-4 in more detail, RUL VDP significantly
correlated RB1 morphological measurements (LA: r=-0.37, p=0.004, LA/BSA: r=-0.42,
p=0.0008) and RLL VDP significantly correlated with RB8 morphological measurements
(WA%: r=0.28, p=0.03, LA: r=-0.28, p=0.03, LA/BSA: r=-0.37, p=0.004).
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Table 3-2. Whole lung and regional measurements for ex-smokers with normal
and elevated VDP
Parameter (±SD)
Whole Lung
**WA%
**LA mm2
**LA/BSA mm2/m2
VDP %
ADC cm2/s
RA950 %
Right upper lobe
RB1 WA%
RB1 LA mm2
RB1 LA/BSA mm2/m2
VDP %
ADC cm2/s
RA950 %
Right middle Lobe
RB5 WA%
RB5 LA mm2
RB5 LA/BSA mm2/m2
VDP %
ADC cm2/s
RA950 %
Right lower lobe
RB8 WA%
RB8 LA mm2
RB8 LA/BSA mm2/m2
VDP %
ADC cm2/s
RA950 %
Left Upper Lobe
LB1 WA%
LB1 LA mm2
LB1 LA/BSA mm2/m2
VDP %
ADC cm2/s
RA950 %
Left Lower Lobe
LB8 WA%
LB8 LA mm2
LB8 LA/BSA mm2/m2
VDP %
ADC cm2/s
RA950 %

Normal
VDP (n=18)

Elevated
VDP (n=42)

p-value

65 (2)
13 (2)
7 (1)
3 (1)
0.26 (0.03)
0.8 (0.5)

65 (2)
14 (4)
7 (2)
7 (3)
0.29 (0.03)
1.4 (1.1)

0.88
0.50
0.57
<0.0001
0.02
0.08

62 (2)
25 (5)
13 (3)
3 (2)
0.24 (0.03)
0.7 (0.6)

61 (4)
25 (11)
13 (6)
5 (4)
0.27 (0.03)
1.2 (1.2)

0.29
0.64
0.39
0.02
0.02
0.08

63 (4)
22 (13)
12 (7)
6 (9)
0.24 (0.03)
1.6 (1.0)

62 (4)
21 (8)
11 (4)
9 (10)
0.27 (0.04)
2.0 (1.8)

0.25
0.80
0.99
0.04
0.04
0.79

62 (3)
21 (8)
11 (5)
5 (3)
0.25 (0.03)
0.6 (0.4)

62 (3)
21 (7)
11 (4)
8 (6)
0.27 (0.03)
1.0 (1.0)

0.43
0.99
0.67
0.02
0.07
0.42

63 (3)
15 (4)
8 (2)
4 (4) (3)
0.25 (0.03)
1.0 (0.6)

63 (3)
18 (6)
9 (3)
8 (8)
0.28 (0.04)
1.8 (1.7)

0.52
0.19
0.34
0.02
0.009
0.22

59 (4)
30 (11)
17 (8)
3 (1)
0.25 (0.03)
0.7 (0.4)

60 (4)
28 (12)
14 (6)
7 (3)
0.27 (0.04)
1.1 (1.1)

0.68
0.27
0.13
<0.0001
0.07
0.42

WA%: Wall area percent, LA: Lumen area, BSA: Body surface area, RB1: Right upper
lobe apical bronchus, RB5: Right middle lobe lateral bronchus, RB8: Right lower lobe
subsegmental bronchus, LB1: Left upper lobe apical bronchus, LB8: Left lower lobe
subsegmental bronchus, RA950: Relative area of the lung parenchyma with attenuation ≤ -
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950HU, VDP: 3He MRI ventilation defect percent, ADC:
coefficient, **Mean of fifth generation airway

3

He MRI apparent diffusion

Figure 3-2. Whole lung and regional emphysema measurements in ex-smokers with
normal (n=18) and abnormally-elevated VDP (n=42). ADC was significantly greater
in apical lung in subjects with elevated VDP. A) Whole lung ADC (p=0.02), B) Right
upper lobe ADC (p=0.02), C) Left upper lobe ADC (p=0.009), D) Right middle lobe
ADC (p=0.04), E) Left lower lobe ADC (p=0.07), F) Right lower lobe ADC (p=0.07).
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Table 3-3. Relationship of 3He MRI VDP with airways disease and emphysema
measurements
Spearman r
p
Whole Lung VDP
**WA%
0.002
0.99
**LA
0.04
0.76
**LA/BSA
-0.04
0.75
ADC
0.40
0.001
RA950
0.34
0.008
Right Upper Lobe VDP
RB1 WA%
0.24
0.06
RB1 LA
-0.37
0.004
RB1 LA/BSA
-0.42
0.0008
ADC
0.32
0.01
RA950
0.15
0.27
Right Middle Lobe VDP
RB5 WA%
-0.11
0.40
RB5 LA
-0.003
0.98
RB5 LA/BSA
-0.02
0.91
ADC
0.46
0.002
RA950
0.24
0.07
Right Lower Lobe VDP
RB8 WA%
0.28
0.03
RB8 LA
-0.28
0.03
RB8 LA/BSA
-0.37
0.004
ADC
0.38
0.003
RA950
0.21
0.11
Left Upper Lobe VDP
LB1 WA%
0.07
0.62
LB1 LA
0.13
0.33
LB1 LA/BSA
-0.01
0.94
ADC
0.35
0.006
RA950
0.23
0.08
Left Lower Lobe VDP
LB8 WA%
0.04
0.73
LB8 LA
0.05
0.68
LB8 LA/BSA
-0.02
0.86
ADC
0.37
0.004
RA950
0.26
0.05
WA%: Wall area percent, LA: Lumen area, BSA: Body surface area WL; Whole lung,
RB1: Right upper lobe apical bronchus, RB5: Right middle lobe lateral bronchus, RB8:
Right lower lobe subsegmental bronchus, LB1: Left upper lobe apical bronchus, LB8:
Left lower lobe subsegmental bronchus, RA950: Relative area of the lung parenchyma
with attenuation ≤ -950HU, VDP: 3He MRI ventilation defect percent, ADC: 3He MRI
apparent diffusion coefficient, **Mean of fifth generation airways
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Figure 3-3. Relationships for whole lung and regional VDP with 3He MRI
emphysema measurements. A) Whole lung (WL) VDP correlated with WL ADC
(r=0.40, p=0.001), B) RUL VDP correlated with RUL ADC (r=0.32, p=0.01), C) RLL
VDP correlated with RLL ADC (r=0.38, p=0.003), D) RML VDP correlated with RML
ADC (r=0.46, p=0.002), E) LUL VDP correlated with LUL ADC (r=0.35, p=0.006), F)
LLL VDP correlated with LLL ADC (r=0.37, p=0.004).
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Figure 3-4. Relationships for regional VDP with CT airways disease measurements.
Right upper lobe (RUL) VDP correlated with A) RB1 LA (r=-0.37, p=0.004), B) RB1
LA/BSA (r=-0.42, p=0.0008) but not C) RB1 WA% (r=0.24, p=0.06). Right lower lobe
(RLL) VDP correlated with D) RB8 LA (r=-0.28, p=0.03), E) RB8 LA/BSA (r=-0.37,
p=0.004) and F) RB8 WA% (r=0.28, p=0.03).
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3.4

Discussion

We acquired 3He MRI and CT in 60 ex-smokers without airflow limitation and made the
following observations: 1) 42 of 60 volunteers reported abnormally-elevated 3He VDP
and these subjects reported normal airflow and lung volume measurements that were not
significantly different from 18 ex-smokers with normal VDP, 2) there was significantly
greater (worse) apical lung 3He ADC in the 42 ex-smokers with abnormally-elevated
VDP as compared to ex-smokers with normal VDP, but there were no other imaging
differences between the subgroups, 3) 3He VDP was significantly correlated with whole
lung and regional ADC, and, 4) whole lung 3He VDP was not correlated with whole lung
airway morphological measurements, although RUL and RLL VDP was associated with
thicker airway walls (WA%) and narrowed airway lumen (LA) in those regions of
interest.
We observed that 42 ex-smokers reported VDP ≥ 95% confidence interval for VDP in
never-smokers (4). Although all participants had a significant smoking history (mean
pack years=28), spirometry, plethysmography and CT showed no evidence of lung
function decline or lung destruction and these same measurements showed no significant
differences in subjects with elevated VDP compared to subjects with normal VDP.
Previous work (8) in ‘healthy’ smokers showed significantly different MRI ventilation
measurements as compared to never-smokers and COPD smokers and our findings build
on this previous work by showing that ex-smokers with abnormally-elevated VDP also
showed significantly greater whole-lung and apical lung 3He ADC. These MRI findings
were not observed using CT measurements of emphysema. In this regard, it is important
to note that 3He ADC provides a surrogate measure of microstructural emphysema (17)
and was previously shown to be sensitive to very mild emphysematous changes by
detecting differences in subjects exposed only to second-hand smoke (18). We observed
that subjects with elevated VDP reported greater whole-lung and apical lung 3He ADC.
Previous work (19) evaluated the anatomical ADC distribution in more severe COPD and
established the presence of elevated ADC in the apical lung regions and this is in
agreement with predominant centrilobular emphysema in such patients. However to our
knowledge the spatial distribution of ADC in ex-smokers without COPD has not yet been
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evaluated. We did not observe differences in CT emphysema (RA950) measurements.
However, previous research (20) showed that CT-derived emphysema measurements may
underestimate the extent of emphysema in very mild disease. The mean RA950 in the exsmokers in our study was very low (mean RA950 = 1.2%) and this may reflect why CT
RA950 was not significantly different between subgroups. Nevertheless, these results
suggest that ex-smokers with a significant smoking history and abnormal 3He VDP but
without airflow limitation may also have a mild or subclinical form of centrilobular
emphysema that is not detected using CT or conventional pulmonary function tests.
Whole lung and regional VDP were correlated with ADC which suggests that ventilation
abnormalities and very mildly abnormal parenchyma co-existed in these otherwise
normal ex-smokers. We evaluated regional (lobar) correlations for 3He VDP and ADC
because a direct spatial comparison previously described in COPD patients (7) was not
feasible here.

This previous approach (7) evaluated the direct spatial relationship

between 3He ventilation defects and emphysema by evaluating the overlap of RA950
(emphysema) regions and 3He ventilation defects. As compared with COPD patients
with severe emphysema (RA950>15%), the ex-smokers here reported very low or normal
RA950 and therefore the spatial overlap of 3He ventilation defects and RA950 could not be
evaluated. We wonder about the long-term consequences of these very mild
abnormalities in ventilation and emphysema measurements and whether these are
predictors of a transition to COPD. Future longitudinal evaluations in these subjects are
warranted and will be undertaken.
It was not expected that whole-lung airway measurements would show differences
between subgroups since it is widely appreciated that obstructive disease is regionally
(and not uniformly) distributed in the lung (21). However it was surprising that we did
not detect or measure abnormal or different regional airway morphologies in the exsmokers with abnormally elevated VDP, especially since whole-lung and lobar VDP was
significantly greater in these participants. We think one explanation for this may be
related to the airways we measured and the fact that they may not have been distal
enough to reflect such mild disease. We did observe that RUL and RLL VDP were
significantly correlated with RB1 and RB8 airway morphological abnormalities, but these
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relationships were not significant in the other lung lobes. Nonetheless, the finding that
airway walls thicken and airway lumens narrow with increasing ventilation heterogeneity
in the RUL and RLL suggests a relationship between airway morphology and ventilation
in these ex-smokers without COPD. These findings also highlight some of the limitations
of CT and advantages of MRI for pulmonary imaging and characterization of very mild
lung disease. As described elsewhere (22, 23), CT measurements are limited because of
the inherent spatial resolution limit achievable on thoracic CT scans. On the other hand,
MRI ADC provides a way to reveal subtle parenchymal changes to the alveolar
microstructure and the subjects in our study certainly exemplify a patient group in whom
MRI is highly advantageous.
We must acknowledge several limitations to our study.

First, we measured five

individual subsegmental airways (RB1, RB5, RB8, LB1 and LB8) and not all
subsegmental airways. We chose these five airways in particular because they were most
easily visible and measureable on thoracic CT and because they lead to the individual
lung lobes of interest.

While it is possible to quantitatively evaluate more distal

subsegmental airways, the reproducibility of this in all subjects would be difficult to
determine. Second, our findings were derived on a VDP threshold determined in neversmokers from a previous 3He MRI study (4). The range of VDP for all subjects in our
study was 2% - 18% and the VDP data distribution was not normally distributed, but
reflected a Poisson distribution centered at 5-6%. This partially explains why 42 of 60
subjects reported abnormal VDP. If this threshold was greater, for example 5%, 33 of 60
subjects would have reported abnormally-elevated VDP. Nevertheless, the results of our
analysis point to very mild emphysema and airways disease in ex-smokers without
airflow limitation. We must also acknowledge that 3He MRI may only be employed at a
limited number of research centres worldwide due to the limited supply of 3He gas and
need for specialized equipment and software. However, pulmonary functional MRI using
hyperpolarized

129

Xe is emerging as an attractive alternative with the potential for

implementation and translation. In this regard, longitudinal measurements in these 60 exsmokers will be undertaken using

129

Xe and more conventional 1H MRI methods. We

also recognize that although this study evaluated 60 ex-smokers – a relatively large study
by MRI standards, the sample size may have limited our ability to detect significant
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relationships for CT airway morphology and emphysema measurements between
subgroups. Finally, while this study did not evaluate current smokers (with or without
airflow limitation), future work investigating MRI ventilation measurements in currentsmokers would also provide an understanding of acute effects of cigarette smoke on
pulmonary ventilation.
In conclusion, in ex-smokers without airflow limitation, 3He MRI identified a subgroup
with abnormally elevated ventilation defect percent – a measure of ventilation
heterogeneity. While there were no other pulmonary function or CT differences in exsmokers with normal or abnormal VDP, there was significantly different MRI ADC and
there was a relationship for whole-lung and regional VDP with ADC and for regional
VDP with regional CT airway morphological abnormalities. Taken together, these data
suggest that ex-smokers with normal airflow and lung volumes may represent a
subclinical COPD phenotype that warrants further longitudinal investigation.
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CHAPTER 4
In Chapter 3 we observed that hyperpolarized 3He MRI ventilation abnormalities in exsmokers without chronic obstructive pulmonary disease (COPD) were spatially related to
airways disease and microstructural emphysema. Results from Chapters 2 and 3 and
previous research from our group and others established that individuals with COPD
exhibit ventilation abnormalities and emphysema throughout the lung. Therefore we
were interested in how individuals could be grouped into clinically meaningful
phenotypes based on the location of pulmonary abnormalities within the lung and
furthermore, how these regional phenotypes might change with disease progression.
Therefore, here we used 3He MRI and CT to phenotype COPD ex-smokers based on the
apical – basal distribution of ventilation abnormalities and emphysema and evaluate the
change in phenotype with disease progression.
The contents of this chapter have been published in COPD: Journal of Chronic
Obstructive Pulmonary Disease (JCOPD) and permission to reproduce the article was
granted by Taylor and Francis Publishing Group on behalf of JCOPD and is provided in
Appendix D.
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4.1

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow
obstruction, mainly due to airways disease, emphysema, or a combination of airway and
parenchymal abnormalities (1). While both airways disease and emphysema influence
the clinical course of COPD, the emphysema phenotype is associated with more rapid
disease progression, more frequent exacerbation episodes and significantly worse
mortality than the airways disease phenotype (2-4).

In this regard, high-resolution

computed tomography (CT) has emerged as a robust method for quantifying and spatially
mapping emphysema and its progression (5-7). At the same time, heterogeneity in the
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clinical presentation of patients (8, 9) with the same lung function and emphysema
measurements, has prompted several CT studies (10-19) to provide a better understanding
of the clinical relevance of the spatial distribution of emphysema. While these previous
studies have yielded important results, the clinical relevance and physiological outcomes
associated with different emphysema (10, 14, 17, 20) and airways disease (21, 22)
distribution is not well-understood.
Hyperpolarized 3He magnetic resonance imaging (MRI) has emerged as another imaging
approach for quantifying airways disease and emphysema phenotypes in COPD (23-25).
3

He and

129

Xe MRI ventilation imaging readily identifies regions of signal void (26) that

are believed to reflect poorly ventilated regions of the parenchyma (27). In COPD
patients,

3

He ventilation defects are highly reproducible over long periods of time in

stable patients (28), predict COPD exacerbations (29), and diminish in response to shortacting bronchodilator therapy (30) and bronchoscopic lung volume reduction using stents
(31).

Previous work (32) showed that 3He ventilation defects in asthma are spatially

related to abnormal airway morphology and it has been suggested (29) that in COPD,
ventilation defects may be related to airways disease, emphysema or a combination of
both.

However, the relationship of the distribution of 3He ventilation defects and

progression of COPD has not yet been investigated. Therefore, our objective here was to
investigate the relationship between COPD severity and the spatial distribution of
ventilation defects measured using MRI and emphysema measured using CT in a
relatively large group of COPD ex-smokers.

4.2
4.2.1

Methods
Study Subjects

This study was registered as NCT02279329 (ClinicalTrials.gov, National Institute of
Health, Maryland, USA). Study subjects with a clinical diagnosis of COPD provided
written informed consent to a protocol that was compliant with the Personal Information
Protection and Electronic Documents Act (PIPEDA, Canada) and Health Insurance
Portability and Accountability Act (HIPAA, USA) and approved by a local research
ethics board and Health Canada.

Each two-hour visit consisted of spirometry,
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plethysmography, the six-minute-walk-test (6MWT) for the six-minute walk distance
(6MWD), St. George’s Respiratory Questionnaire (SGRQ), 3He MRI and inspiratory CT.
Subjects were clinically diagnosed and classified according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria (33) and/or clinical symptoms over a
3 month period in addition to a smoking history of >10 pack years.

4.2.2

Spirometry and Plethysmography

Spirometry measurements, including the forced expiratory volume in one second (FEV1)
and forced vital capacity (FVC), were acquired according to the American Thoracic
Society guidelines (34).

Whole-body plethysmography was used to measure lung

volumes (residual volume (RV) and total lung capacity (TLC)) (MedGraphics
Corporation, St. Paul, Minnesota, USA) and a stand-alone gas analyzer (attached to
plethysmograph) was used to measure diffusing capacity of the lung for carbon monoxide
(DLCO).

4.2.3

Imaging

Subjects were randomized to first receive either MRI or CT and image acquisition was
performed within 15 minutes of each other. For both MRI and CT, image acquisition was
completed within 5-7 minutes of patients being made comfortable in a supine position.
MRI was performed using a 3.0 Tesla Discovery MR750 (General Electric Health Care,
Milwaukee, Wisconsin, USA) system, as previously described (35), using a whole-body
gradient set with a maximum gradient amplitude of 1.94G/cm and a single-channel, rigid
elliptical transmit/receive chest coil (Rapid Biomedical GmbH, Rimpar, Germany) with
patients in inspiratory breath-hold at functional residual capacity (FRC) + 1L.
Anatomical 1H MRI was acquired prior to 3He MRI after inhalation of 1L medical grade
nitrogen (N2) from FRC using the whole-body radiofrequency coil and a 1H fast-spoiled,
gradient-recalled-echo sequence using a partial echo [16s total data acquisition, posterior
to anterior repetition time (TR)/echo times (TE)/flip angle=4.7ms/1.2ms/30○, field of
view (FOV)=40x40cm, bandwidth 24.4 kHz, matrix=128x80, 15-17 slices, 15mm slice
thickness, zero gap] as previously described (35). 3He static-ventilation MR images were
acquired with a mixture of hyperpolarized 3He (5ml/kg body weight) diluted to 1L with
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N2 and using a fast-gradient echo method using a partial echo [14s total data acquisition,
posterior

to

anterior,

TR/TE/flip

angle=4.3ms/1.4ms/7○,

FOV=40x40cm,

bandwidth=48.8kHz, matrix=128x80, 15-17 slices, 15mm slice thickness, zero gap]. 3He
diffusion-weighted MRI was also performed as previously described (27), however we
did not evaluate apparent diffusion coefficients (ADCs) as estimates of emphysema
because these values only report from regions of normal ventilation which would have
biased the ADC-based emphysema estimates.
CT was acquired using a 64 slice Lightspeed VCT system (General Electric Health Care,
Milwaukee, Wisconsin, USA) using a single spiral acquisition from apex to base
(64×0.625mm collimation, 120kVp, 100mA, tube rotation time=500ms, pitch=1.25,
standard reconstruction kernel and 1.25mm slice thickness).

All subjects were

transported from the MRI suite to the CT suite by wheelchair to prevent the potential of
any exercise-induced dilatation of the airways or lung parenchyma. CT was acquired
during inspiratory breath-hold of high-purity, medical grade N2 at the same volume as
MRI (FRC+1L) as previously described (36) to enable direct comparison to MR images.
The total effective dose for each CT scan was 1.8 mSv as calculated using manufacturer
settings and the ImPACT CT dosimetry calculator based on Health Protection Agency
(UK) NRPB-SR250.

4.2.4

Image Analysis

Hyperpolarized 3He MR static-ventilation images were used to generate whole-lung 3He
ventilation defect percent (VDP) using semi-automated software generated using
MATLAB (Mathworks, Natick, Massachusetts, USA) (37).
Inspiratory CT images were evaluated using VIDA Pulmonary Workstation 2.0 (VIDA
Diagnostics, Coralville, Iowa, USA). Emphysema was measured for whole-lung and
individual lung lobes using the relative area of the lung parenchyma with attenuation ≤ 950 Hounsfield units (HU) (RA950). Airway wall area percent for the 5th generation
airways (WA%) and airway wall thickness for airways with an internal perimeter of
10mm (Pi10) were estimated as previously described (38).
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Ventilation defect percent for each lung lobe (right upper lobe (RUL), right lower lobe
(RLL), left upper lobe (LUL), left lower lobe (LLL)) was generated by registering the
thoracic CT segmentation of the lung lobes (VIDA Pulmonary Workstation 2.0) to 3He
MRI ventilation images using deformable registration as previously described (39).

4.2.5

Distribution of Emphysema and Ventilation Defects

Apical-lung (AL) and basal-lung (BL) predominant emphysema phenotypes were defined
using a method adapted from a previously described technique (10) whereby RA950 in the
BL (RA950BL = RA950RLL + RA950LLL) and RA950 in the AL (RA950AL = RA950RUL +
RA950LUL) were used to generate the difference between AL and BL RA950 (∆RA950). A
positive ∆RA950 was indicative of AL-predominant distribution, and a negative ∆RA950
indicated BL-predominant emphysema distribution such that:
AL-predominant emphysema: RA950AL - RA950BL = + ∆RA950

(1)

BL-predominant emphysema: RA950AL - RA950BL = - ∆RA950

(2)

In a similar manner, regional 3He VDP was used to identify AL- and BL-predominant
3

He ventilation defect phenotypes. The ventilation defect percent in BL (VDPBL =

VDPRLL + VDPLLL) was subtracted from the ventilation defect percent in the AL (VDP AL
= VDPRUL + VDPLUL) to generate the difference between AL- and BL-VDP (∆VDP),
whereby a positive ∆VDP indicated an AL-predominant distribution of ventilation
defects and a negative ∆VDP indicated a BL-predominant distribution of ventilation
defects such that:
AL-predominant ventilation defects: VDPAL - VDPBL = + ∆VDP

(3)

BL-predominant ventilation defects: VDPAL - VDPBL = - ∆VDP

(4)

All participants were classified in AL- and BL-predominant subgroups using both CT and
3

He MRI measurements for all lobes except the right middle lobe (RML) because recent

research (40) has shown that the RML contributes disproportionately to imaging
measurements of emphysema.
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4.2.6

Statistics

All statistical tests were performed in IBM SPSS V22 (SPSS Inc., Chicago, Illinois,
USA). A one-way analysis of variance (ANOVA) was used to compare parameters
between COPD grades of severity. Comparisons between imaging measurements of AL
and BL subgroups were performed using unpaired t-tests with Holm-Bonferroni
corrections to adjust for family-wise error. Pearson correlations were used for univariate
analyses and p-values were adjusted for family-wise error. All statistical figures were
created in GraphPad Prism V6 (GraphPad Software Inc., La Jolla, California, USA).

4.3

Results

We evaluated 100 COPD ex-smokers (n=22 GOLD I, n=46 GOLD II and n=32 GOLD
III/IV). Table 4-1 shows the demographic and pulmonary function measurements for all
subjects and stratified by GOLD grade severity. Measurements of pulmonary function
and volumes including FEV1, FVC, FEV1/FVC, RV, RV/TLC and DLCO worsened with
increasing GOLD grade severity (all p<0.0001). Similarly, SGRQ total score increased
(p<0.0001) and 6MWD decreased (p=0.001) with increasing disease severity.

Table 4-1. Demographic and pulmonary function test measurements
Parameter
All
GOLD I
GOLD II GOLD III/IV
p*
(±SD)
(n=100)
(n=22)
(n=46)
(n=32)
Age yr
71 (8)
75 (7)
70 (8)
70 (8)
0.03
Male n (%)
65 (65)
19 (86)
27 (59)
19 (59)
0.06
Pack years
50 (30)
48 (36)
48 (27)
54 (31)
0.6
BMI kg/m2
27 (4)
28 (4)
27 (4)
26 (5)
0.3
6MWD m
377 (91)1 419 (47)2 388 (90)3
323 (98)4
0.001
FEV1%pred
62 (23)
95 (12)
64 (9)
36 (7)
<0.0001
FVC%pred
90 (20)
109 (12)
92 (14)
73 (16)
<0.0001
FEV1/FVC %
50 (12)
63 (5)
52 (8)
37 (8)
<0.0001
RV%pred
160 (48) 123 (30)
148 (34)
202 (45)
<0.0001
RV/TLC %pred
133 (27) 107 (18)
127 (17)
159 (22)
<0.0001
DLCO%pred
55 (20)
69 (19)
57 (16)
42 (18)
<0.0001
SGRQ Total Score
40 (19)
23 (16)
37 (14)
56 (12)
<0.0001
BMI: Body mass index, FEV1: Forced expiratory volume in one second, FVC: Forced
vital capacity, RV: Residual volume, TLC: Total lung capacity, DLCO: Diffusing
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capacity for carbon monoxide, SGRQ: St. George’s Respiratory Questionnaire,
6MWD: Six-minute walk distance, 1n=91, 2n=21, 3n=44, 4n=26, *ANOVA corrected pvalue
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Figure 4-1 shows 3He MR static-ventilation and CT images for COPD ex-smokers
stratified by GOLD grade with ventilation defects and corresponding emphysema.

3

He

ventilation is shown in cyan and emphysema is shown using an RA950 mask (voxels ≤950HU in yellow). It was visibly obvious that ex-smokers (S1, S2, S3, S4 and S5) with
BL-predominant 3He ventilation defects showed ventilation heterogeneity in the lower
lung lobes while ex-smokers (S6, S7, S8, S9 and S10) with AL-predominant 3He
ventilation defects had ventilation abnormalities localized to the upper lung lobes. At the
same time, corresponding CT emphysema masks were not spatially concordant with the
BL and AL ventilation defect phenotypes in milder COPD (as shown in subjects S1 and
S2 as well as in S6 and S7). However in moderate-severe grade ex-smokers (such as S3,
S4 and S5 and also S8, S9 and S10) the spatial relationship between ventilation defects
and CT RA950 was more obvious.
Table 4-2 provides a summary of whole-lung and regional RA950 and VDP as well as
airway measurements for all study subjects and stratified by GOLD grade. Whole-lung
and regional RA950 (RUL, RLL, LUL, LLL, RA950AL, RA950BL) were significantly worse
(all p<0.05) with increasing GOLD grade. Similarly, whole-lung and regional VDP
(RUL, RLL, LUL, LLL, VDPAL, VDPBL) was significantly worse (all p<0.05 except LLL
VDP p=0.05) with increasing disease severity. No significant differences were observed
for ∆RA950 (p=0.7) or ∆VDP (p=0.9) between GOLD grades and there were no
differences for airway Pi10 (p=0.6) or mean fifth generation WA% (p=0.5) or LA (p=1.0)
between GOLD grades. Women had significantly decreased VDP in the RLL and LLL
and significantly different VDPBL and ΔVDP compared to men for GOLD II and GOLD
III/IV while no significant differences were observed for the 3 women in the GOLD I
subgroup (data not shown).
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Figure 4-1. Thoracic 3He MRI and CT of COPD ex-smokers with representative
apical- and basal-lung predominant 3He ventilation defects and corresponding
emphysema. Ex-smokers with basal-lung predominant 3He ventilation defects (S1, S2,
S3, S4 and S5) show ventilation heterogeneity localized to the basal-lung while subjects
with apical-lung predominant ventilation defects (S6, S7, S8, S9 and S10) show
abnormalities localized in the apical lung. Emphysema is shown using a yellow RA950
mask. Note that the trachea was excluded from VDP and RA950 measurements.

Table 4-3 reports whole-lung and regional imaging measurements for MRI and CT ALand BL-predominant phenotypes. Based on 3He MRI VDP, 72 subjects reported BL-
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predominant VDP while 28 reported AL-predominant VDP.

Subjects with AL-

predominant VDP reported significantly greater whole-lung (p=0.03) and upper lobe
(RUL p=0.002, LUL p=0.01, RA950AL p=0.003) emphysema measured using RA950.
Based on CT RA950 measurements, 71 subjects reported AL-predominant RA950 while 29
subjects reported BL-predominant RA950. Subjects with AL-predominant RA950 had
significantly diminished VDP in the RLL (p=0.002) and basal-lung (VDPBL p=0.003).
Figure 4-2 shows the distribution (in percent) for subjects with AL- and BL-predominant
MRI and CT phenotypes by GOLD grade.

BL-predominant ventilation defects

dominated the mild-moderate grades (AL/BL: GOLD I=18%/82%, GOLD II=24%/76%)
while there was a more uniform distribution for severe GOLD grades (AL/BL: GOLD
III=40%/60%, GOLD IV=43%/57%).

The opposite trend was observed for CT

emphysema phenotypes whereby the AL-predominant RA950 phenotype was more typical
in the mild-moderate grade COPD (AL/BL: GOLD I=84%/16%, GOLD II=72%/28%)
and in severe grade COPD, the distribution was more equivalent (AL/BL:

GOLD

III=64%/36%, GOLD IV=43%/57%).
Table 4-4 shows the spatial relationships for whole-lung and regional RA950 with VDP.
The strongest correlations were observed for VDP and RA950 in the apical lobes (RUL:
r=0.77, p<0.0001, LUL: r=0.65, p<0.0001) with moderate to weak correlations in the
basal lobes (RLL: r=0.48, p<0.0001, LLL: r=0.37, p=0.0001).
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Table 4-2. Imaging measurements
Parameter
All
GOLD I
GOLD II
GOLD III/IV
p*
(±SD)
(n=100)
(n=22)
(n=46)
(n=32)
RA950 %
Whole lung
11 (10)
5 (4)
9 (9)
18 (12)
<0.0001
RUL
12 (14)
6 (8)
10 (13)
19 (15)
<0.0001
RLL
9 (11)
2 (2)
7 (8)
17 (13)
<0.0001
LUL
12 (14)
5 (4)
11 (16)
19 (14)
0.001
LLL
8 (9)
3 (2)
6 (5)
15 (12)
<0.0001
RA950AL
24 (27)
11 (10)
21 (28)
38 (28)
<0.0001
RA950BL
17 (19)
5 (3)
12 (12)
32 (24)
<0.0001
∆RA950
7 (19)
6 (9)
9 (21)
6 (20)
0.7
Airways
Pi10 mm
4.2 (0.5)
4.2 (0.2)
4.2 (0.7)
4.3 (0.2)
0.6
WA%
65 (2)
65 (2)
65 (2)
65 (2)
0.5
LA mm2
13 (5)
13 (3)
13 (6)
13 (3)
1.0
VDP %
Whole lung
18 (10)
9 (5)
17 (8)
26 (7)
<0.0001
RUL
20 (18)
11 (11)
18 (17)
30 (19)
<0.0001
RLL
29 (20)
17 (10)
28 (20)
38 (22)
0.001
LUL
19 (15)
11 (6)
19 (14)
25 (17)
0.002
LLL
24 (17)
17 (8)
25 (19)
28 (16)
0.05
VDPAL
40 (31)
22 (15)
37 (29)
55 (33)
<0.0001
VDPBL
53 (35)
34 (17)
52 (37)
66 (35)
0.003
∆VDP
-13 (40)
-12 (15)
-16 (40)
-11 (50)
0.9
RA950: Relative area of the lung with attenuation values ≤ -950HU, HU: Hounsfield
unit, RA950AL=RA950RUL+RA950LUL, RA950BL=RA950RLL+RA950LLL, ∆RA950=RA950ALRA950BL, Pi10: Airway wall thickness of airways with an internal perimeter of 10mm,
WA%: Mean fifth generation airway wall area percent, LA: Mean fifth generation
airway lumen area, VDP: Ventilation defect percent, VDPAL=VDPRUL+VDPLUL,
VDPBL=VDPRLL+VDPLLL, ∆VDP=VDPAL-VDPBL, RUL: Right upper lobe, RLL: Right
lower lobe, LUL: Left upper lobe, LLL: Left lower lobe, *ANOVA corrected p-value
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Table 4-3. 3He MRI and CT apical-lung (AL) and basal-lung (BL) phenotype
measurements
3
He MRI
CT
Parameter
BL VDP AL VDP
p*
BL RA950 AL RA950
p*
(±SD)
(n=72)
(n=28)
(n=29)
(n=71)
RA950 %
Whole lung
9 (8)
16 (13)
0.03
11 (9)
11 (11)
1.0
RUL
9 (11)
20 (17)
0.002
8 (8)
14 (15)
0.3
RLL
8 (10)
11 (11)
1.0
13 (12)
7 (10)
0.3
LUL
9 (12)
20 (16)
0.01
9 (8)
14 (16)
1.0
LLL
7 (9)
9 (11)
0.9
12 (11)
6 (8)
0.07
RA950AL
18 (22)
40 (32)
0.003
17 (15)
28 (30)
0.6
RA950BL
15 (18)
21 (22)
1.0
25 (22)
14 (17)
0.1
∆RA950
3 (17)
19 (17)
0.001
-8 (8)
14 (18)
<0.0001
Airways
Pi10 mm
4.3 (0.5) 4.2 (0.2)
0.8
4.1 (0.8)
4.2 (0.2)
0.9
WA%
65 (2)
65 (2)
1.0
66 (2)
65 (2)
1.0
2
LA mm
13 (5)
14 (3)
1.0
13 (4)
13 (5)
2.0
VDP %
Whole lung
17 (10)
21 (9)
0.4
20 (10)
17 (9)
1.0
RUL
14 (12)
36 (22) <0.0001
15 (11)
22 (20)
0.8
RLL
32 (21)
21 (14)
0.07
41 (23)
24 (17)
0.002
LUL
15 (11)
31 (17) <0.0001
16 (12)
21 (15)
1.0
LLL
27 (18)
17 (9)
0.06
32 (22)
21 (13)
0.03
VDPAL
29 (21)
66 (34) <0.0001
32 (22)
43 (33)
0.8
VDPBL
59 (37)
37 (22)
0.049
73 (42)
45 (28)
0.003
∆VDP
-30 (28) 29 (34) <0.0001 -41 (35)
-2 (36)
<0.0001
RA950: Relative area of the lung with attenuation values ≤ -950HU, HU: Hounsfield
unit, RA950AL= RA950RUL+RA950LUL, RA950BL=RA950RLL+RA950LLL, ∆RA950= RA950ALRA950BL, Pi10: Airway wall thickness of airways with an internal perimeter of 10mm,
WA%: Mean fifth generation airway wall area percent, LA: Mean fifth generation
airway lumen area, VDP: Ventilation defect percent, VDPAL=VDPRUL+VDPLUL,
VDPBL=VDPRLL+VDPLLL, ∆VDP=VDPAL-VDPBL, RUL: Right upper lobe, RLL: Right
lower lobe, LUL: Left upper lobe, LLL: Left lower lobe, *ANOVA corrected p-value

101

Figure 4-2. GOLD Grade distribution of AL- and BL-predominant VDP and RA950
phenotypes. A) Basal-lung ventilation defects predominated in mild-moderate COPD
subjects. AL/BL: GOLD I=18%/82%, GOLD II=24%/76%, GOLD III=40%/60% and
GOLD IV=43%/57%. B) Apical-lung emphysema predominated in mild-moderate COPD
subjects. AL/BL: GOLD I=84%/16%, GOLD II=72%/28%, GOLD III=64%/36% and
GOLD IV=43%/57%.

Table 4-4. Regional relationships for ventilation defects (VDP) and emphysema
(RA950) for all subjects and by GOLD Grade
Pearson Correlation coefficient for VDP and RA950 (p*)
All
GOLD I
GOLD II
GOLD III/IV
Whole lung
0.61 (<0.0001)
0.73 (0.0006)
0.47 (0.003)
0.42 (0.06)
RUL
0.77 (<0.0001)
0.72 (0.001)
0.70 (<0.0001) 0.77 (<0.0001)
LUL
0.65 (<0.0001)
0.44 (0.1)
0.62 (<0.0001)
0.59 (0.001)
RLL
0.48 (<0.0001)
0.34 (0.3)
0.34 (0.02)
0.39 (0.05)
LLL
0.37 (0.0001)
0.28 (0.2)
0.38 (0.02)
0.36 (0.04)
RUL: Right upper lobe, LUL: Left upper lobe, RLL: Right lower lobe, LLL: Left
lower lobe, GOLD: Global initiative for chronic obstructive lung disease, *p-value
corrected for family-wise error
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4.4

Discussion

To provide a better understanding of the apical and basal lung regional distribution of
emphysema and airways disease phenotypes in COPD, we stratified patients based on
functional MRI and parenchymal CT measurements. We observed: 1) patients with mildmoderate COPD reported BL-predominant ventilation defects and AL-predominant
emphysema, and, 2) patients with severe COPD reported ventilation defects and
emphysema that was homogeneously (or evenly) distributed in the apical and basal lung
regions.
Numerous studies have investigated CT measurements of emphysema, their
spatial/regional distribution and their relationship with clinical findings. However, there
is no consensus about the clinical meaning or physiological outcomes that can be directly
related to the distribution of emphysema (10, 14, 17, 20, 41) or airways disease (21, 22).
For example, some studies (12, 14, 16) reported that apical-predominant emphysema was
associated with diminished pulmonary function, while other studies (13, 17, 20, 41, 42)
showed that homogeneous or basal-lung emphysema was related to poorer lung function
in patients. Others have reported that (10) the regional location of emphysema may not
be clinically important. Unlike CT-based measurements of emphysema, MRI ventilation
defects are resultant from both airways disease and emphysema in COPD patients (29).
Similar to previous studies (11, 42-44), we observed that smoking-related emphysema
was more severe in apical lung regions, especially in the milder grade subgroups.
However, we also observed that ventilation abnormalities were predominantly present in
the lung bases in the mild COPD stages.

For both emphysema and ventilation

abnormalities, the apical-basal gradients lessen in more severe disease. The fact that
VDP and RA950 were quantitatively and strongly correlated appears paradoxical, given
their regional differences. However, this may be related to the fact that in COPD
patients, the temporal onset of ventilation abnormalities and emphysema is similar, but
this study showed that their presence and site of initiation are likely regionally different.
Previous MRI studies have shown that in more severe COPD, ventilation defects may
reflect both emphysema and airways disease or collapse (45), and this may explain some
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of the differences in the regional distribution of ventilation abnormalities in severe
COPD.
Patients with mild-moderate and severe disease also showed different distributions of
AL- and BL-predominant phenotypes. Similar to a previous report (12), we observed
that the relationship between basal-lung emphysema and impaired airflow was stronger
than the relationship with apical-lung emphysema. Since ventilation is greater at the lung
bases it would follow that increased emphysema at the bases would have a greater impact
on FEV1 than emphysema at the apices. To our knowledge, the spatial relationship
between ventilation defects and FEV1 has not yet been reported. This finding will be
investigated further in the future as phenotyping COPD patients based on the distribution
of ventilation abnormalities may help explain symptoms or disease progression.
We also wanted to better understand how ventilation abnormalities and emphysema
might be related to one another in the apical and basal lung regions. VDP and RA950
were significantly correlated in all lung regions but showed the strongest correlations in
the apical-lung. Basal-lung ventilation defects predominated in mild-moderate GOLD
grades, and a more homogeneous distribution of ventilation defects was observed in more
advanced grade COPD; these differences suggest that over time, regional ventilation
abnormalities become more homogeneously distributed during disease progression. This
is in agreement with previous micro-CT analyses (1) that showed that in early stages,
there was evidence of mainly terminal airway obliteration and not emphysematous
destruction. In the future, longitudinal studies of ex- and current-smokers who are at risk
of developing COPD may provide a deeper understanding of the regional initiation and
progression of airways disease and emphysema.
Finally, we must also acknowledge a number of study limitations. First, hyperpolarized
3

He MRI is not widely used and likely never will be, because of the high cost and limited

global supply of 3He gas, and this limits the applicability of the results presented here.
However, our team and others (46, 47) are transitioning to pulmonary MRI using
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Xe

gas which is much more readily available (24, 48), less expensive and poised on the
threshold of regulatory approval and clinical translation. We should also note that the
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phenotyping approach used here was adapted from previous work (10) and was based on
the binary classification of AL- and BL-predominant phenotypes. Binary classification
methods based on a threshold do not stratify subjects based on ∆VDP and ∆RA950 so all
subjects with a positive ∆VDP and ∆RA950 were classified as AL-predominant and those
with a negative ∆VDP and ∆RA950 were classified as BL-predominant.

This

straightforward method can certainly be improved by using three- or multi-dimensional
indices and thresholds.

In addition, we did not take into account emphysema or

ventilation heterogeneity distributions between the lung core and rind regions as
previously described (12-14, 49).

CT images were acquired at the same inhalation

volume as MRI (FRC+1L) rather than full inspiration in order to enable the direct
comparison of MRI and CT phenotypes at the same lung volume. For this reason, the
estimates of emphysema generated here based on CT cannot be directly compared with
other quantitative CT emphysema estimates acquired at full inspiration.

We note,

however that in gas-trapped COPD patients, the differences between full inspiration and
FRC+1L is approximately 1L and that the whole-lung RA950 values reported here derived
at a smaller lung volume are similar to those reported in the COPDGene study (18, 50).
Expiratory CT scans were not performed and in future studies, paired inspiratoryexpiratory CT scans and phenotyping ex-smokers using novel parametric response
mapping (PRM) techniques (21) might provide a better understanding of apical- and
basal-predominant phenotypes. Furthermore, although acquired, ADC-based measures of
emphysema from 3He MRI were not used to quantify emphysema here because of the
bias that results from the fact that only well-ventilation regions report ADC. Future
studies comparing regional ADCs with CT RA90 may be useful to further verify the
apical to basal pattern observed here. We must also point out that some of the patients
classified with GOLD I COPD (ie. Subject 1 in Figure 4-1: 69 year-old female,
FEV1=84%pred, FVC=94%pred, FEV1/FVC=69%) were within the lower limit of normal
(LLN) spirometry values for the mean age of this subgroup (75±7 years). The mean
values of 95±12%pred and 109±12%pred for FEV1 and FVC respectively for the GOLD I
subgroup (as show in Table 4-1) were also greater than the LLN as previously described
(51). It is worth noting, however, that for this study, the diagnosis and classification of
COPD included clinical symptoms over a 3 month period, a smoking history of >10 pack
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years as well as the GOLD thresholds. We also acknowledge that this study focused on
COPD patients with mainly mild-moderate disease (grade I COPD=22 subjects and grade
II COPD=46 subjects) and that there was a small number of GOLD III (n=25) and GOLD
IV (n=7) subjects and therefore our findings must be interpreted in this context.
In conclusion, we phenotyped ex-smokers with COPD based on the apical-basal
distribution of emphysema and ventilation defects. We observed that a BL-predominant
distribution of ventilation defects and AL-predominant distribution of emphysema was
present in subjects with mild–moderate airflow obstruction. With increasing disease
severity, there may be a basal-to-apical progression of ventilation abnormalities and an
apical-to-basal progression of emphysema.
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CHAPTER 5
5

Conclusions and Future Directions

This last chapter will provide a summary of the research findings in Chapters 2 – 4 and
address important research questions that remain unanswered. I will also discuss
limitations to the research work presented throughout the thesis and outline future
directions that have been motivated by the work presented in Chapters 2 – 4.

5.1

Overview and Research Questions

COPD is the only one of the leading causes of morbidity and mortality that has a steadily
increasing mortality rate (1). This increasing mortality rate is suspected to be attributable
to poor performance of conventional pulmonary function tests to: 1) characterize early or
subclinical lung disease, 2) to identify susceptible individuals and 3) to diagnose
individuals in the mild stages.

It has become clear over the last few decades that

spirometry alone is unable to fully characterize the extreme heterogeneity of the disease
(2, 3). In this regard, advances in pulmonary imaging with CT and MRI have become
more sophisticated, now able to provide whole-lung and regional quantitative measures
of emphysema and airways disease in vivo. The major goal of this thesis was to exploit
regional and direct measurements of pulmonary ventilation from hyperpolarized 3He MRI
to tease out clinically relevant pre- and subclinical lung disease phenotypes in ex-smokers
with and without airflow limitation. The specific research questions addressed here were:
1) is there a mechanistic link between pre- or subclinical airflow limitation and vascular
disease (Chapter 2)?

2) What is the underlying, pathophysiological phenotype of

3

disease causing He ventilation abnormalities in ex-smokers without airflow limitation
(Chapter 3)? 3) Can the apical-to-basal distribution of MRI ventilation abnormalities and
CT emphysema be used to identify clinically relevant COPD phenotypes (Chapter 4)?
Does the apical – basal phenotype change with COPD progression (Chapter 4)?

5.2

Summary and Conclusions

In Chapter 2 we collected carotid three-dimensional ultrasound and hyperpolarized 3He
MRI from ex- and never-smokers without airflow limitation or a diagnosis of
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cardiovascular disease to better understand the mechanistic link between pre- or
subclinical lung and vascular disease.

First, we observed that ex-smokers showed

significantly more carotid plaque, indicative of carotid atherosclerosis, and more 3He
ventilation heterogeneity, a sign of subclinical lung disease, compared to never-smokers.
Second, carotid ultrasound measurements of plaque, wall thickness and vessel wall
volume correlated with 3He ventilation heterogeneity for all subjects. Together these
results suggest that there is a subclinical phenotype in ex-smokers without airflow
limitation characterized by mild carotid atherosclerosis and airflow limitation that is not
obvious on spirometry.
In Chapter 3 we aimed to better characterize the underlying pathophysiology of 3He
ventilation defects in ex-smokers without airflow limitation using regional 3He MRI and
CT measurements of emphysema and airways disease. In 60 ex-smokers without airflow
limitation, 42 subjects had abnormal 3He ventilation heterogeneity while 18 had normal
ventilation. Those ex-smokers with abnormal 3He ventilation exhibited worse wholelung and apical-lung 3He ADC and we also observed that ventilation defects were
spatially related to abnormal airway morphology and microstructural emphysema (ADC)
in all subjects. These results suggested that there is a phenotype of ex-smokers with
airflow limitation characterized by abnormal

3

He ventilation, abnormal airway

morphology and very mild emphysema.
In Chapter 4 our objectives were: 1) to phenotype COPD ex-smokers based on the
apical-to-basal distribution of 3He ventilation defects and CT emphysema and 2) to
evaluate how apical-basal disease phenotypes change with COPD progression. Out of
100 COPD patients, seventy-two reported basal-lung (BL) -predominant MRI ventilation
defects and 71 reported apical-lung (AL) -predominant CT emphysema. BL-predominant
ventilation defects and AL-predominant emphysema were the major phenotypes in mildmoderate COPD. In severe COPD there was a more uniform distribution for ventilation
defects and emphysema. Together these results suggest that with increasing disease
severity (worse airflow obstruction) there is a basal-to-apical progression of ventilation
abnormalities and an apical-to-basal progression of emphysema.
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5.3

Limitations

This section will provide an overview of the major limitations of each study presented in
this thesis and how they can be overcome in future work.

5.3.1

Study Specific Limitations

The study in Chapter 2 was dependent on the collection of carotid three-dimensional
ultrasound scans from every subject. The quality of carotid ultrasound scans is highly
dependent on; 1) the anatomy of the patient being imaged and 2) having a highly trained
technician perform the ultrasound scan (4). In our study, all ultrasound data acquired was
sufficient quality for analysis but the scans had to be repeated several times for many
individuals. This increased the overall time for ultrasound acquisition and time of each
patient visit at our centre. This led us to believe that such a study might not be feasible in
large cohorts of subjects, especially in patients with disease who are not as mobile and
require careful monitoring even for short study visits. This is an issue because the
relatively small sample size in our study may have limited our power to detect clinically
meaningful differences in pulmonary function or ultrasound measurements of
atherosclerosis. A large-scale cohort study exploiting pulmonary imaging and carotid
ultrasound may provide more useful information on the comorbidity between
atherosclerosis and airflow limitation, however a challenge would be collecting highquality ultrasound data in a feasible timeframe. A second limitation to this study was the
vessel-wall-volume (VWV) measurement (5) that was used to measure carotid
atherosclerosis in the study subjects. We were not surprised that the one-dimensional
measurement of carotid intima-media thickness (IMT) was not significantly different
between ex- and never-smokers as the dynamic range for this parameter is extremely
small which is known to reduce its sensitivity to small changes (6). However, the threedimensional measurement of total plaque volume (TPV) revealed that ex-smokers had
more carotid plaque than never-smokers while VWV, the second three-dimensional
measurement, showed no difference between the two subgroups. This was an unexpected
result because the VWV is the sum of plaque and carotid wall volume and we observed
quantitatively more plaque in the ex-smokers.

However, several carotid ultrasound

studies (7, 8) have established that the VWV measurement is truly dependent on the
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anatomy of the carotid artery and two subjects with a different amount of carotid plaque
may have the same vessel-wall-volume. With this in mind, the refined vessel-wall
measurement, termed the ‘vessel-wall-plus-plaque thickness’ (VWT) (9) which
overcomes the size dependence of vessel wall volume, might provide clinically
meaningful three-dimensional ultrasound findings in these ex- and never-smokers.
In Chapter 3 we endeavored to provide a better understanding of the underlying etiology
of 3He ventilation defects in ex-smokers without airflow limitation using regional MRI
and CT measurements. One major limitation to this study was that for regional airway
measurements we measured only one individual subsegmental airway that feeds into each
lung lobe and not all airways associated with each lobe. We observed significant spatial
relationships between ventilation defects in the right lung lobes and subsegmental airway
morphology feeding into those lobes but did not observe these significant relationships in
the left lung. The lobes of the left lung are larger than those in the right lung (10) and
therefore lobar ventilation in the left lung is spread across more airways. By measuring
only one subsegmental airway in each lobe we may have potentially missed abnormal
airway morphology of other airways in each lobe.

Furthermore, the subsegmental

airways we measured were 3rd – 6th generation airways which are cartilaginous airways of
the conducting zone. We chose to measure these airways in particular because they were
consistently measurable in cross-section and clearly visible on thoracic CT for each and
every subject, whereas higher generation airways were not always visible and
measureable in every subject. Previous work (11) suggested that subsegmental airway
morphology measured on CT reflects that of the small airways, however there is also
evidence (12) that this may not always be the case. We must also acknowledge that the
ability to measure up to a maximum airway generation is an inherent limitation of CT due
to the achievable resolution on these scans (13). A second major limitation to this study
was that we used a threshold cut off to subdivide ex-smokers into abnormally elevated
ventilation defect percent (VDP) and those within the normal range for VDP and
therefore our results are dependent on this threshold value. This threshold was based on
the upper-limit of normal (95% confidence interval) of VDP in a well characterized
group of never-smokers from a previous study (14). We are unsure how our findings
would have changed if a different threshold value (ie. 90% confidence interval) was used.
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Although it is likely we would have observed slightly different results with a more
conservative VDP threshold.
In Chapter 4 our goal was to phenotype COPD ex-smokers based on the apical-to-basal
distribution of ventilation abnormalities and emphysema and to determine if apical-basal
phenotype changes with disease progression. We divided subjects into apical- and basallung predominant phenotypes based on a method previously described by Gietema (15).
In our study phenotypes were defined as follows (where RA950 is the relative area with
attenuation ≤ -950HU): RA950 in the basal-lung (RA950BL = RA950RLL + RA950LLL) and
RA950 in the apical-lung (RA950AL = RA950RUL + RA950LUL) were used to generate the
difference between apical- and basal-lung RA950 (∆RA950) where ∆RA950 = RA950AL RA950BL. A positive ∆RA950 was indicative of apical-lung-predominant emphysema, and
a negative ∆RA950 indicated basal-lung-predominant emphysema. Similarly, regional 3He
VDP was used to specify apical-lung- and basal-lung-predominant 3He ventilation defect
phenotypes where the ventilation defect percent in the basal-lung (VDPBL = VDPRLL +
VDPLLL) was subtracted from the ventilation defect percent in the apical-lung (VDPAL =
VDPRUL + VDPLUL) to generate the VDP difference between the apical- and basal-lung(∆VDP). A positive ∆VDP indicated an apical-lung-predominant ventilation defects and
a negative ∆VDP indicated basal-lung predominant ventilation defects. Therefore the
method we used to phenotype COPD subjects was very specific and it is entirely possible
that our findings may have been different if we chose to use a different apical- basalphenotyping strategy/equation as several others have been described (16-19). At the
same time, the binary classification method we used to phenotype subjects might be
oversimplistic for characterizing such a heterogeneous and multi-component disease such
as COPD. Other strategies that phenotype COPD subjects based on the spatial location
of disease using three- or multi-dimensional thresholds may offer more information on
how the spatial location of disease impacts lung function. In addition, we did not explore
the distribution of ventilation abnormalities and emphysema between the lung core and
rind regions to phenotype COPD subjects as previous studies have done (16-18, 20).
Phenotyping based on lung core – rind distribution may offer another useful method to
identify clinically meaningful COPD subgroups.
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5.3.2

General Limitations

The studies present in Chapters 2 – 4 all focus on using 3He MRI to phenotype exsmokers.

3

He MRI is an extremely costly research technique and is only used in a

handful of research centres worldwide.

It requires expensive spin-exchange optical

pumping polarization equipment, specialized transmit – receive radiofrequency coils and
highly trained physicists and technicians to operate polarization equipment and the MRI
scanner. Therefore, just being able to construct and operate a hyperpolarized noble gas
research centre alone is a large endeavor (21). At the same time, while we predominantly
focused on the use of 3He noble gas, the global supply of this gas is declining and its
price is increasing quickly. Currently, 1 litre of 3He costs in excess of $1K. Therefore
given the limited supply of 3He along with the expense and resources required to operate
a hyperpolarized noble gas MRI research centre, the transition of this imaging method
into clinical setting does not seem likely. Concomitantly, the expense of 3He MRI ties in
with the general limitation common in each study presented in this thesis of small sample
sizes. While we believe our results are clinically relevant, we acknowledge that the
number of subjects used in each study was much smaller than those in other large-scale
lung imaging studies that used CT such as ECLIPSE (22), COPDGene (23) and MESA
(24). Future hyperpolarized noble gas studies may benefit from multi-centre trials where
more subjects can be recruited for imaging as was previously done in the Polarized
Helium to Image the Lung (PHIL) trial (25).
Despite the limitations imposed by the declining levels of 3He, it is important to note that
noble has MR images of ventilation were first proposed (26) with
substantially more abundant and cost effective than
improvements in commercialization of

129

3

He.

129

Xe gas which is

Furthermore, recent

Xe polarization equipment and software have

made global exploitation of 129Xe MRI a possibility.
Along with general limitations imposed by 3He MRI in our studies, there may also be
inherent limitations in our CT measurements. We aimed to provide an understanding on
the structure-function relationships of 3He ventilation abnormalities and airway and
parenchymal disease but it is established that CT is not sensitive to very mild or
subclinical changes to the airways and parenchyma (27). First, due to CT resolution
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limits, even among the most compliant subjects and highest quality scans, airways can
only be counted and measured with confidence up to about the 10th generation (13). And
often there will be extreme heterogeneity among the airway generations that can be
measured in COPD cohorts making the most commonly reported measurements from the
large and central airways of the conducting zone. The highest generation airways we
reported were from the 6th generation airways in Chapter 3 and these were ex-smokers
with normal spirometry and without severe disease. Therefore the resolution limits
imposed by CT may have limited our power to find significant results using these airway
measurements, since the airways being measured were more central than the small
airways < 2mm which are the origin of airflow limitation in smoking related COPD. At
the same time, it has also been shown (27) that CT measurements of emphysema cannot
detect small emphysematous lesions, such as those that may occur in early or mild forms
of COPD. Therefore another limitation inherent in the studies in Chapters 2 – 4 is related
to the ability of CT to measure mild or microstructural emphysema. In this regard, we
found that 3He MRI ADC measurements showed much higher sensitivity to early and
mild emphysema as these measurements predominantly measure microstructural
emphysema.

5.4

Future Directions

5.4.1
Longitudinal Hyperpolarized 3He MRI of Ex-smokers With
and Without Airflow Limitation
Longitudinal imaging studies monitoring pulmonary pathophysiology in susceptible
groups of ex- and current smokers are essential to improve our understanding of COPD
progression and treatment outcomes.

The Thoracic Imaging Network of Canada

(TINCan) is a three-year follow-up pulmonary imaging study of 3He MRI and CT in exsmokers with and without airflow limitation (28). Previous research has established that
that 3He MRI ventilation measurements are reproducible (29), reflect response to therapy
(30) and predict COPD exacerbation episodes (31) and therefore we believe it is valuable
to investigate how and if pulmonary MRI ventilation measurements change over time.
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Thus far, 82 ex-smokers (33 ex-smokers without airflow limitation, 48 ex-smokers with
COPD (FEV1/FVC<70%)) have undergone

3

He MRI, inspiratory CT, pulmonary

function testing and the six-minute walk test and completed the St. George’s Respiratory
Questionnaire at baseline and follow-up at approximately three-years. Figure 5-1 shows
3

He ventilation images at baseline and follow-up and the unventilated lung regions at

follow-up for representative subjects (The change in ventilation heterogeneity, or change
in ventilation defect percent (∆VDP) is calculated as ∆VDP=VDPFollow-up – VDPBaseline).

Figure 5-1. 3He ventilation images in ex-smokers at baseline and follow-up (3yr).
Visually and quantitatively ex-smokers with COPD had a greater change and annual rate
of change (ROC) in 3He ventilation over the three-years. S1 is a 65yr male ex-smoker
without COPD ∆VDP = +3% (ROC=+1%/yr), S2 is a 76yr male ex-smoker with
moderate COPD ∆VDP = +6% (ROC=+2%/yr) and S3 is a 72yr female ex-smoker with
severe COPD ∆VDP = +10% (ROC=3%/yr).
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This longitudinal pulmonary study will address several compelling questions including:
1) Are there regional and/or whole-lung changes in 3He ventilation
heterogeneity from baseline to follow-up in ex-smokers with and without
airflow limitation?
2) Are there differences in ∆VDP and annual rate of change (ROC) in VDP
between ex-smokers with mild, moderate and severe COPD?
3) How do longitudinal pulmonary imaging measurements compare to
longitudinal conventional pulmonary function test and exercise capacity
measurements?
4) How do CT measurements of emphysema and airways disease relate to
longitudinal pulmonary MRI measurements?
5) Do baseline and follow-up MRI measurements predict mortality in ex-smokers
with and without airflow limitation?

5.4.2
Hyperpolarized 3He MRI Apparent Diffusion Coefficients: A
Potential Tool to Evaluate Alpha-1 Antitrypsin Augmentation Therapy
Alpha-1 antitrypsin deficiency (AATD) results in an imbalance of neutrophil elastase and
alpha-1 antitrypsin (AAT) causing panlobular emphysema and airflow limitation. AAT
augmentation therapy is approved for the treatment of AATD-related lung disease and
influences lung function decline in some AATD patients (32). Since 3He MRI ADC
measurements are highly reproducible measurements of alveolar microstructure that are
sensitive to emphysematous changes in the lungs, we believe that acquiring longitudinal
3

He MRI ADC measurements in AATD patients might serve as a sensitive and direct

method to evaluate disease progression and response to AAT augmentation therapy.
Figure 5-2 shows 3He ADC maps in three AATD patients and three ex-smokers with
centrilobular emphysema at baseline and 3-year follow-up. AATD patients reported
elevated 3He ADC in the basal-lung while COPD ex-smokers reported elevated ADC in
the apical-lung. At the same time, AATD patients reported increased whole-lung ADC at
3 year follow-up compared to COPD ex-smokers who reported the same ADC at baseline
and follow-up. The AATD subject receiving weekly augmentation therapy had a smaller
increase in whole-lung ADC (+0.01 cm2/s) compared to subjects not receiving
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augmentation therapy (S2 and S3, +0.02 cm2/s). Similarly, the basal-lung ADC did not
change in the AATD subject on augmentation therapy but increased in both AATD
subjects not receiving therapy.

Figure 5-2. 3He ADC in alpha-1 antitrypsin patients & ex-smokers with emphysema
at baseline and three-year follow-up. S1, 66yr male never-smoker undergoing
augmentation therapy once/week. S2, 62yr female ex-smoker (44pck yr) and S3, 52yr
male never-smoker not receiving augmentation therapy. S4, S5 and S6 are ex-smokers
(>20 pack yr) with moderate (GOLD II) and severe (GOLD III) COPD.
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Future work on this proof-of-concept longitudinal study of 3He MRI ADC measurements
in AATD will provide answers to the following questions:
1) Do 3He MRI ADC measurements change regionally and throughout the whole
lung in AATD patients over time?
2) Are changes in ADC measurements different between AATD patients and COPD
patients with centrilobular emphysema?
3) How do ADC measurements change longitudinally in AATD patients receiving
augmentation therapy compared to those who are not?

5.4.3
Second-Order Texture Analysis of Hyperpolarized 3He MR
Images: Beyond the Ventilation Defect
Current image processing methods for evaluating ventilation heterogeneity on 3He MR
images focus on quantifying the volume of ventilation defects throughout the lung as the
ventilation defect percent (VDP). Unfortunately, these measurements do not exploit the
valuable information inherent in the ventilation signal itself. We and other groups have
observed that patients with the same VDP can have different local and regional
ventilation patterns as depicted on MRI and different respiratory diseases, suggesting that
there are measureable differences in ventilation heterogeneity that are not reflected by the
VDP measurement alone. Figure 5-3 shows an example of this where the 3He ventilation
images from an ex-smoker without COPD, a COPD ex-smoker and an asthmatic subject
have the same VDP but each subject has different regions of ventilation heterogeneity
and second-order texture measurements of ventilation signal. Therefore we believe that a
texture analysis approach of analyzing the

3

He ventilation signal may provide

physiologically-relevant information on underlying disease processes.

122

Figure 5-3. 3He static-ventilation and 3He texture maps and measurements for a
representative ex-smoker without airflow limitation, COPD subject and asthmatic
subject.
The Ex-smoker is a 79 year-old female with FEV1=88%, VDP=10%, f3=0.96, f12=-0.34
and f13=0.98, the COPD subject is a 57 year-old female with FEV1=93%, VDP=10%,
f3=0.97, f12=-0.35 and f13=0.98 and the Asthmatic is a 49 year-old female with
FEV1=69%, VDP=10%, f3=0.97, f12=-0.35 and f13=0.97.

The preliminary work for this research was focused on 1) developing a second-order
texture analysis algorithm that measures sixteen (f1 – f16) texture features through
statistical evaluation of a grey level co-occurrence matrix (GLCM) (33), 2) using the
algorithm to collect texture measurements from ex-smokers without COPD, ex-smokers
with COPD and asthmatics with similar VDP and 3) performing statistical analyses on
texture measurements to investigate any differences between lung disease phenotypes and
testing the sensitivity and specificity of texture measurements for predicting lung disease
phenotype. A semi-automated second-order texture analysis algorithm was created in
MATLAB and is shown in Figure 5-4.
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Figure 5-4. Second-order texture analysis algorithm for hyperpolarized 3He MR
images
Texture information was only of interest in the 3He ventilation signal and not from the
regions surrounding it. Therefore we constructed an algorithm that could semiautomatically extract the 3He ventilation signal without the surrounding signal void and
then calculate texture parameters of the signal. 1, is the raw data 3He static-ventilation
MR image coronal centre slice. 2 is the 3He static-ventilation MR image coronal centre
slice with the trachea is removed. 3 is the filtered 3He image (filtered with a 10×10
median filter) which is used to extract 4, the maximum entropy threshold mask. 4 is then
multiplied by 1 to generate 5 which is the 3He ventilation signal with no surrounding
noise. Four gray-level co-occurrence matrices (6, one for each direction of interest; (1,0), (-1,-1), (0,-1) and (1,-1)) are generated from 5 and are subsequently used to extract
the sixteen texture features used in this study (f1-f16).
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The sixteen second-order texture parameters measured by the semi-automated algorithm
from are listed in Table 5-1 (33).

Table 5-1. Second-order texture measurements
f1 :
Angular Second Moment
f2 :
Contrast
f3 :
Correlation
f4 :
Variance
f5 :
Homogeneity
f6 :
Sum Average
f7 :
Sum Variance
f8 :
Sum Entropy
f9 :
Entropy
f10 : Difference Variance
f11 : Difference Entropy
f12 : Information Measures of Correlation 1
f13 : Information Measures of Correlation 2
f14 : Cluster Shade
f15 : Cluster Prominence
f16 : Autocorrelation

Sixty subjects consisting of 20 ex-smokers without COPD, 20 ex-smokers with COPD
and 20 asthmatics with VDP < 20% were included in a preliminary analysis which found
that f3, f12 and f13 were significantly different on one-way analysis of variance (ANOVA)
analysis (Table 5-2).
This early work with second-order texture analysis in 3He MRI provided compelling data
and motivated subsequent research from our group using texture analysis in asthmatics.
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Table 5-2. Second-order texture measurements for all study subjects
Ex-smokers
Mild COPD
Asthma
ANOVA
(n=20)
(n=20)
(n=20)
p-value*
-4
f1 (×10 )
100 (10)
80 (80)
100 (8)
0.70
f2
70 (62)
63 (44)
63 (48)
0.88
f3
0.95 (0.01)
0.96 (0.01)
0.96 (0.01)
0.003
f4
4610 (3420)
5080 (3210)
6350 (4830)
0.36
f5
0.29 (0.07)
0.29 (0.06)
0.30 (0.07)
0.84
f6
120 (42)
120 (39)
140 (60)
0.47
f7 (×103)
17 (13)
19 (12)
23 (19)
0.35
f8
5 (0.4)
5 (0.4)
5 (0.4)
0.44
f9
8 (0.7)
8 (0.6)
8 (0.7)
0.76
f10
70 (62)
63 (44)
63 (48)
0.88
f11
2.7 (0.4)
2.7 (0.3)
2.6 (0.4)
0.89
f12
-0.31 (0.03)
-0.34 (0.03)
-0.34 (0.03)
0.009
f13
0.97 (0.01)
0.98 (0.01)
0.98 (0.01)
0.02
3
f14 (×10 )
38 (159)
118 (160)
41 (154)
0.21
f15 (×104)
3630 (6070)
5080 (5760)
4950 (6180)
0.71
f16
4570 (3390)
5050 (3190)
6310 (4810)
0.35
f1: Angular second moment, f2 : Contrast, f3: Correlation, f4 : Variance, f5 :
Homogeneity, f6 : Sum Average, f7 : Sum Variance, f8 : Sum Entropy, f9 :
Entropy, f10 : Difference Variance, f11 : Difference Entropy, f12 :
Information Measures of Correlation 1, f13 : Information Measures of
Correlation 2, f14 : Cluster Shade, f15 : Cluster Prominence, f16 :
Autocorrelation

The Future of Texture Analysis in Pulmonary MRI: Applications in

129

Xe and

19

F

MRI
The theory and data presented in this subsection laid the groundwork for the manuscript
titled ‘Second-Order Texture Measurements of 3He Ventilation MRI: Proof-of-Concept
Evaluation of Asthma Bronchodilator Response’ published in Academic Radiology
(DOI: 10.1016/j.acra.2015.10.010). The manuscript was co-authored by Nanxi Zha,
Damien Pike, Sarah Svenningsen, Dante PI Capaldi, David G McCormack and Grace
Parraga.
This manuscript confirmed that texture analysis methods can be applied to

3

He

ventilation MR images and used to extract measurements that quantify ventilation
heterogeneity and change in response to therapy (34, 35). However, in the future it is
likely that pulmonary MRI studies using inhaled gases may transition from the use of 3He

126

to

129

Xe and fluorinated (19F) gases. Therefore, owing to this previous research that has

revealed clinically meaningful results in 3He, scientists and clinicians should start
investigating and implementing texture analysis algorithms (first, second, third and/or
higher order) in

129

Xe and

19

F MR images. Texture analysis algorithms and texture

measurements, unlike quantitative measurements of ventilation defects, take advantage of
ventilation signal present within the lung.
ventilation defects are larger in
This means that

129

129

Early work with

129

Xe has shown that

Xe MR images compared to 3He MR images (36).

Xe MR images have less ventilation signal from which to extract

texture measurements from compared to 3He MR images. This may cause the texture
measurements to be different between

129

Xe to 3He MR images and importantly, the

clinically important change in response to therapy previously observed in 3He MR images
may also change or not be detected using texture measurements from 129Xe or 19F images.
Future work using 129Xe and 19F MRI should focus on providing a better understanding of
how/if texture measurements show clinically relevant changes in response to therapy in
these images analogous to those observed with 3He MRI. Since most previous work with
pulmonary MRI and pulmonary ventilation has focused on ventilation defects (regions of
signal void), a deeper understanding of pulmonary ventilation signal present in the lung
through texture measurements could provide scientists and clinicians with novel findings
related to ventilation heterogeneity and lung disease phenotypes.

5.5

Significance and Impact

Spirometry measurements are continuously used as the gold-standard for assessing
pulmonary function and airflow limitation in COPD patients.

Although expiratory

airflow measurements are globally used as diagnostic criteria for COPD, it is now widely
known that these measurements alone do not adequately characterize the heterogeneity of
COPD with regards to lung function and structure. In light of this, imaging phenotypes
of COPD have emerged as a solution to identify and characterize clinically relevant
components of pulmonary structure and function in patients beyond conventional
pulmonary function testing. In this thesis we demonstrated that 3He MRI measurements
of pulmonary structure and function provide a way to phenotype ex-smokers without
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airflow limitation and COPD patients.
spirometry there was

3

In this regard, in ex-smokers with normal

He MRI evidence of pulmonary structural and functional

abnormalities that were concordant with carotid atherosclerosis and mild microstructural
emphysematous destruction or gas trapping. In COPD patients, 3He MRI provided a way
to identify distinct apical- and basal-lung predominant disease phenotypes and we
observed that these phenotypes were different according to disease severity.
Taken together, these results show how hyperpolarized noble gas MRI can be used as a
tool to identify and characterize clinically relevant structural and functional changes that
occur in COPD. As advances in pulmonary imaging continue, and novel quantitative
measurements emerge to evaluate lung disease, the important findings from this thesis
will serve as a foundation for knowledge for understanding COPD phenotypes.
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APPENDIX
APPENDIX A – Imaging Evidence of the Relationship Between
Carotid Atherosclerosis and Chronic Obstructive Pulmonary
Disease
As the focus of this thesis is on pulmonary imaging phenotypes of COPD, and given that
the study in Chapter 1 provides an overview and understanding on the relationships
between MR imaging measurements of airflow limitation and 3DUS measurements of
carotid atherosclerosis, In Appendix A we have provided the review article titled
‘Imaging Evidence of the Relationship between Atherosclerosis and Chronic Obstructive
Pulmonary Disease’ which is published in Imaging in Medicine (DOI: 10.2217/iim.
13.70, 2013). Permission to reproduce the chosen section(s) of this article was granted
by Future Medicine® and is provided in Appendix D.
D Pike, TJ Lindenmaier, DD Sin and G Parraga. Imaging Evidence of the Relationship
between Atherosclerosis and Chronic Obstructive Pulmonary Disease. Imaging in
Medicine; DOI: 10.2217/iim. 13.70, 2013

REVIEW ARTICLE:
Imaging Evidence of the Relationship between Atherosclerosis
and Chronic Obstructive Pulmonary Disease
D Pike, TJ Lindenmaier, DD Sin and G Parraga

ABSTRACT
Tobacco smoking is a risk factor for both pulmonary disease and atherosclerosis and a
number of studies have provided experimental and epidemiological evidence about the
potential links between chronic obstructive pulmonary disease (COPD) and
atherosclerosis that is not explained by tobacco smoking alone. While this evidence is
very compelling, the direct mechanisms that potentially accelerate atherosclerosis
development in patients with COPD have not been established. At the same time, major
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advances in quantitative pulmonary and vascular non-invasive imaging tools have
advanced the development and validation of surrogate or intermediate endpoints of these
chronic disorders. This article provides a review of emerging and established imaging
methods that have the potential to quantify pulmonary disease and atherosclerosis noninvasively and robustly, in the same patients over time; we summarize studies that
endeavored to evaluate lung structure-function and atherosclerosis in order to provide
novel insights on disease pathogenesis and progression.

INTRODUCTION AND OVERVIEW: Is there a relationship between chronic lung

and vascular disease that is not explained by smoking history?
There is increasing evidence that chronic obstructive pulmonary disease (COPD) and
atherosclerosis may be directly and mechanistically related beyond shared risk factors of
cigarette smoking and exposure to environmental pollutants. Large scale investigations
such as the Lung Health Study (1), the Multi-ethnic Study of Atherosclerosis (MESA)
Lung Study (2) and the Atherosclerosis Risk in Communities (ARIC) study (3), along
with population based studies on COPD mortality and morbidity (4-6) have established
that impaired lung function is a risk factor for vascular disease, independent of cigarette
smoking.

While atherosclerosis and chronic pulmonary disease share common risk

factors such as cigarette smoke, air pollution, biomass exposure, poor nutrition and in
much of the developed world, low socio-economic status (7), the relationship between
COPD and atherosclerosis-related morbidities such as ischemic heart disease and stroke
extend beyond these shared risk factors. However, the exact mechanisms underlying this
relationship are not well understood (8).
As shown in Figure 1, recently, van Eeden and others have proposed the “lung
permeability” theory as an important mechanism behind the relationship between COPD
and atherosclerosis (8).

These authors and others suggest that inhalation of the

environmental irritant (e.g. cigarette smoke, air pollution particles, respiratory viral or
bacterial microbes) is the inciting event.

In response, the host mounts a robust

inflammatory reaction to control and eliminate these environmental irritants, preventing
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the direct translocation of toxic chemicals, respiratory pathogens and air pollution
particles into the systemic circulation and enabling the host defenses to remove these
unwanted visitors. To promote this process, airway epithelial cells, alveolar macrophages
and various circulating hematopoietic cells (eg. neutrophils) synthesize cytokines,
chemokines and reactive oxygen and nitrogen species in the lungs. Because the lungs are
highly vascularized, it is possible although not proven, that during periods of
inflammatory and oxidant stress, the alveolar-capillary interface may become highly
permeable and allow inflammatory mediators to migrate into the systemic circulation.
Some of these inflammatory mediators (e.g. interleukin-6 (IL-6) and interleukin 1-beta)
can coax the liver to increase production of secondary mediators of inflammation such as
C-reactive protein, fibrinogen, serum amyloid protein and pro-coagulant factors, and the
bone marrow to increase the synthesis and release of leukocytes into the systemic
circulation, causing an amplification of the inflammatory signal. With chronic lung insult
(as in the case of cigarette smoking or living in highly polluted areas), the alveolarcapillary interface may “re-model” and become persistently “leaky”, leading to a state of
chronic (low-grade) systemic inflammation even after the environmental exposure is
removed (as in the case of smoking cessation).

The constantly elevated level of

inflammatory markers may contribute to the genesis and progression of atherosclerosis.
However recent work in this area (9, 10) has shown that systemic inflammation is not the
only factor contributing to atherogenesis in COPD. In fact, systemic inflammation is
common to several COPD comorbidities (9) and it was recently shown that COPD
patients with cardiovascular disease differ only in levels of IL-6 (10). This suggests there
must be other drivers of cardiovascular disease in COPD. Potential mediators such as
nutrition, inactivity, genetic factors or medication may promote vascular dysfunction in
COPD patients.
To date, the large majority of studies evaluating links between pulmonary and vascular
disease have focused on pulmonary function tests to assess lung function and mainly
carotid atherosclerosis intermediate endpoints such as intima media thickness.

One

major limitation of “global” pulmonary function tests is that they provide no anatomical
or regional information of the lungs (11). This limitation has been surmounted by the
advent of non-invasive pulmonary imaging techniques that can directly quantify
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pulmonary structure-function correlates and enable accurate phenotyping of disease (1214).
The risk of atherosclerosis can be monitored with or without vascular imaging
techniques.

Commonly, blood level measurements of lipids such as low density

lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides and less frequently,
inflammatory mediators such as C-reactive protein and myeloperoxidase are used to
provide surrogate measures of lipid profile and systemic inflammation which may play a
role in atherogenesis. In addition to blood sampling, the ankle brachial index (ABI) -the
ratio of the systolic pressure of the ankle to the arm, is also widely used as another “nonimaging” surrogate measure of atherosclerosis (15, 16). Although these non-imaging
methods have been used in pulmonary-vascular disease studies, they are limited in the
fact that they provide measurements of “generalized” atherosclerosis or vascular disease
(15). From a direct imaging perspective, carotid ultrasound (US) measurements have
emerged as reliable tools for evaluating atherosclerosis burden because they correlate
well with future cardiovascular events (17, 18) and importantly, the method is relatively
rapid, inexpensive and uncomplicated to acquire and quantify. Although there is still
some controversy as to which ultrasound measurement best estimates risk of outcomes
such as stroke (19), there is no disagreement that extensive development of non-invasive
imaging methods to directly quantify atherosclerosis (20-24) has stimulated the
development of improved medical treatment options and improved outcomes (25).
As several excellent reviews are available on chronic respiratory disease (26) and
cardiovascular risk (7, 27-29), and owing to the limited use of angiography (30-33) and
intravascular ultrasound (IVUS) (34, 35) for research purposes outside of coronary artery
disease, here we focus on emerging pulmonary and atherosclerosis imaging techniques.
There are few studies published that use imaging to interrogate pulmonary and vascular
disease in the same patients. As summarized in Table 1, a number of key studies have
primarily used imaging to investigate the relationship between carotid atherosclerosis and
pulmonary function in COPD. Collectively, these studies provide a strong foundation for
future studies that may incorporate novel imaging methods of both pulmonary and
vascular disease in smokers and ex-smokers.
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Iwamoto [105]

van Gestel [107]

Dransfield [124]

Kim [106]

McAllister [113]

Matsuoka [112]

Frantz [118]

Barr [2]

Lahousse [57]

Rasmussen [111]
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(n)

Ebrahim [55]
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87/14

55/45

43/57

49/51

41/59

57/43

52/48

98/2

154/86

78/22

100/0

43/57

79/21

38/62

100/0

53/47

Sex
M/F

Korea

Danish LCST
(Denmark)

Rotterdam
(Netherlands)

MESA (USA)

Sweden

LTRC (USA)

MESA (USA)

Korea

NLST (USA)

Netherlands

Japan

ARIC (USA)

Netherlands

France

Sweden

Britain

Location

- FEV1, FVC, FEV1/FVC
- TLC, RV, DLCO
- FEV1, FVC, FEV1/FVC
-CT for LAA

- FEV1, FVC, FEV1/FVC
-COPD based on GOLD
- FEV1, FVC, FEV1/FVC

-CT percent emphysema
- FEV1, FVC, FEV1/FVC, DLCO

-Carotid US

-Carotid US
-ABI
-CT coronary calcification
-Carotid US, MRI

-CT coronary calcification

-CT coronary calcification

-CT aortic calcification

-CT of pulmonary vessels, LAA
- FEV1, FVC, FEV1/FVC, DLCO

- FEV1, FVC and FEV1/FVC
-CT percent emphysema

-CT coronary calcification
-MRI aortic distensibility

-Correlation between coronary artery calcification and FEV1
-COPD severity related to calcification risk score

-Correlation between coronary artery calcification and FEV1
-COPD severity related to calcification risk score

-Carotid wall thickening higher in subjects with COPD
-Carotid artery plaques with a lipid core more prevalent in COPD

-FEV1, FVC and FEV1/FVC associated with ABI
-Upper-lobe emphysema associated with ABI and IMT

-More subjects with a COPD diagnosis had plaques
-FEV1, VC and DLCO lower and RV higher in subjects with ICA plaques

-Aortic calcification related to %CSA<5mm2 but not with LAA or FEV1

-Lower FEV1 and FEV1/FVC associated with aortic calcification

-IMT higher in COPD subjects
-MT negatively correlated with FEV1, FVC and FEV1/FVC

- FEV1, FVC and FEV1/FVC

-CT aortic calcification

-Carotid US

-IMT associated with COPD severity
-Increased IMT associated with increased risk of total mortality in COPD patients

-COPD based on GOLD

-COPD subjects had greater aortic calcification
-Aortic calcification correlated with percent emphysema

-IMT and plaque highest in smokers with COPD
- negative correlation between FEV1 and IMT

-Decreased FEV1 associated with <ABI and >IMT

-Decreased stroke volume in COPD

-Subjects within lowest quintile of PEF > IMT

- lower FEV1 and VC in men with atherosclerosis

-Cross-sectional association with FEV1 and IMT

Study Results

- FEV1, FVC, FEV1/FVC

- FEV1, FVC, FEV1/FVC

-Breathing maneuvers

-PEF

- FEV1, VC

- FEV1

Pulmonary
measurements

-CT percent emphysema

-Carotid US

-Carotid US

-ABI

-Real time MRI flow

-Carotid US

-Calf plethysmography
-ABI, Doppler US

-Carotid US

Cardiovascular
measurements

Table 1. Summary of studies investigating lung and heart disease using imaging
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ARIC: Atherosclerosis Risk in Communities Study, NLST: National Lung Screening Trial, MESA: Multi-Ethnic Study of
Atherosclerosis, LTRC: Lung Tissue Research Consortium, LCST: Danish Lung Cancer Screening Trial IMT: Intima media thickness,
CT: Computed tomography, MRI: Magnetic Resonance imaging, US: Ultrasound, ABI: Ankle-brachial index, FEV1: Forced
expiratory volume in one second, FVC: Forced vital capacity, DLCO: Diffusing capacity of the lung for carbon monoxide, PEF: Peak
expiratory flow, GOLD: Global initiative for Chronic Obstructive Lung Disease, PA: Pulmonary artery, A: Aorta, LAA: Low
attenuation area, CSA: Cross sectional area
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Figure 1: Schematic for proposed mechanism explaining atherosclerosis burden in
patients with chronic lung disease related to smoking or environmental toxins.
Chronic exposure to toxins, mainly cigarette smoke and/or air pollution triggers an
inflammatory response within the lung airspaces that is dominated by alveolar
macrophages. The inflammatory markers within the alveoli spill [8] into the vascular
system where they stimulate the liver and bone marrow to release various inflammatory
and coagulation mediators such as; C-reactive protein (CRP), fibrinogen, platelets and
leukocytes. The systemic inflammatory response that follows promotes atherogenesis in
combination with high levels of circulating cholesterol, coagulation factors and
inflammatory mediators.

139

IMAGING ATHEROSCLEROSIS:
Carotid Arteries
Carotid atherosclerosis is the main cause of transient ischemic attack and ischemic stroke,
and is believed to be closely linked to atherosclerosis in the coronary and peripheral
vascular beds that cause myocardial infarction, and leg claudication, respectively (36).
As shown in Figure 1 and in more detail in Figure 2, the carotid artery bifurcates within
the neck and in most subjects, this allows for direct and non-invasive imaging through the
neck tissues using ultrasound methods.

In the longitudinal or transverse view,

atherosclerotic plaque is typically observed near the bifurcation and in the internal carotid
artery and in the axial view, wall thickening and lumen stenosis can be visualized.
Several imaging techniques have evolved to better understand the morphology of
atherosclerosis and monitor its progression over time. B-mode carotid ultrasound is a
non-invasive,

relatively

inexpensive

imaging

technique

that

provides

direct

morphological measurements at the site of future cardiovascular events (18, 37). Doppler
ultrasound is commonly used for evaluating carotid stenosis (38). For research purposes,
three-dimensional US (3DUS) and carotid magnetic resonance imaging (MRI) are unique
among carotid imaging methods in their ability to readily distinguish between different
atherosclerotic tissue components and plaque. This provides a way to potentially assess
carotid plaque vulnerability (20). Distinct from carotid atherosclerosis imaging, imaging
the heart using thoracic computed tomography (CT) for the detection and quantification
of coronary artery calcifications has also emerged as a means to non-invasively evaluate
atherosclerosis risk (33).
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Figure 2: Schematic for Carotid Artery Atherosclerosis.
Axial or Cross-sectional view: The common carotid artery (CCA) is shown with
atherosclerotic plaque in yellow under a thin fibrous cap within the intima layer and
modest lumen narrowing or arterial stenosis.
Longitudinal or Transverse view: The CCA bifurcates approximately at the jaw line
into the internal carotid artery (ICA) and the external carotid artery (ECA), at the
bifurcation (BF) point. The lumen-intima, and media-adventitia boundaries and calcified
atherosclerotic plaque are readily visible in both the axial and longitudinal views of the
artery.

B-mode ultrasound
Brightness-mode (B-mode) ultrasound (US) is typically used to image carotid arteries for
atherosclerotic burden principally because it is non-invasive, it is relatively inexpensive
and it is widely available in most clinical facilities. To obtain a two-dimensional (2D)
grey-scale image, high frequency ultrasound pulses are transmitted to internal tissues and
their reflections (which themselves are dependent on the different acoustic impedances of
the tissues) are converted to different pixel intensities (39, 40). A good example of this is
provided in Figure 3 and shows the IMT measurement that is now recognized as robust
and reliable for evaluating atherosclerotic burden (41). It provides a 1D measurement of
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the mean distance between the lumen-intima and media-adventitia boundaries of the
common carotid artery (CCA) (40). To standardize IMT measurements, guidelines were
established by the Mannheim Intima-Media Thickness Consensus (42, 43). The 2D
ultrasound images used to segment IMT are either generated by navigating a
reconstructed 3D volume to visualize the desired plane (44), or by directly acquiring a 2D
image using the ultrasound probe (23).

Importantly, IMT measurements do not

incorporate a measure of carotid plaque, as users are encouraged to perform IMT
segmentation only in regions of the CCA that are void of plaque to ensure they capture an
accurate representation of the intima-media layer(42, 43).
Doppler ultrasound
Carotid Doppler ultrasound incorporates B-mode and Doppler ultrasound imaging (45).
The recorded B-mode 2D image provides structural and anatomical information about the
vessel and surrounding tissues, while the Doppler component provides useful information
about the blood flow in the vessel (46). This offers a way to determine the velocity of
blood in a vessel and provides information regarding the degree of stenosis in the artery
(46). Atherosclerotic stenosis and blood flow velocity are directly proportional; therefore
arteries with larger plaques present with a greater blood velocity (46). Even though
carotid disease is still diagnosed using conventional angiography, carotid Doppler US is
suggested to be the most accurate non-invasive imaging modality in screening individuals
for carotid artery stenosis (38, 46).
Three-dimensional ultrasound
Figure 4 shows a schematic for the methodology of three dimensional (3D) ultrasound
(US) volume acquisition. These scans differ slightly from 2D acquisition because the US
probe is translated along the neck of the individual. This “linear translation” (21) along
the neck acquires a series of 2D images that are co-registered spatially into a 3D volume
(40). As shown in Figure 3, several measurements have been developed to date that
utilize reconstructed 3DUS volumes in order to monitor atherosclerotic disease
progression. These measurements include 2D total plaque area (TPA) measurement, and
the 3D total plaque volume (TPV) and vessel wall volume (VWV) measurement (47-50).
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The TPA ultrasound measurement provides a 2D measurement that quantifies the area of
a plaque along the longitudinal view of the artery. The user is required to outline the
plaque as it appears in its largest dimension which can be somewhat subjective. The
segmentation can be performed on the US scanner by finding the plane of interest and
freezing and magnifying the image (47) and the cursor is used to trace around the
selected plaque (47). The reconstructed 3D volume can also be used to isolate the
longitudinal view of interest and perform the measurement by tracing the perimeter of the
plaque using computer software. Previous research (47, 51) has demonstrated that TPA
is associated with serum cholesterol levels, hypertension myocardial infarction, risk of
stroke and risk of death.
Three-dimensional TPV and VWV measurements have been developed to monitor
atherosclerotic disease progression, while providing useful information about the
development of atherosclerotic plaques. The first technical development of TPV (48)
used a manual segmentation approach where the volume of the plaque was generated
from the area of a series of axial slices.

However, more recently, TPV has been

generated using a semi-automated approach (52) and this has helped to improve speed
and reproducibility of the measurements.
A 3D IMT measurement that includes plaque can be generated from 3DUS – the 3DUS
vessel wall volume (VWV) (41). 3DUS VWV provides a circumferential wall thickness
measurement, including plaque (41, 53) and can be used to track changes over short time
scales (54) and recent research has shown that these measurements correlate well with
age and sex (40).

Ultrasound imaging measurements have been widely used to

understand cardiovascular disease and patient outcomes (47, 55), although it is difficult to
distinguish between atherosclerotic plaque components.
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Figure 3: B-mode and 3DUS of the Common Carotid Artery.
Top panel: Conventional B-mode ultrasound common carotid artery image in the
transverse plane and the generation of intima-media thickness (IMT) measurement.
Bottom panel: 3DUS common carotid artery in the axial or cross-sectional plane with the
generation of total plaque volume (TPV), and vessel wall volume (VWV) ultrasound
measurements.
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Figure 4: Three-Dimensional Ultrasound Image Acquisition.
Left panel: Typical 3DUS scanning procedure. The subject is supine with head turned to
enable access to R or L carotid artery. The mechanical mover shown in the left panel
holds the transducer in place and translates it up the neck. Middle panel: Schematic for
transducer acquiring a series of two-dimensional images that are co-registered to generate
a three-dimensional (3D) volume. Right panel: 3D volume for the common carotid artery
in the axial or transverse plane.

Carotid magnetic resonance imaging
Magnetic resonance imaging (MRI) provides a way to distinguish between soft tissues,
allowing for the evaluation of plaque composition and potentially, plaque vulnerability to
rupture and thrombosis (56). Plaque vulnerability is typically assessed by examining
different characteristics such as the fibrous cap, lipid core and localized calcifications in
the carotid arteries (20, 57). In particular, the thickness of the fibrous cap is of great
interest, since rupturing of this component would expose the necrotic lipid core to the
blood flow which is believed to cause thromboembolic events; recent studies (58) have
shown that carotid MRI findings correlate with histology and are sensitive in detecting
thin and ruptured fibrous layers (59). Other studies (60, 61) have reported the use of a
gadolinium-based contrast agent to obtain a higher contrast between atherosclerotic
plaque characteristics and have found that the contrast between plaque structures can be
enhanced even more.
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Thoracic computed tomography
As shown in Figure 5, thoracic CT can be used to reveal and quantify calcifications
within the coronary arteries as a surrogate measurement of advanced coronary artery
disease and atherosclerosis (33). Such calcified lesions within the arterial wall are much
denser than surrounding cardiovascular tissue and are visualized as regions of greater xray attenuation on thoracic CT scans. Commonly, a threshold of ≥130HU is used to
identify calcified lesions on thoracic CT based on the scoring method previously
described by Agatston (62). This approach has been the most widely-used quantification
method for coronary calcifications and studies have shown that Agatston scores correlate
with future cardiovascular events (63, 64). The use of coronary artery calcifications has
not been widely-used however to evaluate the relationship between vascular and
pulmonary disease.

Figure 5: Axial CT view of Chronic Obstructive Pulmonary Disease Patients with
Coronary Calcifications.
Yellow arrows point to coronary calcifications which are easily visible by increased x-ray
attenuation within cardiovascular tissues.
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IMAGING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
COPD is characterized by chronic airflow limitation and systemic inflammation and is
currently the fourth leading cause of death worldwide, affecting approximately 10% of
the population over 40 years of age (65). COPD is a heterogeneous disease comprised of
airway inflammation, alveolar destruction (emphysema), mucociliary dysfunction,
pulmonary hypertension, and small airway remodeling (11, 66). Traditionally, COPD is
diagnosed using the spirometry thresh-hold of the forced expiratory volume in one
second (FEV1) <70% of the forced vital capacity (FVC). However, it has been suggested
that FEV1 and FVC are relatively insensitive to the pathophysiological changes that occur
well before lung function declines (66). Consequently, FEV1 and FVC alone do not
sufficiently characterize lung disease onset, progression or response to treatment,
especially early in the disease (67, 68). Moreover, spirometry provides only a global
measurement of overall lung disease with no regional structural or functional information
to identify the diseased area or the underlying pathology.

These drawbacks have

provided the major motivation behind the development and optimization of sensitive and
non-invasive pulmonary imaging modalities that can locate, characterize and quantify
pathophysiological changes that cause lung function decline.
Pulmonary imaging offers several advantages for characterization of COPD: 1) it is
sensitive to early structural and functional changes in the lungs (69-73), 2) it allows
visualization of the pathophysiological processes contributing to airflow limitation (14,
74), 3) it provides regional information of which anatomical locations of the lung are
affected by disease (14, 75), and, 4) patients can potentially be stratified for treatment
based on lung disease phenotype identified using pulmonary imaging (74, 76-78).
Thoracic X-ray computed tomography of COPD
The development of quantitative tools to measure airway dimensions and parenchyma
structure using high-resolution computed tomography (CT) have made it the pulmonary
imaging modality of choice (13, 14, 78, 79). As previously mentioned, pulmonary
function tests do not correlate well with morphological changes in the lung (11, 67, 68).
CT however, is well suited to distinguish whether lung function decline is attributable to
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emphysema or airways disease. Thoracic CT images of pulmonary structure are based on
tissue attenuation of x-rays in the lung parenchyma and surrounding vasculature.
Therefore, high-resolution images of pulmonary structure can be acquired without the use
of contrast agents.
Smoking-related emphysema is characterized by alveolar destruction which leads to
increased lung volume, decreased surface area for gas exchange and either localized or
uniform emphysematous lesions to the lung parenchyma (66). The emphysematous
lesions have markedly reduced density which can be identified by regions of lower x-ray
attenuation values in Hounsfield units from the density frequency histogram taken from
CT images (78). One approach for quantifying the extent of emphysema has employed a
threshold cutoff for voxels with attenuation values below a predetermined Hounsfield
unit as emphysematous tissue (78). CT attenuation thresholds have been used to identify
emphysema at -910HU (80), -950HU (81), -960HU and -970HU (82). However, -950HU
has emerged as the most common cutoff to distinguish between emphysematous and
healthy lung tissue (81).

Another widely-used method for determining emphysema

severity is with a “percentile cutoff” (eg. the lowest 15th percentile) that identified the
percent of emphysematous tissue based on the frequency distribution of attenuation
values across a group of subjects (78, 82, 83). Both techniques are considered acceptable
for cross-sectional COPD studies.

However, the Alpha-1 Foundation workshop

committee recommended (84) that only the percentile cutoff approach be used for
longitudinal studies since technical variations have less influence on these measurements
(84). Another technique for quantifying emphysema also incorporated attenuation cutoff
values, but used a statistical approach to identify low attenuation clusters (LAC) (85, 86).
Briefly, the size of an emphysematous lesion (connected voxels below a certain
attenuation value) is plotted against the total number of “clusters” of connected voxels on
a log-log plot (cluster size on x axis, number of clusters on y-axis). The slope of this
relationship, which follows a power law, represents the size of the emphysematous lesion
(87). Typically flatter curves with lower slope values represent larger emphysematous
lesions.
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Airways disease can be assessed using CT-derived measurements of airways dimensions.
Airway remodeling in COPD is prominently caused by inflammation within the airway
wall epithelium and mucous plugs in the airway lumen (66).

Therefore, CT

measurements of airway wall area (WA) and lumen area (LA) are of interest for
evaluating the severity of airways disease. The primary limitation of CT airway analysis
lies within the limits of x-ray resolution and dose (78).

Previous work (88) has

established that the major site of airflow limitation in COPD is in airways <2 mm in
diameter. These airways, however, are difficult to visualize on CT (89). Many different
computational algorithms have been used to measure airways (90-93) however, it remains
unknown which algorithm provides the most useful airway data (84). Figure 6 shows
representative coronal CT images and CT-derived airway trees and LAC maps for two
healthy (FEV1/FVC≥.70) and two COPD subjects (FEV1/FVC<.70). Compared to the
healthy subjects, the COPD patients have larger and greater heterogeneity of attenuation
values which are reflected in the large LAC clusters corresponding to these low
attenuation regions. These images are a good representation of how CT along with
quantification software can be used to evaluate disease severity.
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Figure 6: Thoracic x-ray Computed tomography (CT) in Healthy older subjects and
patients with Chronic Obstructive Pulmonary Disease.
Left panels: CT coronal and axial centre slice scans Right panels: Corresponding CTderived volume rendered airway tree next to co-registered airway tree with low
attenuation cluster (LAC) map for two healthy subjects (S1 and S2) and two COPD
subjects (S3 and S4).
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Magnetic Resonance Imaging of COPD
Until recently, pulmonary magnetic resonance imaging (MRI) has been challenging
owing to the low proton (1H) density (and in contrast high air density) within the lungs.
Conventional MRI generates signal and tissue contrast based on the perturbation of 1H
which is bound to both water and fat in most tissues of the body. Distinct from other
organs, the lungs have very low proton density which results in low contrast and little to
no morphological information on pulmonary 1H MR images (25). This has motivated the
development and optimization of MRI techniques that are able to visualize lung structure
and function. Namely, hyperpolarized noble gas MRI and ultra-short echo time (UTE)
1

H MRI have emerged as promising methods to non-invasively image the lungs and have

been used to study COPD.
Hyperpolarized noble-gas MRI provides a way to visualize lung function by imaging
ventilation within the lung. As shown in Figure 7, this breath-hold technique can be
performed using hyperpolarized 3He or 129Xe gases (94) to generate images of ventilation
within the lungs. These “static-ventilation” (SV) images provide functional information
by visualizing gas distribution, and as shown in Figure 8, ventilation distribution in
healthy subjects is homogeneous, with gas filling all regions within the lung (95). In
contrast, COPD patients have regions of signal void, or ventilation defects, which
represent areas of the lung that do not participate in ventilation (25).
hyperpolarized 3He and

129

To quantify

Xe MRI data the volume of gas visualized in the images can

be normalized to patient’s thoracic cavity volume to generate a ventilation defect volume
(VDV) (96), a ventilation defect percent (VDP) (97) and percent ventilation volume
(PVV) (71). Although it is likely that ventilation defects represent disease, the exact
etiology underlying them is not entirely clear. In COPD, these ventilation abnormalities
may be due to airway disease, emphysema or a combination of both diseases. Another
possibility is that these areas may be slow filling and are not ventilated during the breathhold scan. In the future, uncovering the pathophysiology of noble gas ventilation defects
in COPD will require the accurate registration of structural CT images with functional
MR images, integrating other lung structural modalities such as optical coherence
tomography (98) and comparing MRI data with histology (99).

Beyond functional
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imaging, noble gas MRI can also be used to probe lung microstructure by using
diffusion-weighted MRI which can characterize the dimensions of acinar ducts and
alveoli, the main structures involved in gas exchange (12, 100, 101). By sensitizing the
MRI system to diffusion of the noble gas atoms, apparent diffusion coefficient (ADC)
maps can be generated and quantified to assess lung microstructure (100). In COPD,
emphysema is associated with acinar duct enlargement and alveolar destruction (66).
These larger alveolar spaces in diseased subjects will generate higher ADC values on
diffusion-weighted MRI scans compared to small, intact alveoli of a healthy volunteer
(75, 99) because the gas atoms have a larger distance per unit time to travel. This is
represented in Figure 8 where the ADC maps display brighter colors as
COPD/emphysema severity increases, representing an increase in ADC values and larger
airspaces in these subjects. A limitation to diffusion-weighted MRI in noble gas imaging
of the lungs is related to the ventilation patterns mentioned previously. ADC values can
be extracted only for regions of the lung that participate in ventilation, therefore in
patients with high VDP the structure of the VDV cannot be probed.
Independent of MRI methods that employ tracer gases to visualize lung structure and
function, conventional 1H MRI using short echo times can be used to visualize pulmonary
structure (12). Such methods have been employed to try to reduce air-tissue interface
artifacts (102) which are typically abundant on pulmonary MRI, allowing acquisition of
images that can provide structural information by differentiating between regions of low
and high proton density (103). This has potentially useful applications to COPD because
low proton-density regions may represent emphysematous lesions whereas regions of
high proton density could represent areas of other diseases or lung injuries such as edema
(25, 103).

Imaging Relationships Between Lung Disease and Atherosclerosis
While cardiovascular and respiratory diseases are the first and third leading causes of
death in the United States (104), both diseases are typically evaluated as separate
conditions.

However, the last two decades have seen numerous studies providing

imaging evidence that both diseases are related (1, 2, 5, 6, 57, 105-115). These studies,
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summarized in Table 1, have established two important clinical findings: 1) COPD
patients have an increased burden of atherosclerosis in the form of carotid atherosclerosis
and coronary artery plaque, and, 2) the relationship linking lung and heart diseases is
complex and involves both structural and functional abnormalities to the lungs and
vascular system.

Figure 7: Conventional anatomical 1H MR and functional 3He and
images.

129

Xe MR
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Top panel: Anatomical 1H MRI, and, Bottom panels: corresponding 3He (aqua-blue) and
129
Xe (purple) MRI co-registered to anatomical MRI (grey-scale) for a healthy and COPD
subject.

Application of Carotid Ultrasound to Lung and Atherosclerosis Studies
Carotid ultrasound semi-automated measurements of IMT make it well-suited to be used
in large-scale studies investigating atherosclerosis and lung disease. Studies using carotid
ultrasound to investigate a relationship between atherosclerosis and lung disease started
to emerge over a decade ago (55, 116, 117). In one study (55), subjects from the British
Regional Heart Study were evaluated and the investigators observed a cross-sectional
relationship between carotid IMT and spirometry. Shortly after, a significant association
between spirometry and Doppler ultrasound measurements of stenosis in an elderly
population of Swedish men was reported (117).

Another study (116) used carotid

ultrasound to examine carotid IMT and the development of carotid plaques in relation to
peak expiratory flow (PEF) in an elderly cohort from France. Consistent with the two
other studies, they found that reduced lung function (reduced PEF) was associated with
increased atherosclerotic burden through elevated IMT and increased carotid plaque
occurrence. Four years later this area of research was revisited (3) in a large cohort
recruited from the Atherosclerosis Risk in Communities (ARIC) study. Using carotid
ultrasound IMT and the ankle-brachial index (ABI) or the ratio of ankle to arm systolic
blood pressure in tandem with spirometry measurements, a cross-sectional association
was observed between spirometry and IMT and ABI. This study invited future research
on the coincident findings of lung disease and atherosclerosis using a number of imaging
techniques.

Subsequent work focused on the relationship of carotid ultrasound

measurements of atherosclerosis and spirometry measurements of pulmonary function.
Several years later, a study (105) in 305 Japanese volunteers showed that COPD smokers
had significantly greater IMT and plaque compared to smokers and non-smokers without
airflow limitation. Furthermore it was observed that FEV1 was independently associated
with IMT after adjustment for age, BMI and blood pressure. The finding that IMT was
elevated in patients with airflow limitation was replicated two years later (106) in a
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Korean study that showed greater IMT in COPD patients compared to non-COPD
subjects. This group also observed a significant correlation between IMT and spirometry
(FEV1, FEV1/FVC and FVC). There is evidence that this relationship may work in both
directions, meaning that cardiovascular disease patients may have equally high risk of
developing respiratory diseases as COPD patients are of developing cardiovascular
conditions.

Another research team obtained pre-operative spirometry and carotid

ultrasound measurements in a group of vascular surgery patients undergoing aortic or
carotid artery surgeries and classified the patients based on severity of COPD (107).
They observed that subjects with spirometry evidence of airflow limitation had
significantly greater IMT than non-COPD vascular surgery patients. In the five-year
follow-up period nearly 30% of vascular surgery patients died, and after adjusting for
confounders, elevated IMT was associated with increased total mortality. This work was
in agreement with another investigation that evaluated (118) relationships between
carotid plaque, FEV1 and VC along with total lung capacity (TLC), residual volume (RV)
and diffusion capacity of the lung for carbon monoxide (DLCO).

The researchers

observed that subjects with plaque had statistically significantly lower FEV1, VC and
DLCO and higher RV but no significant difference in TLC. This was the first study to
probe pulmonary measurements beyond spirometry and PEF, and showed that these
relationship were complex, with lung structure-function implications (118).

Application of Carotid Magnetic Resonance Imaging to Lung and Atherosclerosis
Studies
Few studies have utilized carotid MRI to study lung and heart disease that is coincident in
patients. One recent study (57) evaluated a subgroup from the Rotterdam cohort (119)
using carotid MRI, carotid ultrasound and pulmonary function tests. The results were
consistent with other studies, showing elevated carotid wall thickening in subjects with
airflow limitation. However the carotid MRI data added valuable information about
carotid plaque characteristics in COPD subjects that had not previously been reported.
They showed that:1) the severity of stenosis measured using carotid MRI was greater in
COPD patients, 2) subjects without COPD had higher incidence of plaque calcification
than subjects with COPD, and, 3) carotid plaque in COPD patients were more likely to
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have a large lipid core, a recognized plaque component that is associated with
cerebrovascular events (120). These results were the first to associate carotid plaque
characteristics with COPD cases and increased awareness that COPD is a risk factor for
cardiovascular disease and importantly for debilitating ischemic events such as stroke.
Application of Pulmonary Imaging to Lung and Atherosclerosis Studies
Thus far, pulmonary imaging has not played a large role in studies focused on the
relationship between lung and heart disease in smokers. In Figure 9, we show the direct
comparison of carotid 3DUS total plaque volume and intima media thickness with
hyperpolarized 3He MRI ventilation defect percent in a never- and 2 ex-smokers with
normal pulmonary function and without airflow limitation from our own centre. In a
similar approach, a study from the Emphysema and Cancer Action Project (EMCAP)
(121) incorporated the use of thoracic CT to evaluate flow-mediated dilation (FMD) of
the brachial artery in a group of ex-smokers with early or very mild COPD. The results
showed that low FEV1 and greater indices of emphysema was associated with attenuated
FMD, suggesting that vascular endothelial function is influenced by lung function and
structure. Other findings from the Multi-Ethnic Study of Atherosclerosis (MESA) Lung
Study (2, 122) also used thoracic CT to measure emphysema in subjects without
cardiovascular disease, and evaluated subclinical atherosclerosis with carotid ultrasound
and cardiac CT to determine vascular phenotypes. Inverse associations were observed
between spirometry and IMT, similar to previously described (3, 55, 105-107), but novel
insights with respect to the relationship between emphysema and vascular disease were
also provided. Although whole lung emphysema percent was not related to IMT, upperlobe emphysema was significantly related with internal carotid IMT. Other studies (123,
124), have furthered our understanding of this relationship between emphysema and
vascular disease by showing that emphysema percentage is related not only to carotid
atherosclerosis, but also to calcification scores in the aorta, coronary arteries, as well as
aortic and mitral annuli.

Collectively, these studies provide strong evidence of a

relationship between atherosclerosis and emphysema and support the notion of complex,
heterogeneous vascular and lung disease in ex-smokers.
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Figure 8: 3He MRI ventilation and ADC maps.
Top Row: Healthy older never-smoker. Bottom Rows: Four representative COPD
subjects with GOLD stages I– IV. Greyscale 1H anatomical MRI is co-registered to
aqua-blue ventilation pattern from 3He MRI. Corresponding apparent diffusion
coefficient (ADC) maps generated from diffusion-weighted MRI using b=1.6 s/cm2.
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Application of Thoracic and Vascular Imaging to Evaluate Pulmonary and
Cardiovascular Disease
The development of cardiovascular imaging modalities that can provide surrogate
measurements of vascular disease has played an important role in characterizing lungvascular disease phenotypes. In 2003, real-time MRI of aortic flow (125) was used to
quantify left ventricle stroke volume and cardiac performance in healthy control and
COPD subjects (114). The investigators observed that the COPD subjects had decreased
cardiac performance compared to healthy volunteers and that the non-uniform breathing
patterns in the COPD patients resulted in decreased stroke-volume. Taken together these
results provided evidence that the abnormal breathing patterns and shallow respiration
that may accompany COPD may be related to cardiovascular complications. Thoracic
CT has also been used to provide a way to measure vascular changes and coronary artery
calcification in patients with lung disease. Three studies in particular (111-113), have
used thoracic CT to investigate the relationship between aortic calcification and
pulmonary physiology using pulmonary function tests.

Importantly, associations

between the severity of aortic calcification were reported with lung function and
morphologic parameters. Interestingly, (112) this work showed that pulmonary vascular
alterations were correlated with aortic calcification, whereas other studies (111, 113)
showed associations between aortic calcifications and FEV1. A number of studies (126128) have also investigated vascular dysfunction and arterial stiffness in COPD patients
using pulse wave velocity (PWV), a functional measurement of vascular tone. These
findings showed that COPD patients exhibit increased arterial stiffness (126) and
furthermore, that the degree of arterial stiffness was related to the severity of airflow
limitation (127, 128).

FUTURE PERSPECTIVE
A number of recent studies have demonstrated the value of emerging and wellestablished vascular and pulmonary imaging approaches for furthering our understanding
on the direct relationship between advanced lung and vascular disease in smokers and ex-
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smokers that cannot be explained on the basis of tobacco-smoking alone. In particular,
carotid ultrasound measurements are valuable tools for the evaluation of cardio- and
cerebrovascular risk.
Beyond the evaluation and screening for inflammatory markers, the incorporation of
carotid ultrasound and perhaps other atherosclerosis imaging methods into the clinical
workflow and treatment plan for COPD may help identify significant peripheral,
cardiovascular or cerebrovascular atherosclerosis.

Similarly, the acquisition of

spirometry and other pulmonary function measurements in ex-smokers with
cardiovascular disease or vascular risk factors would help detect airflow limitation that
might otherwise go undiagnosed (8, 106). In mild COPD especially, cardiovascular
events are a major source of morbidity and mortality (8), so it is possible that advanced
imaging of both diseases may help treatment decisions that improve outcomes overall and
cardiovascular events in particular. Regardless, it is important to keep in mind that the
underlying mechanisms linking COPD and atherosclerosis are still not clear, and as
recently described (9, 10) systemic inflammation may only provide a partial explanation
for the links between COPD and advanced progressive atherosclerosis.
The incorporation of pulmonary functional imaging into vascular disease studies will
provide new insight on the role of pulmonary morphological changes in the
pathophysiology of vascular disease. Such studies will build on previous findings of
emphysema in subjects with subclinical atherosclerosis (2, 123, 124). In addition, the
notion of different vascular and lung disease phenotypes (74, 76, 77, 129-132) also holds
promise for this area of research. In the future, a large-scale prospective study should be
executed to monitor longitudinal changes in vascular and pulmonary conditions using
sophisticated imaging techniques. Longitudinal monitoring of vascular and pulmonary
disease in ex-smokers will provide more insight onto the genesis and progression of
vascular disease changes in COPD patients and using imaging, there is potential to
monitor treatment effects and phenotype relationships.

At present, there is some

evidence supporting a mechanistic link between pulmonary and vascular disease that is
not explained by tobacco smoking alone, however the direct mechanisms that potentially
accelerate atherosclerosis in ex-smokers with COPD have not been firmly established.
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At the same time, major advances in quantitative pulmonary and vascular non-invasive
imaging tools have advanced the development and validation of surrogate or intermediate
endpoints of these chronic disorders. Based on this foundation of previous research,
there is a clear role for novel vascular and pulmonary imaging methods to identify the
direct potential links in future studies.
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APPENDIX B – Pulmonary Imaging Abnormalities in an
Adult Case of Congenital Lobar Emphysema
Appendix B reports pulmonary imaging findings in a rare case of congenital lobar
emphysema in an adult. While imaging of congenital pulmonary disorders is not the
focus of this thesis, data from this Case Report highlights how imaging measurements of
airway morphology and emphysema can be used to identify and characterize bullous
emphysema which is a phenotype of chronic obstructive pulmonary disease. The contents
of Appendix B have been previously published in the Journal of Radiology Case Reports
and permission to reproduce the article was granted by Dr. Roland Talanow, MD, PhD
(editor-in-chief) and is provided in Appendix D.
D Pike, S Mohan, W Ma, JF Lewis and G Parraga. Pulmonary Imaging Abnormalities in
an Adult Case of Congenital Lobar Emphysema. The Journal of Radiology Case
Reports; DOI: 10.3941/jrcr.v9i2.2048 2015

Pulmonary Imaging Abnormalities in an Adult Case of
Congenital Lobar Emphysema
D Pike, S Mohan, W Ma, JF Lewis and G Parraga
Congenital lobar emphysema (CLE) is a rare pulmonary abnormality that is typically
detected in the neonatal period, although rare cases have been reported in early adulthood
(1). CLE is commonly associated with bronchial abnormalities/obstruction and vascular
dysfunction, resulting in ventilation-perfusion mismatch, hyperinflation and dyspnea (2).
Diagnosis is often based on x-ray computed tomography (CT) findings of hyperlucent
and/or hyperinflated lung lobes along with malformations of the pulmonary vasculature
or mediastinum. Here, we used imaging to quantitatively evaluate the function and
morphology of alveolar and airway structures in a young adult with acute breathlessness
and chest pain.
A twenty-year-old female with a one-year, five-cigarette/day smoking history and no
previous chronic respiratory disease presented with severe chest pain and shortness of
breath. Chest x-ray showed localized left upper lobe (LUL) hyperlucency whereupon she
provided written informed consent to a Health Canada and local ethics board approved
research protocol.

The subject underwent two visits, 75 days apart that included

spirometry, plethysmography and hyperpolarized 3He magnetic resonance imaging (MRI)
to evaluate regional pulmonary ventilation as well as parenchymal morphology using the
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3

He apparent diffusion coefficient (ADC) – a surrogate measurement of emphysema (3).

MRI was performed in breath-hold after inhalation of a 1L 3He/N2 gas mixture from
functional residual capacity (FRC) using a fast-gradient-recalled-echo (FGRE) sequence,
previously described (4).

3

He MRI ventilation images were quantified to generate

ventilation defect percent (VDP) (4) which is the volume of the lung not participating in
ventilation, normalized to total lung volume. For the generation of 3He ADC, diffusionweighted images were acquired as previously described (4). To evaluate parenchymal
microstructure, we adapted a method (3) whereby

and

were defined as the

longitudinal and transverse diffusion coefficients in the acinar ducts respectively with R
representing the outer radius and h the depth of the intra-acinar duct.
Thoracic CT was acquired once within twenty minutes of MRI using a 64-slice
Lightspeed VCT scanner (GEHC, Milwaukee, WI, USA) as previously described (4).
Pulmonary Workstation 2.0 (VIDA Diagnostics, Iowa City, IA, USA) was used to
generate emphysema measurements including the relative area of the lung with
attenuation values <-950HU (RA950), low attenuation clusters (LAC), and as well airway
measurements including airway wall area percent (WA%) and lumen area (LA).
Spirometry, plethysmography and diffusing capacity of carbon monoxide (DLCO)
measurements showed there was modestly abnormal forced expiratory volume in one
second (FEV1, V1:V2 70%:75%), and highly abnormal residual volume (RV, V1:V2
125%:150%), and airways resistance (Raw, V1:V2 185%:180%), but normal DLCO
(V1:V2 100%:115%).

Figure 1 shows CT low attenuating area (LAA) and low

attenuation clusters (LAC) and 3He MRI ventilation imaging with a large LUL ventilation
defect spatially coincident with the CT- and 3He MRI-defined emphysematous region.
3

He MRI morphometric maps (higher intensity representing greater acinar duct

dimensions) are also shown for the intra-acinar duct outer radius (R), depth (h), and inner
radius (R-h). Quantitative LUL measurements showed abnormal RA950 (LUL: 13%,
other lobes: 0%), LAC (LUL: -1.5, other lobes: -2.3 to -1.8) and VDP (LUL: 29%, other
lobes: 1%-7%). For the LUL, acinar outer and inner radii were markedly abnormal
(490µm and 310µm respectively) compared to the other lung lobes (300-310µm and 130140µm respectively). CT airway measurements for the subsegmental bronchus leading to
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the LUL were abnormal (WA%: 50%, LA: 19mm2) compared to other airways of the
same generation (WA%: 57%-66%, LA: 10mm2- 16mm2).

Figure 1: Thoracic CT and 3He MRI measurements, co-registration and analysis in the
axial, sagittal and coronal planes for the 20 year-old female with congenital lobar
emphysema presented in this case.
CT LAA: CT low attenuation area (LAA, in red, attenuation <-950HU) with the thoracic
CT as the background (in grey-scale), CT LAC: 3D low attenuation clusters (LAC)
analysis generated using VIDA Pulmonary Workstation 2.0, 3He MRI-CT: 3He MRI
static ventilation image (in blue) registered to thoracic CT (in grey-scale), 3He MRI
ADC: 3He MRI apparent diffusion coefficient (ADC) maps for b=1.6cm2/s, where
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brighter yellow-green represents higher ADC values, R:intra-acinar duct outer radius
generated from 3He MRI co-registered with thoracic CT (in grey-scale), h: intra-acinar
duct depth generated from 3He MRI co-registered with thoracic CT (in grey-scale), R-h:
intra-acinar duct inner radius co-registered with thoracic CT (in grey-scale).
In Figure 2, the CT-derived airway tree is shown in yellow co-registered with the 3He
MRI ventilation image with the hyperlucent region outlined in white and the fissure
between the LUL and LLL shown in black. The left upper subsegmental bronchus is
abnormally terminated with the proximal end apparently disconnected from the rest of the
airway tree. Relative dimensions for this abnormal airway and a similar generation
normal airway are shown in schematic along with acinar duct morphological
measurements for normal and abnormal LUL parenchyma estimated using 3He MRI and
the Weibel model (5) assumptions.

Figure 2: Registered CT airway tree with 3He MRI and CT for the 20 year-old female
with congenital lobar emphysema presented in this case. The white contour outlines the
emphysematous region in the left upper lobe (LUL), the black contour outlines the entire
LUL. There is a noticeable mediastinal shift onto the contralateral right lung due to
hyperinflation in the LUL. The subsegmental bronchus feeding into the LUL was
abnormally terminated and not connected to the rest of the airway tree and dimensions of
the resulting airway segment were abnormal (top panel). Acinar duct schematics for the
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abnormal LUL parenchyma (middle panel) and normal parenchyma (bottom panel) are
shown to scale and were estimated using Weibel model assumptions.
DISCUSSION
Albeit a rare diagnosis in adults, CLE is an important differential for unilateral
hyperlucent lung. The number of adult diagnoses has recently increased due to incidental
radiological findings, but to our knowledge, this is the first report of quantitative, noninvasive regional measurements of airway morphology, parenchymal microstructure and
3

He ventilation. Thoracic CT showed that the hyperlucent region was highly localized,

with a mediastinal shift to the contralateral right side likely related to LUL over-inflation
- a common finding in CLE. Interestingly, we also observed focal obliteration of the
proximal aspect of the tertiary bronchi serving the LUL apico-posterior segment (the
LUL-LB1+2 bronchus). This leads to a lack of connection between this segment and the
central airways although there was no evidence of localized endobronchial mucus
plugging, foreign body or other masses resulting in extra-luminal compression. The
distal segment of the apico-posterior bronchus was present but highly abnormal with a
thinner wall (decreased WA%) and widening of the lumen (high LA) compared to similar
airways in other regions, consistent with an occult atretic bronchus.

The precise

relationship between bronchial atresia and CLE is unknown although the timing and level
of embryofetal airway obstruction may explain the variety of congenital lung lesions.
We also observed a markedly elevated (worse) LUL VDP compared to the other lobes
and a heterogeneous pattern of 3He signal filling inwards from the edges of the
emphysematous region of the apico-posterior region. We propose collateral ventilation
into the emphysematous area as a potential mechanism for this finding, first described in
excised emphysematous lungs (6) and COPD patients (7). In emphysema, there is lower
resistance to collateral flow that may involve the 1-2 micrometer pores of Kohn, the 30
micrometer channels described by Lambert, or the 80-150 micrometer interbronchiolar
paths described by Martin (8).
In contrast to healthy lung tissue in the unaffected lobes, there was an elevated outer and
inner radius of the LUL acinar ducts as previously shown in patients with emphysema.
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There was also an elevated acinar duct sleeve depth and this is a novel finding that
contrasts with results in emphysema ex-smokers where decreased alveolar duct sleeve
depths were reported.
Finally, although we observed significant airway and parenchymal abnormalities, airflow
limitation was mild and DLCO was normal in this adult patient. There was evidence of
gas trapping and very high airways resistance, both of which may be related to the atretic
bronchus and slower time constants for LUL emptying which may have been worsened
by collateral ventilation. The increased airways resistance may also be driving collateral
ventilation into the emphysematous lobe and hyperinflation– a potential source of severe
symptoms in this patient.

Other pathologies that should be considered when

encountering hyperlucencies on x-ray or CT that resemble CLE (in infants or adults)
include; bronchial atresia, congenital pulmonary airway malformations (CPAM) and
spontaneous or traumatic pneumothorax.
Bronchial atresia is generally asymptomatic and most commonly diagnosed incidentally
using x-ray or CT, similar to CLE. CLE often coexists with bronchial atresia making it
difficult to differentiate these pathologies independently. In adult cases, both bronchial
atresia and CLE show locally hyperinflated/emphysematous regions however, bronchial
atresia patients exhibit mucoceles (club-like or rounded shape pathologies at the proximal
ends of segmental or subsegmental bronchi) which are easily visualized on thoracic CT.
Further investigation with bronchoscopy after the location of mucoceles may then
identify blind-ending bronchi characteristic of bronchial atresia.
Congenital pulmonary airway malformations (CPAMs) appear on CT as cysts attached to
segmental bronchi and are frequently observed concomitant with other congenital lung
lesions such as bronchopulmonary sequestration or bronchial atresia. The diagnoses of
CPAM typically occurs in the neonatal period and is sub-categorized into one of five
subtypes with “type 3 CPAM” being the most similar to CLE because it affects at least
one entire lobe. In prenatal cases, ultrasound most often identifies the presence of CPAM
as hyperechoic lesions with microcystic patterns. If these malformations are not detected
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until adulthood, recurrent pulmonary infections are the most common finding that
subsequently may result in incidental chest x-ray or CT findings.
Finally, CLE may resemble pneumothorax on chest x-ray and/or CT as evidenced by a
prominent mediastinal shift opposite the hyperlucent lobe.

However, CLE and

pneumothorax can be differentiated using conventional chest x-ray where the absence of
bronchovascular abnormalities indicates pneumothorax and not CLE. Pneumothorax is
more easily differentiated from other diagnoses of localized hyperlucency because these
cases most frequently report to urgent care following trauma to the thorax, when the
possibility of congenital lesions can be ruled out.
It is important to note that with the increasing use of chest CT, all these pulmonary
pathologies may be observed in young adults and frequently, the exact genesis of the
malformations may never be determined. In summary, quantitative thoracic imaging
provides a way to definitively diagnose and quantify the critical structure-function
relationships in an adult case of CLE in whom established measurements of pulmonary
function (DLCO, FEV1) do not.

TEACHING POINT
In a 20 year old with acute, severe chest pain and dyspnea, thoracic CT and 3He MRI
revealed an abnormal atrectic bronchus leading to a left upper lobe (LUL) congenital
lobar emphysema with acinar duct morphologies that were very different from smokingrelated emphysematous bullae. There was also functional imaging evidence of collateral
ventilation leaking from the fissure into the LUL, providing an explanation for severe
symptoms in this adult in whom pulmonary function (Diffusing capacity of carbon
monoxide (DLCO), Forced expiratory volume in one second (FEV1)) measurements do
not.
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TABLES
Table 1: Summary Table for Congenital Lobar Emphysema (CLE)
Etiology

 Characterized by compression of lung tissue – emphysema,
that is usually localized to one but can be several lung lobes
 Usually the upper lobes are affected (>50% of cases)
 Trapped gas within the localized emphysematous region
causes displacement of the mediastinum into the opposite
lung
 Prevalence of 1 in 20,000 to 1 in 30,0000

Incidence
 Affects males more than females 3:1
Gender Ratio
Age Predilection
Risk Factors

Treatment

Prognosis

Findings on Imaging

 Nearly all cases present within the first year after birth but
rare cases have been diagnosed in adulthood
 Prenatal vascular abnormalities
 Congenital heart disease (ventricular septal defects, ductus
arteriosus)
 Lobectomy is the accepted treatment for CLE
 In older patients conservative management may be effective
 In infants and neonates an emergency thoracotomy is
sometimes performed
 Following surgical intervention, patients generally develop
normal lung function without respiratory impairment in
follow-up (>1 year)
 Localized hyperlucency or regions of reduced density (<950HU) on x-ray computed tomography (CT) scans
 Mediastinal shift towards the opposite lung from the
affected lobe
 Tracheo-bronchial and abnormalities
 Localized abnormalities to the pulmonary vasculature in the
affected lung lobe

X-ray
Pulmonary Causes

CT

 . Usually asymptomatic  Hilar-mass like shadows with

and diagnosed
hyperexpansion, oligemia and
incidentally on x-ray in
hyperlucency of the peripheral lung
an older child or adult.
fields in the affected lobe.

 Since no
communication exists
with the normal
tracheobronchial tree,
infection is rare.

Presence of a mucocele (club-like or rounded in
shape) with focal interruption of a lobar,
segmental, or subsegmental bronchus.
Hyperinflation of the affected lobe or segment
and emphysematous changes of the peripheral
lung fields and occlusion of the bronchus
central to the mucocele are diagnostic criteria.

 Dyspnea, tachypnea,
 Hyperlucency of involved lobe,
 Localized hyperlucency and loss of
wheezing, tachycardia
most commonly left upper lobe
parenchymal density in an individual lung
and cyanosis are
(LUL).
lobe.
common symptoms.
 Herniation of hyperinflated lobe to  Attenuated sparse vasculature of the
 Fifty percent
opposite side with mediastinal shift emphysematous lobe. Loss of distal airways
symptomatic in the
and adjacent lobe collapse.
in localized emphysematous lobe,
neonatal period.
 Flattening of ipsilateral diaphragm. compressive atelectasis of other lobes.
 Abnormally narrowed bronchus or bronchial
 Scant lung markings are usually
atresia may be present, however many cases
present within the radiolucent area.
do not have any demonstrable airway
anomaly.

Clinical

Bronchoscopy: A blindending bronchus may be found
in up to 50% of cases, which is
pathognomonic. Helpful to
exclude acquired causes of
bronchial obstruction such as
foreign body, strictures and
tumors.

MRI: Prominent region of
signal void on 3He MRI
ventilation images. Elevated
apparent diffusion coefficients
(ADC) on diffusionweighted 3He MR images.
Abnormal outer and inner radii
and acinar duct sleeve depth in
localized emphysematous lobe

Other Modalities

 .Rare cystic lung lesions Localized patchy density
 Over-nflation with malformed multiple air
arising from
representing the cystic mass with an cysts (irregular and thin walled) connected to
Ultrasound: Usually for preCongenital
proliferation of tubular
area of hyperinflation and
the segmental bronchus and well demarcated
natal diagnosis revealing a
bronchial structures.
parenchymal oligemia.
from the normal lung parenchyma.
pulmonary
homogenously hyperechoic
 5 subtypes with 80%  Type 3 CPAM can involve an entire
lesion with microcystic pattern.
airway
diagnosed in the
lobe or several lobes.
neonatal period.
malformations
 TCPAMs hat present during
 In adulthood, recurrent
adulthood most commonly present
(CPAM)
pulmonary infection is
in the lower lobes.
the most common
symptom.
to bronchial compression from extrinsic factors (cardiomegaly, lymphadenopathy), endobronchial obstruction (tumor, foreign body, mucus plug)
Others: Airways obstruction due
and obliterative bronchiolitis, Unilateral bullus/bullae and post-pneumonectomy are other differentials.

Bronchial
Atresia

Congenital
Lobar
Emphysema

Disease

Table 2. Differential Diagnosis Table for Congenital Lobar Emphysema
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X-ray

CT

Most sensitive imaging modality to detect
pneumothorax.
Can detect small pneumothoraces,
hydropneumothorax, loculated pneumothorax,
bronchopleural fistulas, underlying
emphysema/bullous lung diseases.

Pleural Space Causes
 ,Dyspnea, tachypnea,  Visceral pleural line (and lung) is 
tachycardia, cyanosis,
separated from parietal pleural (and
decreased breath
chest wall) with hyperlucency of 
sounds, tracheal
gas in between.
deviation in tension
 Tracheal deviation and mediastinal
pneumothorax.
shift maybe present..
 May be spontaneous,
traumatic or iatrogenic.

Clinical

Others: A contralateral pleural effusion may sometimes appear as a hyperlucent hemithorax

Pneumothorax

Disease

Table 2. Differential Diagnosis Table for Congenital Lobar Emphysema Continued

Ultrasound: Used in point-ofcare situations eg: emergency
department/ICU. Absence of
‘lung sliding’,
seen as a shimmering line due
to sliding of visceral and
parietal pleural relative to each
other is suspicious for a
pneumothorax.

Other Modalities
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ABBREVIATIONS
CLE: Congenital lobar emphysema
CPAM: Congenital pulmonary airway malformations
LUL: Left upper lobe
LLL: Left lower lobe
3
He MRI: Hyperpolarized helium-3 magnetic resonance imaging
FGRE: Fast gradient recalled echo sequence
CT: Computed tomography
VDP: Ventilation defect percent
ADC: Apparent diffusion coefficient
RA950: Relative area of the lung with attenuation values <-950HU
LAA: Low attenuation areas
LAC: Low attenuation clusters
WA: Airway wall area
LA: Airway lumen area
FEV1: Forced expiratory volume in one second
Raw: Airways resistance
DLCO: Diffusing capacity of the lung for carbon monoxide
FRC: Functional residual capacity
DL: Longitudinal diffusion coefficient of acinar ducts
DT: Transverse diffusion coefficient of the acinar ducts
R: Outer radius of the intra-acinar ducts
h: Depth of the intra-acinar ducts
KEYWORDS
Congenital Lobar Emphysema, Bronchial Atresia, Hyperpolarized 3He, Magnetic
Resonance Imaging, Computed Tomography, Emphysema, Airways Disease
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presentations at the University of Western Ontario Medical
Biophysics Seminar are nominated for the Alan C. Groom Seminar
Award

Oct. 2013

Radiological Society of North America (RSNA) Research Trainee
Prize
International
Awarded to honor the most outstanding scientific contribution
submitted and accepted to the RSNA international meeting for
presentation
$1000

Sep. 2013

Western Graduate Research Scholarship, The University of Western
Ontario
Institutional
Awarded to a full time graduate student who has maintained firstclass academic average
$4,500

July 2013

Radiological Society of North America Research Trainee Nominee
International
The highest ranked abstracts submitted to the international meeting
are nominated by the RSNA committee for the Trainee Research Prize

Apr. 2013

University of Western Ontario School of Graduate Studies Out of
Province Scholarship
Institutional
Awarded to the highest ranked full time out-of-province graduate
students at The University of Western Ontario
$500

Jan. 2013

International Society for Magnetic Resonance in Medicine
International Conference Abstract Award
International
Awarded to the authors of the highest ranked scientific abstracts
submitted to the ISMRM International Conference
$440

Western Graduate Research Scholarship, The University of Western
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Sep. 2012

Ontario
Institutional
Awarded to a full time graduate student who has maintained firstclass academic average
$4,500

Sep. 2012

University of Western Ontario School of Graduate Studies Out of
Province Scholarship
Institutional
Awarded to the highest ranked full time out-of-province graduate
students at The University of Western Ontario
$500

Sep. 2012

Canadian Institutes of Health Research (CIHR) Strategic Training
Program in Vascular Research
Provincial
Awarded to graduate trainees who show the potential to perform
transdisciplinary research and provide high-impact contributions to the
understanding, treatment and prevention of vascular diseases
$24,000

Apr. 2011

Harlow University Travel Award (Memorial University Biochemistry
Research Program)
Institutional
Awarded to undergraduate students who are undertaking a semester of
studies at Memorial University Harlow Campus based on academic
merit
$500
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PEER-REVIEWED PUBLICATIONS AND PROCEEDINGS
A. Peer Reviewed Journal Manuscripts (16 Published)
Published (16)
1. J Cheng, D Pike, T Chow, M Kirby, G Parraga and B Chiu. Three-Dimensional
Ultrasound Measurements of Carotid Vessel Wall and Plaque Thickness and
their Relationship with Pulmonary Abnormalities in Ex-smokers Without
Airflow Limitation. The International Journal of Cardiovascular Imaging; DOI:
10.1007/s10554-016-0931-z
2. D Pike, M Kirby, R Eddy, F Guo, DPI Capaldi, A Ouriadov, DG McCormack
and G Parraga. Regional Heterogeneity of Chronic Obstructive Pulmonary
Disease Phenotypes: Pulmonary 3He Magnetic Resonance Imaging and
Computed Tomography. The Journal of Chronic Obstructive Pulmonary
Disease; DOI: 10.3109/15412555.2015.1123682
3. C Davis, K Sheikh, D Pike, S Svenningsen, DG McCormack, D O’Donnell, JA
Neder and G Parraga. Ventilation Heterogeneity in Never-smokers and COPD:
Comparison of Pulmonary Functional Magnetic Resonance Imaging with Poorly
Communicating Fraction derived from Plethysmography. Academic Radiology;
DOI: 10.1016/j.acra.2015.10.022
4. DPI Capaldi, N Zha, F Guo, D Pike, DG McCormack, IA Cunningham and G
Parraga. Pulmonary Imaging Biomarkers of Gas-trapping and Emphysema in
COPD: 3He MRI and CT Parametric Response Maps. Radiology; DOI:
10.1148/radiol.2015151484
5. N Zha, D Pike, S Svenningsen, DPI Capaldi, DG McCormack and G Parraga.
Second-Order Texture Measurements of 3He Ventilation MRI: Proof of Concept
Evaluation of Asthma Bronchodilator Response. Academic Radiology DOI:
10.1016/j.acra.2015.10.010
6. M Kirby, D Pike, DG McCormack, DD Sin, S Lam, HO Coxson and G Parraga.
Do Imaging Measurements of Emphysema and Airway Disease Explain
Symptoms and Exercise Capacity in Mild-moderate COPD? Radiology; DOI:
10.1148/radiol.2015150037
7. D Pike, M Kirby, F Guo, DG McCormack and G Parraga. Ventilation
Heterogeneity in Ex-smokers without Airflow Limitation. Academic Radiology;
DOI: 10.1017/j.acra.2015.04.006
8. D Pike, S Mohan, W Ma, JF Lewis and G Parraga. Pulmonary Imaging
Abnormalities in an Adult Case of Congenital Lobar Emphysema. The Journal
of Radiology Case Reports; DOI: 10.3941/jrcr.v9i2.2048 2015
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9. M McDonald, M Mannion, D Pike, K Lewis, A Flynn, M Browne, L Madera,
MRP Coombs, D Hoskin, M Rise and V Booth. Structure-Function
Relationships in Histidine Rich Antimicrobial Peptides From Cod. Biochemica
et Biophysica Acta (BBA) Biomembranes; DOI: 10.1016/j.bbamem.2015.03.030
10. M Kirby, D Pike, DG McCormack, DD Sin, S Lam, HO Coxson and G Parraga.
Thoracic Imaging Network of Canada (TINCan) Study Objectives. The Journal
of
Chronic
Obstructive
Pulmonary
Disease
Foundation:
DOI:
10.15326/JCOPDF.2014.1.2.0136, 2014
11. W Ma, K Sheikh, S Svenningsen, D Pike, F Guo, R Etemad-Rezai, J Leipsic,
HO Coxson, DG McCormack and G Parraga. Ultra-short echo-time pulmonary
MRI: Evaluation and reproducibility in COPD subjects with and without
bronchiectasis.
Journal of Magnetic Resonance Imaging; DOI:
10.1002/jmri.24680, 2014
12. M Kirby, D Pike, HO Coxson, DG McCormack and G Parraga. Hyperpolarized
3
He Ventilation Defects Predict Pulmonary Exacerbations in Mild-moderate
COPD. Radiology; DOI: 10.1148/radiol.14140161, 2014
13. D Pike, M Kirby, TJ Lindenmaier, K Sheikh, C Neron, DG Hackam, JD Spence,
A Fenster, NAM Paterson, HO Coxson, DG McCormack, DD Sin and G Parraga.
Pulmonary Abnormalities and Carotid Atherosclerosis in Ex-smokers without
Airflow Limitation. Journal of Chronic Obstructive Pulmonary Disease; DOI:
10.3109: 1-0, 2014
14. D Pike, TJ Lindenmaier, DD Sin and G Parraga. Imaging Evidence of the
Relationship between Atherosclerosis and Chronic Obstructive Pulmonary
Disease. Imaging in Medicine; DOI: 10.2217/iim. 13.70, 2013
15. TJ Lindenmaier, DN Buchanan, D Pike, T Hartley, RD Reid, JD Spence, R
Chan, M Sharma, PL Prior, N Suskin and G Parraga. One, two and threedimensional ultrasound measurements of carotid atherosclerosis before and after
cardiac rehabilitation: preliminary results of a randomized controlled trial.
Cardiovascular Ultrasound; DOI: 11 (1):39, 2013
16. D Pike and G Parraga. COPD: More imaging, more phenotypes...better care?
Canadian Respiratory Journal; DOI: 20 (2):90, 2013
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B. Peer Reviewed Presentations and Conference Proceedings (11 Oral (Podium)
Presentations, 33 Poster Presentations)
Oral (Podium) Presentations and Conference Proceedings (11)
1. E Lessard, A Ouriadov, D Pike*, DPI Capaldi, DG McCormack and G Parraga.
Novel Biomarkers of Lung Function Destruction and Emphysema Progression in
COPD Using Inhaled Gas MRI Morphometry. The American Thoracic Society
Annual Scientific Meeting 2016, San Francisco, CA, USA
*Speaker
2. RL Eddy, D Pike, M Kirby, K Sheikh, GA Paulin, M Kirby, DG McCormack
and G Parraga. Testing the Fletcher-Peto Assumptions using Pulmonary
Imaging Biomarker Longitudinal Measurements. The American Thoracic
Society Annual Scientific Meeting 2016, San Francisco, CA, USA
3. D Pike, N Zha, DPI Capaldi, F Guo, S Mattonen, A Ward, DG McCormack and
G Parraga. Second-order Texture Analysis of Hyperpolarized 3He MRI:
Measuring Ventilation Signal to Treat COPD. The National Student Research
Forum 2016. Galveston, TX, USA
4. DPI Capaldi, N Zha, D Pike, K Sheikh, DG McCormack and G Parraga.
Pulmonary Magnetic Resonance Imaging and CT Parametric Response Mapping
Phenotypes in Ex-smokers with and without Chronic Obstructive Pulmonary
Disease. Imaging Network Ontario Symposium 2015. London, ON, Canada
5. N Zha, DPI Capaldi, D Pike, DG McCormack, IA Cunningham and G Parraga.
Principal component analysis of the CT density histogram to generate parametric
response maps of COPD. Imaging Network Ontario Symposium. London, ON,
Canada
6. N Zha, DPI Capaldi, D Pike, DG McCormack, IA Cunningham and G Parraga.
Principal Component Analysis of the CT Density Histogram to Generate
Parametric Response Maps of COPD. The International Society for Optical
Engineering Annual Scientific Meeting 2015, Orlando, FL, USA
7. S Svenningsen, G Paulin, D Pike, S Mohan, DG McCormack and G Parraga.
Pulmonary Functional Imaging of Bronchiectasis: A First Look at Ventilation
Abnormalities and their Relationship with Pulmonary Function and Symptoms.
The London Health Research Day Symposium 2014, London, ON, Canada
8. S Svenningsen, G Paulin, D Pike, S Mohan, DG McCormack and G Parraga.
Pulmonary Functional Imaging of Bronchiectasis: A First Look at Ventilation
Abnormalities and their Relationship with Pulmonary Function and Symptoms.
The American Thoracic Society Annual Scientific Meeting 2014, San Diego, CA,
USA

202

9. F Guo, D Pike, S Svenningsen, HO Coxson, JJ Drozd, J Yuan, A Fenster and G
Parraga. Development and Applications of Pulmonary Structure-Function
Registration Methods. The International Society for Optical Engineering Annual
Scientific Meeting 2014, San Diego, CA, USA
10. D Pike, M Kirby, F Guo, DD Sin, HO Coxson, DG McCormack and G Parraga.
Sex, Airways Disease and Emphysema in Ex-smokers with and without Airflow
Limitation. Imaging Network of Ontario Symposium 2014, Toronto, ON,
Canada
11. D Pike, M Kirby, S Svenningsen, HO Coxson, NAM Paterson, DG McCormack
and G Parraga. Are Hyperpolarized 3He Magnetic Resonance Imaging
Ventilation Defects Clinically Relevant in Ex-smokers without Airflow
Limitation? Radiological Society of North America Annual Scientific Meeting
2013, Chicago, IL, USA
Associated Award (International): The Radiological Society of North
America Research Trainee Prize, $1000
Peer Reviewed Poster Presentations and Conference Proceedings (33)
1.

E Lessard, A Ouriadov, D Pike, DG McCormack and G Parraga. Longitudinal
Three-Year Decline in Alpha-1 Antitrypsin Deficiency: Regional Worsening in
Emphysema and Ventilation. The American Thoracic Society Annual Scientific
Meeting 2016, San Francisco, CA, USA

2. D Pike, DPI Capaldi, S Mattonen, F Guo, A Ward, DG McCormack and G
Parraga. Second-Order Texture Analysis of Hyperpolarized 3He MRI – Beyond
the Ventilation Defect. The International Society of Magnetic Resonance in
Medicine Annual Scientific Meeting 2015, Toronto, ON, Canada
3. DPI Capaldi, N Zha, D Pike, K Sheikh, DG McCormack, G Parraga. 3He MRI
and CT Parametric Response Mapping of Small Airways Disease: The BattleGround for Ground Truth. The International Society of Magnetic Resonance in
Medicine Annual Scientific Meeting 2015, Toronto, ON, Canada
4. DPI Capaldi, K Sheikh, S Svenningsen, D Pike, DG McCormack, G Parraga.
MRI Measurements of Regional Ventilation Heterogeneity: Ventilation Defect
Clusters. The International Society of Magnetic Resonance in Medicine Annual
Scientific Meeting 2015, Toronto, ON, Canada
5. D Pike, A Ouridov, S Mohan, DG McCormack and G Parraga. Evaluation of
Emphysema in Alpha-1 Antitrypsin Deficiency Patients using 3He MRI – A
Potential Tool for Monitoring Response to Augmentation Therapy. The
American Thoracic Society Annual Scientific Meeting 2015, Denver, CO, USA
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6. D Pike, M Kirby, D Capaldi, N Zha, DG McCormack, HO Coxson and G
Parraga. Differences in Pulmonary Ventilation in Ex-smokers with and without
COPD after Three years: Longitudinal Results of the TINCan Cohort. The
American Thoracic Society Annual Scientific Meeting 2015, Denver, CO, USA
7. C Davis, D Pike, S Svenningsen, DG McCormack, D O’Donnell, JA Neder, G
Parraga, Ventilation Heterogeneity in Older Never-Smokers and GOLD stage IIV COPD: Poorly Communicating Fraction and MRI Ventilation defects in the
TINCan Cohort. The American Thoracic Society Annual Scientific Meeting 2015,
Denver, CO, USA
8. D Pike, M Kirby, D Capaldi, N Zha, DG McCormack, HO Coxson and G
Parraga. Differences in Pulmonary Ventilation in Ex-smokers with and without
COPD after Three years: Longitudinal Results of the TINCan Cohort. London
Health Research Day 2015, London, ON, Canada
9. D Pike, M Kirby, D Capaldi, N Zha, DG McCormack, HO Coxson and G
Parraga. Differences in Pulmonary Ventilation in Ex-smokers with and without
COPD after Three years: Longitudinal Results of the TINCan Cohort. Imaging
Network Ontario Symposium 2015, London, ON, Canada
10. C Davis, D Pike, S Svenningsen, DG McCormack, D O’Donnell, JA Neder, G
Parraga, Ventilation Heterogeneity in Older Never-Smokers and GOLD stage IIV COPD: Poorly Communicating Fraction and MRI Ventilation defects in the
TINCan Cohort. London Health Research Day 2015, London, ON, Canada
11. DPI Capaldi, N Zha, D Pike, K Sheikh, DG McCormack and G Parraga.
Pulmonary Magnetic Resonance Imaging and CT Parametric Response Mapping
Phenotypes in Ex-smokers with and without Chronic Obstructive Pulmonary
Disease. Imaging Network Ontario Symposium 2015, London, ON, Canada
12. N Zha, DPI Capaldi, D Pike, DG McCormack, IA Cunningham and G Parraga.
Principal component analysis of the CT density histogram to generate parametric
response maps of COPD. London Health Research Day 2015, London, ON,
Canada
13. S Svenningsen, G Paulin, A Wheatley, D Pike, J Suggett, DG McCormack and
G Parraga. Oscillating Positive Expiratory Pressure (oPEP) Therapy in Chronic
Obstructive Pulmonary Disease and Bronchiectasis. European Respiratory
Society Congress 2014, Munich, Germany
14. D Pike, TL Lindenmaier; LM Mielniczuk, DG McCormack and G Parraga. An
Airways Disease Phenotype is related to Pulmonary Artery Abnormalities in
COPD. The American Thoracic Society Annual Scientific Meeting 2014. San
Diego, CA, USA
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15. D Pike, M Kirby, F Guo, DD Sin, HO Coxson, DG McCormack and G Parraga.
Sex, Airways Disease and Emphysema in Ex-smokers with and without Airflow
Limitation. The American Thoracic Society Annual Scientific Meeting 2014.
San Diego, CA, USA
16. D Pike, M Kirby, S Svenningsen, DD Sin, DG McCormack, HO Coxson and G
Parraga. Pulmonary Computed Tomography and 3He Magnetic Resonance
Imaging of GOLD Unclassified Ex-smokers: Does Imaging Matter? The
American Thoracic Society Annual Scientific Meeting 2014. San Diego, CA,
USA
17. D Pike, M Kirby, DD Sin, DG McCormack, HO Coxson and G Parraga.
Pulmonary Imaging of Chronic Obstructive Pulmonary Disease in Ex-smokers:
Thoracic Imaging Network of Canada (TINCan) Cross-sectional Evaluation.
The American Thoracic Society Annual Scientific Meeting 2014. San Diego, CA,
USA
Associated Award (International): American Thoracic Society Respiratory
Structure and Function Scholarship, $500
18. W Ma, K Sheikh, D Pike, S Svenningsen, HO Coxson, DG McCormack and G
Parraga. Conventional Pulmonary MRI and CT of Bronchiectasis and
Emphysema: Tissue density measurements and relationship to pulmonary
function tests. The American Thoracic Society Annual Scientific Meeting 2014.
San Diego, CA, USA
19. D Pike, M Kirby, DD Sin, DG McCormack, HO Coxson and G Parraga.
Thoracic Imaging Network of Canada (TINCan): Answering Clinically
Relevant Pulmonary Structure-Function Questions Through Imaging. Imaging
Network of Ontario Symposium 2014, Toronto, ON, Canada
20. D Pike, M Kirby, S Svenningsen, DD Sin, DG McCormack, HO Coxson and G
Parraga. Imaging Global Initiative for Chronic Obstructive Pulmonary Disease
(GOLD) Unclassified Ex-smokers: A Hyperpolarized 3He MRI and Thoracic
CT Investigation. Imaging Network of Ontario Symposium 2014, Toronto, ON,
Canada
21. F Guo, D Pike, S Svenningsen, HO Coxson, JJ Drozd, J Yuan, A Fenster and G
Parraga. Deformable Pulmonary Structure-Function Registration Methods:
Towards Pulmonary Image-Guidance Methods for Improved Airway Targeted
Therapies and Outcomes. Imaging Network of Ontario Symposium 2014,
Toronto, ON, Canada
22. D Pike, M Kirby, DD Sin, DG McCormack, HO Coxson and G Parraga.
Pulmonary Imaging of Chronic Obstructive Pulmonary Disease in Ex-smokers:
Thoracic Imaging Network of Canada (TINCan) Cross-sectional Evaluation.
The London Health Research Day Symposium 2014, London, ON, Canada
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23. F Guo, D Pike, S Svenningsen, HO Coxson, JJ Drozd, J Yuan, A Fenster and G
Parraga. Deformable Pulmonary Structure-Function Registration Methods:
Towards Pulmonary Image-Guidance Methods for Improved Airway Targeted
Therapies and Outcomes. The London Health Research Day Symposium 2014,
London, ON, Canada
24. S Mohan, D Pike, W Ma, JF Lewis and G Parraga. Pulmonary Imaging
Abnormalities in an Adult Case of Congenital Lobar Emphysema. The London
Health Research Day Symposium 2014, London, ON, Canada
25. W Ma, K Sheikh, D Pike, S Svenningsen, HO Coxson, DG McCormack and G
Parraga. Conventional Pulmonary MRI and CT of Bronchiectasis and
Emphysema: Tissue density measurements and relationship to pulmonary
function tests. The London Health Research Day Symposium 2014, London,
ON, Canada
26. D Pike, M Kirby, A Wheatley, D. McCormack and G Parraga. Evaluation of
Airway Morphology in Chronic Obstructive Pulmonary Disease of
Hyperpolarized Helium-3 Magnetic Resonance Imaging and Computed
Tomography. International Society for Magnetic Resonance in Medicine 2013,
Salt Lake City, UT, USA
Associated Award (International): International Society for Magnetic
Resonance in Medicine Abstract Scholarship, $450
27. D Pike, M Kirby, K Sheikh, D Buchanan, C Neron, J.D. Spence, N.A.
Paterson, H.O. Coxson, D.G. McCormack and G Parraga. Airways Disease in
Asymptomatic Ex-smokers without Airflow Limitation: Relationship to
Carotid Atherosclerosis. The American Thoracic Society Annual Scientific
Meeting 2013, Philadelphia, PA, USA
28. D Pike, M Kirby, K Sheikh, D Buchanan, C Neron, JD Spence, NAM
Paterson, HO Coxson, DG McCormack and G Parraga. On the Relationship
Between Carotid Atherosclerosis and Airways Disease in Ex-smokers without
Airflow Limitation. Imaging Network Ontario 2013, Toronto, ON, Canada
29. D Pike, M Kirby, A Wheatley, DG McCormack and G Parraga. Airway
Morphology in Chronic Obstructive Pulmonary Disease using Hyperpolarized
3
He Magnetic Resonance Imaging and x-ray Computed Tomography. London
Imaging Discovery Day 2013, London, ON, Canada
30. D Pike, M Kirby, A Wheatley, DG McCormack and G Parraga. Evaluation of
Airway Morphology in Chronic Obstructive Pulmonary Disease of
Hyperpolarized Helium-3 Magnetic Resonance Imaging and Computed
Tomography. London Health Research Day 2013, London, ON, Canada
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31. M Kirby, D Pike, A Wheatley, NAM Paterson, D.G. McCormack and G
Parraga. Hyperpolarized Helium-3 Magnetic Resonance Imaging Phenotypes
of Chronic Obstructive Pulmonary Disease: Relationship to Exacerbations.
American Thoracic Society 2013, Philadelphia, PA, USA
32. M McDonald, M Mannion, D Pike, K Lewis, M Browne, M Rise and V Booth.
High Resolution Structures and Structure-Function Relationships in HistidineRich Antimicrobial Peptides from Cod. Biophysical Society Annual Scientific
Meeting 2013, Philadelphia, PA, USA
33. D Pike, M Morrow and V Booth. Characterizing Membrane Interactions of
Antimicrobial Peptide MSI-78 Using 31P Nuclear Magnetic Resonance.
Memorial University of Newfoundland Research Symposium 2012, St. John’s,
NL, Canada
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ACADEMIC CONFERENCES WITH PROCEEDINGS FEATURED
2016

American Thoracic Society Conference, San Francisco, CA, International
National Student Research Forum, Galveston, TX, International
Memorial University Medical Research Conference, St. John’s, NL, Provincial

2015

International Society of Magnetic Resonance in Medicine (ISMRM) Conference,
Toronto, ON, International
American Thoracic Society Conference, Denver, CO, International
Imaging Network of Ontario, Toronto, ON, National
London Health Research Day, London, ON, Provincial

2014

International Society of Magnetic Resonance in Medicine Conference (ISMRM),
Milan, ITA, International
American Thoracic Society Conference, San Diego, CA, International
Imaging Network of Ontario, Toronto, ON, National
London Imaging Discovery Day, London, ON, Provincial
London Health Research Day, London, ON, Provincial

2013

Radiological Society of North America (RSNA), Chicago, IL, International
International Society of Magnetic Resonance in Medicine (ISMRM) Conference,
Salt Lake City, UT, International
American Thoracic Society Conference, Philadelphia, PA, International
Imaging Network of Ontario, Toronto, ON, National
London Imaging Discovery Day, London, ON, Provincial
London Health Research Day, London, ON, Provincial

PROFESSIONAL MEMEBERSHIPS
Feb. 2016 – present
Jan. 2016 – present
Sep. 2015 - present
Jan. 2013 – present
Jan. 2013 – present
Jan. 2013 – present
Jan. 2012 – present

Canadian Interventional Radiology Association (CIRA)
Clinician Investigator Training Association of Canada (CITAC)
Canadian Medical Association (CMA)
Radiological Society of North America (RSNA)
American Thoracic Society (ATS)
Canadian Thoracic Society (CTS)
International Society of Magnetic Resonance in Medicine (ISMRM)
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RESEARCH EDUCATION DEVELOPMENT
2015

Medical Resident Research Trainee Supervision
Resident (PGY-3 Internal Medicine): Michael Mitar, MD
Project: Longitudinal Evaluation of Emphysema in Alpha-1 Antitrypsin
Deficiency Patients using Diffusion-weighted 3He MRI: Monitoring
Response to Augmentation Therapy
Abstract: Evaluation of Emphysema in Alpha-1 Antitrypsin Deficiency
Patients using 3He MRI – A Potential Tool for Monitoring Response to
Augmentation Therapy.

2015

Medical Resident Research Trainee Supervision
Resident (PGY-2 Internal Medicine): Chris Davis, MD
Manuscript: C Davis, K Sheikh, D Pike, S Svenningsen, DG McCormack,
D O’Donnell, JA Neder and G Parraga. Ventilation Heterogeneity in
Never-smokers and COPD: Comparison of Pulmonary Functional
Magnetic Resonance Imaging with Poorly Communicating Fraction
derived from Plethysmography.
Academic Radiology; DOI:
10.1016/j.acra.2015.10.022

2014

Medical Student Research Trainee Supervision
Pre-clerkship MD Candidate: Nanxi Zha, BEeng
Manuscript:
N Zha, D Pike, S Svenningsen, DPI Capaldi, DG
McCormack and G Parraga. Second-Order Texture Measurements of 3He
Ventilation MRI: Proof of Concept Evaluation of Asthma Bronchodilator
Response. Academic Radiology DOI: 10.1016/j.acra.2015.10.010

2013

Medical Resident Research Trainee Supervision
Resident (PGY-2 Internal Medicine): Sindu Mohan, MD
Manuscript: D Pike, S Mohan, W Ma, JF Lewis and G Parraga.
Pulmonary Imaging Abnormalities in an Adult Case of Congenital Lobar
Emphysema.
The Journal of Radiology Case Reports; DOI:
10.3941/jrcr.v9i2.2048 2015

2012

Undergraduate Summer Student Supervision
Student: William Alexander, Faculty of Engineering, Memorial University
6 Week Project: Differential Scanning Calorimetry of Bacterial

Membranes
2011

Undergraduate Summer Student Supervision
Student: Kathleen O’Grady, Faculty of Engineering, Memorial University
6 Week Project: 31P Solid State Nuclear Magnetic Resonance of Dynamic
Systems
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RELEVANT GRADUATE COURSEWORK
Conceptual Magnetic Resonance Imaging (Instructor: Charles McKenzie PhD) – 93%
Principles of Medical Imaging (Instructors: David Holdsworth PhD, Maria Drangova
PhD, Keith St. Lawrence PhD, Ting Yim-Lee PhD) – 80%
Nuclear Magnetic Resonance (Instructor: Blaine Chronik PhD) – 84%
Vascular Imaging (Instructor: Aaron Fenster PhD, FCCPM) – 99%
Research Ethics and Biostatistics (Instructor: Aaron Fenster PhD, FCCPM) – 94%
Inferencing From Data Analysis (Instructor: Yves Bureau PhD) – 85%
Scientific Communications (Instructor: Terry Thompson PhD) – 94%
Digital Image Processing (Instructor: Hanif Ladak PhD, P. Eng) – 92%
Imaging Principles (Instructor: Ian Cunningham PhD, FCCPM, FAAPM) – 90%

LEADERSHIP, VOLUNTEER AND COMMUNITY ACTIVITIES
2016

Volunteer, Memorial University Faculty of Medicine Clinical Research
Interest Group – Co-founder and President
Volunteer, Memorial University Faculty of Medicine Undergraduate (MD)
Research Representative
Volunteer, Memorial University Faculty of Medicine Undergraduate (MD)
Radiology Representative

2015

Volunteer, Memorial University Faculty of Medicine Medical Doctor
(MD) Research Representative
Volunteer, Memorial University Faculty of Medicine Medical Doctor
(MD) Radiology Representative
Volunteer, Memorial University Faculty of Medicine Medical Doctor
(MD) Research Representative
Volunteer, Camp Delight Oncology Camp Counsellor and Mentor
Volunteer, Memorial University Faculty of Medicine Monte Carlo
Fundraiser
Volunteer, Schulich Medicine and Dentistry Society Medical Biophysics
Graduate Recruitment Committee
Member, London Ontario Soccer League
Volunteer, Track 3 Ski School Instructor
Volunteer, Schulich Medicine and Dentistry Society Medical Biophysics
Graduate Representative

2014

Volunteer, Schulich Medicine and Dentistry Society Medical Biophysics
Graduate Recruitment Committee
Volunteer, Schulich Medicine and Dentistry Society Medical Biophysics
Graduate Representative
Participant/Member, MEC Charity Road Race Series (London, Ontario)
Member, London Ontario Soccer League
Volunteer, Track 3 Ski School Instructor
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Member, Network of Imaging Students (NOISe)
2013

Participant/Member, Forest City Road Race Series (London, Ontario)
Member, London Ontario Soccer League
Volunteer, Track 3 Ski School Instructor
Member, Network of Imaging Students (NOISe)

2012

Participant, Forest City Road Race Series Half-Marathon (London,
Ontario)
Participant, MEC Charity Road Race Series (London, Ontario)
Member, Network of Imaging Students (NOISe)
Volunteer, Canadian Ski Patrol (Nationwide On-hill Certification), St.
John’s, NL
Volunteer, Memorial University Campus Foodbank, St. John’s Campus
Member, Hockey Newfoundland and Labrador, Provincial Goaltending
Development Committee
Member, Memorial University Faculty of Biochemistry Vice President of
Athletics
Volunteer, Hockey Newfoundland and Labrador Midget AAA
Goaltending Coach

2011

Volunteer, Canadian Ski Patrol (Nationwide On-hill Certification), St.
John’s, NL
Volunteer, Memorial University Campus Foodbank, St. John’s Campus
Volunteer, Women in Science and Engineering (WISE), Mentor
Member, Hockey Newfoundland and Labrador, Regional Goaltending
Development Committee
Volunteer, Hockey Newfoundland and Labrador Midget AAA
Goaltending Coach

2010

Volunteer, Canadian Ski Patrol (Nationwide On-hill Certification), St.
John’s, NL
Volunteer, Memorial University Campus Foodbank, St. John’s Campus
Volunteer, Memorial University Science Matters, Career Development
Programme
Member, Hockey Newfoundland and Labrador, Regional Goaltending
Development Committee
Volunteer, Hockey Newfoundland and Labrador Midget AAA
Goaltending Coach

2009

Volunteer, Canadian Ski Patrol (Nationwide On-hill Certification), St.
John’s, NL
Volunteer, Memorial University Campus Foodbank, St. John’s Campus
Member, Hockey Newfoundland and Labrador, Regional Goaltending
Development Committee

